| Level/ Typ |
Code |
Anzeigename |
Codesystem |
Beschreibung |
| 0-L |
A |
Alimentäres System und Stoffwechsel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01 |
Stomatologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01a |
Stomatologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AA |
Mittel zur Kariesprophylaxe |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AA01 |
Natriumfluorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AA02 |
Natriummonofluorphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AA03 |
Olaflur |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AA04 |
Zinn(II)-fluorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AA30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AA51 |
Natriumfluorid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB |
Antiinfektiva und Antiseptika zur oralen Lokalbehandlung |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB02 |
Wasserstoffperoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB03 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB04 |
Amphotericin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB05 |
Polynoxylin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB06 |
Domiphen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB07 |
Oxychinolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB08 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB09 |
Miconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB10 |
Natamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB11 |
Verschiedene |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB12 |
Hexetidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB13 |
Tetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB14 |
Benzoxoniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB15 |
Tibezoniumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB16 |
Mepartricin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB17 |
Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB18 |
Clotrimazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB19 |
Natriumperborat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB21 |
Chlortetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB22 |
Doxycyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AB23 |
Minocyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AC |
Corticosteroide zur oralen Lokalbehandlung |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AC01 |
Triamcinolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AC02 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AC03 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AC54 |
Prednisolon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AD |
Andere Mittel zur oralen Lokalbehandlung |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AD01 |
Epinephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AD02 |
Benzydamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AD05 |
Acetylsalicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AD06 |
Adrenalon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AD07 |
Amlexanox |
2.16.840.1.113883.6.73 |
|
| 0-L |
A01AD11 |
Verschiedene |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02 |
Mittel bei säure bedingten Erkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02A |
Antacida |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AA |
Magnesium-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AA01 |
Magnesiumcarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AA02 |
Magnesiumoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AA03 |
Magnesiumperoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AA04 |
Magnesiumhydroxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AA05 |
Magnesiumsilikat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AA10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB |
Aluminium-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB01 |
Aluminiumhydroxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB02 |
Algeldrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB03 |
Aluminiumphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB04 |
Dihydroxyalumiumnatriumcarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB05 |
Aluminiumacetoacetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB06 |
Aloglutamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB07 |
Aluminiumglycinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AB10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AC |
Calcium-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AC01 |
Calciumcarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AC02 |
Calciumsilikat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AC10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AD |
Kombinationen und Komplexe von Aluminium-, Calcium- und Magnesium-haltigen Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AD01 |
Einfache Salzkombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AD02 |
Magaldrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AD03 |
Almagat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AD04 |
Hydrotalcit |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AD05 |
Almasilat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AF |
Antacida mit Karminativa |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AF01 |
Magaldrat und Karminativa |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AF02 |
Einfache Salzkombinationen und Karminativa |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AG |
Antacida mit Spasmolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AH |
Antacida mit Natriumbicarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02AX |
Antacida, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02B |
Mittel bei peptischem Ulkus und gastroesophagealer Refluxkrankheit |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA |
Histamin-H2-Rezeptorantagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA01 |
Cimetidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA02 |
Ranitidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA03 |
Famotidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA04 |
Nizatidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA05 |
Niperotidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA06 |
Roxatidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA07 |
Ranitidinbismutcitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA08 |
Lafutidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA51 |
Cimetidin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BA53 |
Famotidin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BB |
Prostaglandine |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BB01 |
Misoprostol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BB02 |
Enprostil |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BC |
Protonenpumpenhemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BC01 |
Omeprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BC02 |
Pantoprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BC03 |
Lansoprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BC04 |
Rabeprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BC05 |
Esomeprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BC06 |
Dexlansoprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BD |
Kombinationen zur Eradikation von Helicobacter pylori |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BD01 |
Omeprazol, Amoxicillin und Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BD02 |
Lansoprazol, Tetracyclin und Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BD03 |
Lansoprazol, Amoxicillin und Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BD04 |
Pantoprazol, Amoxicillin und Clarithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BD05 |
Omeprazol, Amoxicillin und Clarithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BD06 |
Esomeprazol, Amoxicillin und Clarithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BD08 |
Bismutsubcitrat, Tetracyclin und Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX |
Andere Mittel bei peptischem Ulkus und gastroesophagealer Refluxkrankheit |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX01 |
Carbenoxolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX02 |
Sucralfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX03 |
Pirenzepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX04 |
Methiosulfoniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX05 |
Bismutsubcitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX06 |
Proglumid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX07 |
Gefarnat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX08 |
Sulglicotid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX09 |
Acetoxolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX10 |
Zolimidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX11 |
Troxipid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX12 |
Bismutsubnitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX13 |
Alginsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX51 |
Carbenoxolon, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX71 |
Carbenoxolon, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02BX77 |
Gefarnat, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A02X |
Andere Mittel bei säure bedingten Erkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03 |
Mittel bei funktionellen gastrointestinalen Störungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03A |
Mittel bei funktionellen Störungen des Darms |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA |
Synthetische Anticholinergika, Ester mit tertiären Aminogruppen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA01 |
Oxyphencyclimin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA03 |
Camylofin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA04 |
Mebeverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA05 |
Trimebutin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA06 |
Rociverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA07 |
Dicycloverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA08 |
Dihexyverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA09 |
Difemerin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AA30 |
Piperidolat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB |
Synthetische Anticholinergika, quartäre Ammonium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB01 |
Benzilon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB02 |
Glycopyrronium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB03 |
Oxyphenonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB04 |
Penthienat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB05 |
Propanthelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB06 |
Otiloniumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB07 |
Methanthelinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB08 |
Tridihexethyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB09 |
Isopropamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB10 |
Hexocyclium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB11 |
Poldin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB12 |
Mepenzolat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB13 |
Bevonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB14 |
Pipenzolat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB15 |
Diphemanil |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB16 |
(2-Benzhydryloxyethyl)diethylmethyl-ammoniumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB17 |
Tiemoniumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB18 |
Prifiniumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB19 |
Timepidiumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB21 |
Fenpiverinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AB53 |
Oxyphenonium, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AC |
Synthetische Spasmolytika, Amide mit tertiären Aminen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AC02 |
Dimethylaminopropionylphenothiazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AC04 |
Nicofetamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AC05 |
Tiropramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AD |
Papaverin und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AD01 |
Papaverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AD02 |
Drotaverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AD30 |
Moxaverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AE |
Auf Serotonin-Rezeptoren wirkende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AE01 |
Alosetron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AE02 |
Tegaserod |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AE03 |
Cilansetron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX |
Andere Mittel bei funktionellen Störungen des Darms |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX01 |
Fenpipran |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX02 |
Diisopromin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX03 |
Chlorbenzoxamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX04 |
Pinaverium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX05 |
Fenoverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX06 |
Idanpramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX07 |
Proxazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX08 |
Alverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX09 |
Trepibuton |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX10 |
Isomethepten |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX11 |
Caroverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX12 |
Phloroglucinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX13 |
Silikone |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX30 |
Trimethyldiphenylpropylamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03AX58 |
Alverin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03B |
BELLADONNA UND DERIVATE, REIN |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BA |
Belladonna-Alkaloide, tertiäre Amine |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BA01 |
Atropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BA03 |
Hyoscyamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BA04 |
Belladonna-Gesamtalkaloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BB |
Belladonna-Alkaloide, halbsynthetisch, quartäre Ammonium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BB01 |
Butylscopolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BB02 |
Methylatropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BB03 |
Methylscopolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BB04 |
Fentonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03BB05 |
Cimetropiumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03C |
Spasmolytika in Kombination mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA |
Synthetische Anticholinergika in Kombination mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA01 |
Isopropamid und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA02 |
Clidinium und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA03 |
Oxyphencyclimin und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA04 |
Otiloniumbromid und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA05 |
Glycopyrronium und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA06 |
Bevonium und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA07 |
Ambutonium und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA08 |
Diphemanil und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA30 |
Emepronium und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CA34 |
Propanthelin und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CB |
Belladonna und Derivate in Kombination mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CB01 |
Methylscopolamin und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CB02 |
Belladonna-Gesamtalkaloide und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CB03 |
Atropin und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CB04 |
Methylhomatropin und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CB31 |
Hyoscyamin und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03CC |
Andere Spasmolytika in Kombination mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03D |
Spasmolytika in Kombination mit Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DA |
Synthetische Anticholinergika in Kombination mit Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DA01 |
Tropenzilon und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DA02 |
Pitofenon und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DA03 |
Bevonium und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DA04 |
Ciclonium und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DA05 |
Camylofin und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DA06 |
Trospium und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DA07 |
Tiemoniumiodid und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DB |
Belladonna und Derivate in Kombination mit Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DB04 |
Butylscopolamin und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03DC |
Andere Spasmolytika in Kombination mit Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03E |
Spasmolytika und Anticholinergika in Kombination mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03EA |
Spasmolytika, Psycholeptika und Analgetika in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03ED |
Spasmolytika in Kombination mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03F |
Prokinetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03FA |
Prokinetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03FA01 |
Metoclopramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03FA02 |
Cisaprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03FA03 |
Domperidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03FA04 |
Bromoprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03FA05 |
Alizaprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A03FA06 |
Cleboprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04 |
Antiemetika und Mittel gegen Übelkeit |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04A |
Antiemetika und Mittel gegen Übelkeit |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AA |
Serotonin-5HT3-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AA01 |
Ondansetron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AA02 |
Granisetron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AA03 |
Tropisetron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AA04 |
Dolasetron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AA05 |
Palonosetron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD |
Andere Antiemetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD01 |
Scopolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD02 |
Ceriumoxalat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD04 |
Chlorbutanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD05 |
Metopimazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD10 |
Dronabinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD11 |
Nabilon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD12 |
Aprepitant |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD51 |
Scopolamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A04AD54 |
Chlorbutanol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05 |
Gallen- und Lebertherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05A |
Gallentherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AA |
Gallensäure-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AA01 |
Chenodeoxycholsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AA02 |
Ursodeoxycholsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AB |
Zubereitungen zur Gallentherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AB01 |
N-(Hydroxymethyl)nicotinamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AX |
Andere Mittel zur Gallentherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AX01 |
Piprozolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AX02 |
Hymecromon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05AX03 |
Cyclobutyrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05B |
Lebertherapie, Lipotrope Substanzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05BA |
Lebertherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05BA01 |
Argininglutamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05BA03 |
Silymarin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05BA04 |
Citiolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05BA05 |
Epomediol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05BA06 |
Ornithinoxoglurat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05BA07 |
Tidiacicarginin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A05C |
Mittel zur Gallentherapie und Lipotrope Substanzen in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06 |
Laxanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06A |
Laxanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AA |
Gleitmittel, Emollientia |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AA01 |
Dickflüssiges Paraffin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AA02 |
Docusat-Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AA51 |
Dickflüssiges Paraffin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB |
Kontaktlaxanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB01 |
Oxyphenisatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB02 |
Bisacodyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB03 |
Dantron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB04 |
Phenolphthalein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB05 |
Rizinusöl |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB06 |
Sennoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB07 |
Cascara |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB08 |
Natriumpicosulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB09 |
Bisoxatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB20 |
Kontaktlaxanzien in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB30 |
Kontaktlaxanzien in Kombination mit Belladonna-Alkaloiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB52 |
Bisacodyl, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB53 |
Dantron, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB56 |
Sennoside, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB57 |
Cascara, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AB58 |
Natriumpicosulfat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC |
Quellmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC01 |
Ispaghula (Flohsamen) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC02 |
Ethulose |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC03 |
Sterculia |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC05 |
Leinsamen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC06 |
Methylcellulose |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC07 |
Triticum (Weizenkleie) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC08 |
Polycarbophil-Calcium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC51 |
Ispaghula, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC53 |
Sterculia, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AC55 |
Leinsamen, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD |
Osmotisch wirkende Laxanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD01 |
Magnesiumcarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD02 |
Magnesiumoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD03 |
Magnesiumperoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD04 |
Magnesiumsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD10 |
Mineralsalze in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD11 |
Lactulose |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD12 |
Lactitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD13 |
Natriumsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD14 |
Pentaerythrityl |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD15 |
Macrogol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD16 |
Mannitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD17 |
Natriumphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD18 |
Sorbitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD19 |
Magnesiumcitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD21 |
Natriumtartrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD61 |
Lactulose, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AD65 |
Macrogol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG |
Klysmen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG01 |
Natriumphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG02 |
Bisacodyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG03 |
Dantron, inkl. Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG04 |
Glycerol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG06 |
Öl |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG07 |
Sorbitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG10 |
Docusat-Natrium, inkl. Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG11 |
Laurylsulfat, inkl. Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AG20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AH01 |
Methylnaltrexon bromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AX |
Andere Laxanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AX01 |
Glycerol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A06AX02 |
Kohlendioxid-freisetzende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07 |
Antidiarrhoika und intestinale Antiphlogistika/Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07A |
Intestinale Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA |
Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA01 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA02 |
Nystatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA03 |
Natamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA04 |
Streptomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA05 |
Polymyxin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA06 |
Paromomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA07 |
Amphotericin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA08 |
Kanamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA09 |
Vancomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA10 |
Colistin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA11 |
Rifaximin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA12 |
Fidaxomicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA51 |
Neomycin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AA54 |
Streptomycin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AB |
Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AB02 |
Phthalylsulfathiazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AB03 |
Sulfaguanidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AB04 |
Succinylsulfathiazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AC |
Imidazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AC01 |
Miconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AX |
Andere intestinale Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AX01 |
Broxychinolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AX02 |
Acetarsol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AX03 |
Nifuroxazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07AX04 |
Nifurzid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07B |
Intestinale Adsorbenzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BA |
Kohle-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BA01 |
Medizinische Kohle |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BA51 |
Medizinische Kohle, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BB |
Bismut-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BC |
Andere intestinale Adsorbenzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BC01 |
Pektin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BC02 |
Kaolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BC03 |
Crospovidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BC04 |
Attapulgit |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BC05 |
Diosmectit |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BC30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07BC54 |
Attapulgit, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07C |
Elektrolyte mit Kohlenhydraten |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07CA |
Elektrolyte zur oralen Rehydrierung |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07D |
Motilitätshemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07DA |
Motilitätshemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07DA01 |
Diphenoxylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07DA02 |
Opium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07DA03 |
Loperamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07DA04 |
Difenoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07DA05 |
Loperamidoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07DA52 |
Morphin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07DA53 |
Loperamid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07E |
Intestinale Antiphlogistika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EA |
Corticosteroide mit lokaler Wirkung |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EA01 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EA02 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EA03 |
Prednison |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EA04 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EA05 |
Tixocortol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EA06 |
Budesonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EA07 |
Beclometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EB |
Antiallergika, exkl. Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EB01 |
Cromoglicinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EC |
Aminosalicylsäure und ähnliche Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EC01 |
Sulfasalazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EC02 |
Mesalazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EC03 |
Olsalazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07EC04 |
Balsalazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07F |
Mikrobielle Antidiarrhoika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07FA |
Mikrobielle Antidiarrhoika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07FA01 |
Milchsäurebildner |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07FA02 |
Saccharomyces boulardii |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07FA51 |
Milchsäurebildner, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07X |
Andere Antidiarrhoika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07XA |
Andere Antidiarrhoika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07XA01 |
Albumintannat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07XA02 |
Ceratonia |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07XA03 |
Calcium-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07XA04 |
Racecadotril |
2.16.840.1.113883.6.73 |
|
| 0-L |
A07XA51 |
Albumintannat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08 |
Abmagerungsmittel, Exkl. Diätetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08A |
Abmagerungsmittel, Exkl. Diätetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA |
Zentral wirkende Abmagerungsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA01 |
Phentermin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA02 |
Fenfluramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA03 |
Amfepramon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA04 |
Dexfenfluramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA05 |
Mazindol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA06 |
Etilamfetamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA07 |
Cathin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA08 |
Clobenzorex |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA09 |
Mefenorex |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA10 |
Sibutramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AA56 |
Ephedrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AB |
Peripher wirkende Abmagerungsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A08AB01 |
Orlistat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09 |
Digestiva, Inkl. Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09A |
Digestiva, Inkl. Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AA |
Enzym-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AA01 |
Diastase |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AA02 |
Multienzyme (Lipase, Protease etc.) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AA03 |
Pepsin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AA04 |
Tilactase |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AB |
Säure-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AB01 |
Glutaminsäurehydrochlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AB02 |
Betainhydrochlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AB03 |
Salzsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AB04 |
Zitronensäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AC |
Enzym- und Säure-haltige Zubereitungen, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AC01 |
Pepsin- und Säure-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A09AC02 |
Multienzyme und säure-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10 |
Antidiabetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10A |
Insuline Und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AA |
Insulins |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AB |
Insuline und Analoga zur Injektion, schnell wirkend |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AB01 |
Insulin (human) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AB02 |
Insulin (Rind) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AB03 |
Insulin (Schwein) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AB04 |
Insulin lispro |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AB05 |
Insulin aspart |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AB06 |
Insulin glulisin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AB30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AC |
Insuline und Analoga zur Injektion, intermediär wirkend |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AC01 |
Insulin (human) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AC02 |
Insulin (Rind) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AC03 |
Insulin (Schwein) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AC04 |
Insulin lispro |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AC30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AD |
Insuline und Analoga zur Injektion, intermediär wirkend kombiniert mit schnell wirkend |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AD01 |
Insulin (human) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AD02 |
Insulin (Rind) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AD03 |
Insulin (Schwein) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AD04 |
Insulin lispro |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AD05 |
Insulin aspart |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AD30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AE |
Insuline und Analoga zur Injektion, lang wirkend |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AE01 |
Insulin (human) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AE02 |
Insulin (Rind) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AE03 |
Insulin (Schwein) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AE04 |
Insulin glargin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AE05 |
Insulin detemir |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AE30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AF |
Insuline und Analoga zur Inhalation |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10AF01 |
Insulin (human) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10B |
Antidiabetika, Exkl. Insuline |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BA |
Biguanide |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BA01 |
Phenformin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BA02 |
Metformin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BA03 |
Buformin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB |
Sulfonylharnstoff-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB01 |
Glibenclamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB02 |
Chlorpropamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB03 |
Tolbutamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB04 |
Glibornurid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB05 |
Tolazamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB06 |
Carbutamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB07 |
Glipizid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB08 |
Gliquidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB09 |
Gliclazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB10 |
Metahexamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB11 |
Glisoxepid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB12 |
Glimepirid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BB31 |
Acetohexamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BC |
Sulfonamide (heterozyklisch) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BC01 |
Glymidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD |
Kombinationen mit oralen Antidiabetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD01 |
Phenformin und Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD02 |
Metformin und Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD03 |
Metformin und Rosiglitazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD04 |
Glimepirid und Rosiglitazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD05 |
Metformin und Pioglitazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD06 |
Glimepirid und Pioglitazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD07 |
Metformin und Sitagliptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD08 |
Metformin und Vildagliptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BD13 |
Metformin und Alogliptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BF |
Alpha-Glukosidasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BF01 |
Acarbose |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BF02 |
Miglitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BF03 |
Voglibose |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BG |
Thiazolidindione |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BG01 |
Troglitazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BG02 |
Rosiglitazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BG03 |
Pioglitazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BH01 |
Sitagliptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BH02 |
Vildagliptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BH04 |
Alogliptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BX |
Andere Antidiabetika, exkl. Insuline |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BX01 |
Guar-Mehl |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BX02 |
Repaglinid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BX03 |
Nateglinid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10BX04 |
Exenatid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10X |
Andere Antidiabetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10XA |
Aldosereduktasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
A10XA01 |
Tolrestat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11 |
Vitamine |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11A |
Multivitamine, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11AA |
Multivitamine mit Mineralstoffen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11AA01 |
Multivitamine und Eisen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11AA02 |
Multivitamine und Calcium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11AA03 |
Multivitamine und andere Mineralstoffe, inkl. Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11AA04 |
Multivitamine und Spurenelemente |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11AB |
Multivitamine, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11B |
Multivitamine, Rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11BA |
Multivitamine, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11C |
Vitamin A und D, inkl. deren Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CA |
Vitamin A, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CA01 |
Retinol (Vitamin A) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CA02 |
Betacaroten |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CB |
Vitamin A und D in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC |
Vitamin D und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC01 |
Ergocalciferol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC02 |
Dihydrotachysterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC03 |
Alfacalcidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC04 |
Calcitriol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC05 |
Colecalciferol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC06 |
Calcifediol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC07 |
Paricalcitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11CC20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11D |
Vitamin-B1, rein und in Kombination mit Vitamin-B6 und Vitamin-B12 |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11DA |
Vitamin-B1, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11DA01 |
Thiamin (Vitamin-B1) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11DA02 |
Sulbutiamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11DA03 |
Benfotiamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11DB |
Vitamin-B1 in Kombination mit Vitamin-B6 und/oder Vitamin-B12 |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11E |
Vitamin-B-Komplex, inkl. Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11EA |
Vitamin-B-Komplex, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11EB |
Vitamin-B-Komplex mit Vitamin C |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11EC |
Vitamin-B-Komplex mit Mineralstoffen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11ED |
Vitamin-B-Komplex mit anabolen Steroiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11EX |
Vitamin-B-Komplex, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11G |
Ascorbinsäure (Vitamin C), inkl. Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11GA |
Ascorbinsäure (Vitamin C), rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11GA01 |
Ascorbinsäure (Vitamin C) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11GB |
Ascorbinsäure (Vitamin C), Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11GB01 |
Ascorbinsäure (Vitamin C) und Calcium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11H |
Andere Vitaminpräparate, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA |
Andere Vitaminpräparate, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA01 |
Nicotinamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA02 |
Pyridoxin (Vitamin-B6) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA03 |
Tocopherol (Vitamin E) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA04 |
Riboflavin (Vitamin-B2) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA05 |
Biotin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA06 |
Pyridoxalphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA07 |
Inositol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA30 |
Dexpanthenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA31 |
Calciumpantothenat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11HA32 |
Pantethin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11J |
Andere Vitaminpräparate, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11JA |
Kombinationen von Vitaminen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11JB |
Vitamine mit Mineralstoffen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A11JC |
Vitamine, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12 |
Mineralstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12A |
Calcium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA |
Calcium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA01 |
Calciumphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA02 |
Calciumglubionat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA03 |
Calciumgluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA04 |
Calciumcarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA05 |
Calciumlactat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA06 |
Calciumlactogluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA07 |
Calciumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA08 |
Calciumglycerylphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA09 |
Calciumcitratlysin-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA10 |
Calciumglucoheptonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA11 |
Calciumpangamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA12 |
Calciumacetat, wasserfrei |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA20 |
Calcium (verschiedene Salze in Kombination) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AA30 |
Calciumlaevulat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AX |
Calcium, Kombinationen mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12AX01 |
Calciumcarbonat und Colecalciferol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12B |
Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12BA |
Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12BA01 |
Kaliumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12BA02 |
Kaliumcitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12BA03 |
Kaliumhydrogentartrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12BA04 |
Kaliumhydrogencarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12BA05 |
Kaliumgluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12BA30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12BA51 |
Kaliumchlorid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12C |
Andere Mineralstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CA |
Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CA01 |
Natriumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CA02 |
Natriumsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CB |
Zink |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CB01 |
Zinksulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CB02 |
Zinkgluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CB03 |
Zinkprotein-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC |
Magnesium |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC01 |
Magnesiumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC02 |
Magnesiumsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC03 |
Magnesiumgluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC04 |
Magnesiumcitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC05 |
Magnesiumaspartat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC06 |
Magnesiumlactat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC07 |
Magnesiumlevulinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC08 |
Magnesiumpidolat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC09 |
Magnesiumorotat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC10 |
Magnesiumoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC11 |
Magnesiumcarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CC30 |
Magnesium (verschiedene Salze in Kombination) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CD |
Fluorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CD01 |
Natriumfluorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CD02 |
Natriummonofluorphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CD51 |
Natriumfluorid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CE |
Selen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CE01 |
Natriumselenat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CE02 |
Natriumselenit |
2.16.840.1.113883.6.73 |
|
| 0-L |
A12CX |
Andere Mineralstoff-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
A13 |
Tonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A13A |
Tonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14 |
Anabolika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14A |
Anabole Steroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA |
Androstan-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA01 |
Androstanolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA02 |
Stanozolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA03 |
Metandienon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA04 |
Metenolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA05 |
Oxymetholon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA06 |
Quinbolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA07 |
Prasteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA08 |
Oxandrolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AA09 |
Norethandrolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AB |
Estren-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AB01 |
Nandrolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AB02 |
Ethylestrenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14AB03 |
Oxaboloncipionat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A14B |
Andere Anabolika |
2.16.840.1.113883.6.73 |
|
| 0-L |
A15 |
Appetit stimulierende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16 |
Andere Mittel für das alimentäre System und den Stoffwechsel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16A |
Andere Mittel für das alimentäre System und den Stoffwechsel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AA |
Aminosäuren und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AA01 |
Levocarnitin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AA02 |
Ademetionin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AA03 |
Glutamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AA04 |
Mercaptamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AA05 |
Carglumsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AA06 |
Betain |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB |
Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB01 |
Alglucerase |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB02 |
Imiglucerase |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB03 |
Agalsidase alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB04 |
Agalsidase beta |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB05 |
Laronidase |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB06 |
Sacrosidase |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB07 |
Alglucosidase alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB08 |
Galsulfase |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB09 |
Idursulfase |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AB10 |
Velaglucerase Alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AX |
Sonstige Mittel für das alimentäre System und den Stoffwechsel |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AX01 |
Alpha-Liponsäure (Thioctsäure) |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AX02 |
Anetholtrithion |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AX03 |
Natriumphenylbutyrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AX04 |
Nitisinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AX05 |
Zinkacetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AX06 |
Miglustat |
2.16.840.1.113883.6.73 |
|
| 0-L |
A16AX07 |
Sapropterin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B |
Blut und Blut bildende Organe |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01 |
Antithrombotische Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01A |
Antithrombotische Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA |
Vitamin-K-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA01 |
Dicoumarol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA02 |
Phenindion |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA03 |
Warfarin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA04 |
Phenprocoumon |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA07 |
Acenocoumarol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA08 |
Ethylbiscoumacetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA09 |
Clorindion |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA10 |
Diphenadion |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AA11 |
Tioclomarol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB |
Heparingruppe |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB01 |
Heparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB02 |
Antithrombin III |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB04 |
Dalteparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB05 |
Enoxaparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB06 |
Nadroparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB07 |
Parnaparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB08 |
Reviparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB09 |
Danaparoid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB10 |
Tinzaparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB11 |
Sulodexid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB12 |
Bemiparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AB51 |
Heparin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC |
Thrombozytenaggregationshemmer, exkl. Heparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC01 |
Ditazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC02 |
Cloricromen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC03 |
Picotamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC04 |
Clopidogrel |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC05 |
Ticlopidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC06 |
Acetylsalicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC07 |
Dipyridamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC08 |
Carbasalatcalcium |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC09 |
Epoprostenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC10 |
Indobufen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC11 |
Iloprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC13 |
Abciximab |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC15 |
Aloxiprin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC16 |
Eptifibatid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC17 |
Tirofiban |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC18 |
Triflusal |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC19 |
Beraprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC21 |
Treprostinil |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AC56 |
Acetylsalicylsäure und Esomeprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD |
Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD01 |
Streptokinase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD02 |
Alteplase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD03 |
Anistreplase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD04 |
Urokinase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD05 |
Fibrinolysin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD06 |
Brinase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD07 |
Reteplase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD08 |
Saruplase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD09 |
Ancrod |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD10 |
Drotrecogin alfa (aktiviert) |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD11 |
Tenecteplase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AD12 |
Protein C |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AE |
Direkte Thrombininhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AE01 |
Desirudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AE02 |
Lepirudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AE03 |
Argatroban |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AE04 |
Melagatran |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AE05 |
Ximelagatran |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AE06 |
Bivalirudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AE07 |
Dabigatran etexilat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AX |
Andere antithrombotische Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AX01 |
Defibrotid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AX04 |
Chondroitinsulfat B |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AX05 |
Fondaparinux |
2.16.840.1.113883.6.73 |
|
| 0-L |
B01AX06 |
Rivaroxaban |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02 |
Antihämorrhagika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02A |
Antifibrinolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AA |
Aminosäuren |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AA01 |
Aminocapronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AA02 |
Tranexamsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AA03 |
Aminomethylbenzoesäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AB |
Proteinasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AB01 |
Aprotinin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AB02 |
Alfa1-Antitrypsin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AB03 |
C1-Inhibitor |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02AB04 |
Camostat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02B |
Vitamin K und andere Hämostatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BA |
Vitamin K |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BA01 |
Phytomenadion |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BA02 |
Menadion |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BB |
Fibrinogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BB01 |
Fibrinogen, human |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC |
Lokale Hämostatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC01 |
Absorbierbarer Gelatineschwamm |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC02 |
Oxidierte Zellulose |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC03 |
Tetragalacturonsäurehydroxymethylester |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC05 |
Adrenalon |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC06 |
Thrombin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC07 |
Kollagen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC08 |
Calciumalginat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC09 |
Epinephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC10 |
Fibrinogen, human |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BC30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD |
Blutgerinnungsfaktoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD01 |
Gerinnungsfaktoren IX, II, VII und X in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD02 |
Gerinnungsfaktor VIII |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD03 |
Faktor-VIII-Inhibitor bypass Aktivität |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD04 |
Gerinnungsfaktor IX |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD05 |
Gerinnungsfaktor VII |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD06 |
Von-Willebrand-Faktor und Gerinnungsfaktor VIII in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD07 |
Gerinnungsfaktor XIII |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD08 |
Eptacog alfa (aktiviert) |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD09 |
Nonacog alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD10 |
von-Willebrand-Faktor |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BD30 |
Thrombin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BX |
Andere systemische Hämostatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BX01 |
Etamsylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BX02 |
Carbazochrom |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BX03 |
Batroxobin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BX04 |
Romiplostim |
2.16.840.1.113883.6.73 |
|
| 0-L |
B02BX05 |
Eltrombopag |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03 |
Antianämika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03A |
Eisen-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA |
Eisen zweiwertig, orale Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA01 |
Eisen(II)-Glycinsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA02 |
Eisen(II)fumarat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA03 |
Eisen(II)gluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA04 |
Eisen(II)carbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA05 |
Eisen(II)chlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA06 |
Eisen(II)succinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA07 |
Eisen(II)sulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA08 |
Eisen(II)tartrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA09 |
Eisen(II)aspartat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA10 |
Eisen(II)ascorbat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AA11 |
Eisen(II)iodat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB |
Eisen dreiwertig, orale Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB01 |
Eisen(III)-Natrium-citrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB02 |
Eisen(III)oxid-Saccharose-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB03 |
Natriumferedetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB04 |
Eisen(III)hydroxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB05 |
Dextriferron |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB06 |
Eisen(III)citrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB07 |
Chondroitinsulfat-Eisen(III)-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB08 |
Eisen(III)acetyltransferrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AB09 |
Eisen(III)proteinsuccinylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AC |
Eisen dreiwertig, parenterale Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AC01 |
Dextriferron |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AC02 |
Eisen(III)oxid-Saccharose-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AC03 |
Eisen(III)sorbit-Zitronensäure-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AC05 |
Eisen(III)sorbit-Gluconsäure-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AC06 |
Eisen(III)oxid-Dextran-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AC07 |
Eisen(III)-Natrium-Gluconat-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AD |
Eisen in Kombination mit Folsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AD01 |
Eisen-Aminosäure-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AD02 |
Eisen(II)fumarat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AD03 |
Eisen(II)sulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AD04 |
Dextriferron |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AE |
Eisen in anderen Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AE01 |
Eisen, Vitamin-B12 und Folsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AE02 |
Eisen, Multivitamine und Folsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AE03 |
Eisen und Multivitamine |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AE04 |
Eisen, Multivitamine und Mineralstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03AE10 |
Verschiedene Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03B |
Vitamin-B12 und Folsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BA |
Vitamin-B12 (Cyanocobalamin und Analoga) |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BA01 |
Cyanocobalamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BA02 |
Cyanocobalamin-Tannin-Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BA03 |
Hydroxocobalamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BA04 |
Cobamamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BA05 |
Mecobalamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BA51 |
Cyanocobalamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BA53 |
Hydroxocobalamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BB |
Folsäure und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BB01 |
Folsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03BB51 |
Folsäure, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03X |
Andere Antianämika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03XA |
Andere Antianämika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03XA01 |
Erythropoietin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03XA02 |
Darbepoetin alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
B03XA03 |
Methoxy-Polyethylenglycol-Epoetin beta |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05 |
Blutersatzmittel und Perfusionslösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05A |
Blut und verwandte Produkte |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA |
Blutersatzmittel und Plasmaproteinfraktionen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA01 |
Albumin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA02 |
Andere Plasmaproteinfraktionen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA03 |
Fluorocarbon-Blutersatzmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA05 |
Dextran |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA06 |
Gelatine-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA07 |
Hydroxyethylstärke |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA08 |
Hämoglobin crosfumaril |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05AA09 |
Haemoglobin raffimer |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05B |
I.V.-Lösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BA |
Lösungen zur parenteralen Ernährung |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BA01 |
Aminosäuren |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BA02 |
Fett-Emulsionen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BA03 |
Kohlenhydrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BA04 |
Proteinhydrolysate |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BA10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BB |
Lösungen mit Wirkung auf den Elektrolythaushalt |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BB01 |
Elektrolyte |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BB02 |
Elektrolyte mit Kohlenhydraten |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BB03 |
Trometamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BC |
Osmodiuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BC01 |
Mannitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05BC02 |
Harnstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05C |
Spüllösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA |
Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA01 |
Cetylpyridinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA02 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA03 |
Nitrofural |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA04 |
Sulfamethizol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA05 |
Taurolidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA06 |
Mandelsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA07 |
Noxytiolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA08 |
Ethacridinlactat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA09 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CA10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CB |
Salzlösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CB01 |
Natriumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CB02 |
Natriumcitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CB03 |
Magnesiumcitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CB04 |
Natriumbicarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CB10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CX |
Andere Spüllösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CX01 |
Glucose |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CX02 |
Sorbitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CX03 |
Glycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CX04 |
Mannitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05CX10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05D |
LÖSUNGEN ZUR PERITONEALDIALYSE |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05DA |
Isotone Lösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05DB |
Hypertone Lösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05X |
ADDITIVA ZU I.V.-LÖSUNGEN |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA |
Elektrolytlösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA01 |
Kaliumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA02 |
Natriumbicarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA03 |
Natriumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA04 |
Ammoniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA05 |
Magnesiumsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA06 |
Kaliumphosphat, inkl. Kombinationen mit anderen Kaliumsalzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA07 |
Calciumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA08 |
Natriumacetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA09 |
Natriumphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA10 |
Magnesiumphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA11 |
Magnesiumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA12 |
Zinkchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA13 |
Salzsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA14 |
Dinatrium-1-glycerinphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA15 |
Kaliumlactat |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA16 |
Kardioplege Lösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA30 |
Kombinationen von Elektrolyten |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XA31 |
Elektrolyte in Kombination mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XB |
Aminosäuren |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XB01 |
Argininhydrochlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XB02 |
Alanylglutamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XB03 |
Lysin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XC |
Vitamine |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XX |
Andere Additiva zu i.v.-Lösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05XX02 |
Trometamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05Z |
Hämodialysekonzentrate und Hämofiltrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05ZA |
Hämodialysekonzentrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
B05ZB |
Hämofiltrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06 |
Andere Hämatologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06A |
Andere Hämatologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AA |
Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AA02 |
Fibrinolysin und Desoxyribonuclease |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AA03 |
Hyaluronidase |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AA04 |
Chymotrypsin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AA07 |
Trypsin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AA10 |
Desoxyribonuclease |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AA11 |
Bromelaine |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AA55 |
Streptokinase, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AB |
Andere Hämprodukte |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AB01 |
Hematin |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AC01 |
C1-Inhibitor, plasma derived |
2.16.840.1.113883.6.73 |
|
| 0-L |
B06AC04 |
Conestat alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
C |
Kardiovaskuläres System |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01 |
Herztherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01A |
Herzglykoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA |
Digitalisglykoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA01 |
Acetyldigitoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA02 |
Acetyldigoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA03 |
Digitalisblätter |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA04 |
Digitoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA05 |
Digoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA06 |
Lanatosid C |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA07 |
Deslanosid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA08 |
Metildigoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA09 |
Gitoformat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AA52 |
Acetyldigoxin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AB |
Scillaglykoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AB01 |
Proscillaridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AB51 |
Proscillaridin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AC |
Strophanthusglykoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AC01 |
g-Strophanthin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AC03 |
Cymarin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AX |
Andere Herzglykoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01AX02 |
Peruvosid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01B |
Antiarrhythmika, Klasse I und III |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA |
Antiarrhythmika, Klasse Ia |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA01 |
Chinidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA02 |
Procainamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA03 |
Disopyramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA04 |
Spartein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA05 |
Ajmalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA08 |
Prajmalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA12 |
Lorajmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA51 |
Chinidin, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BA71 |
Chinidin, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BB |
Antiarrhythmika, Klasse Ib |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BB01 |
Lidocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BB02 |
Mexiletin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BB03 |
Tocainid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BB04 |
Aprindin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BC |
Antiarrhythmika, Klasse Ic |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BC03 |
Propafenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BC04 |
Flecainid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BC07 |
Lorcainid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BC08 |
Encainid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BD |
Antiarrhythmika, Klasse III |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BD01 |
Amiodaron |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BD02 |
Bretyliumtosilat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BD03 |
Bunaftin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BD04 |
Dofetilid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BD05 |
Ibutilid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BG |
Andere Klasse-I-Antiarrhythmika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BG01 |
Moracizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BG07 |
Cibenzolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01BG11 |
Vernakalant |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01C |
Kardiostimulanzien, Exkl. Herzglykoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA |
Adrenerge und dopaminerge Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA01 |
Etilefrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA02 |
Isoprenalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA03 |
Norepinephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA04 |
Dopamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA05 |
Norfenefrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA06 |
Phenylephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA07 |
Dobutamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA08 |
Oxedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA09 |
Metaraminol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA10 |
Methoxamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA11 |
Mephentermin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA12 |
Dimetofrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA13 |
Prenalterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA14 |
Dopexamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA15 |
Gepefrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA16 |
Ibopamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA17 |
Midodrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA18 |
Octopamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA19 |
Fenoldopam |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA21 |
Cafedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA22 |
Arbutamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA23 |
Theodrenalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA24 |
Epinephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA26 |
Ephedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CA51 |
Etilefrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CE |
Phosphodiesterasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CE01 |
Amrinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CE02 |
Milrinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CE03 |
Enoximon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CE04 |
Bucladesin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CX |
Andere Kardiostimulanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CX06 |
Angiotensinamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CX07 |
Xamoterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01CX08 |
Levosimendan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01D |
Bei Herzerkrankungen Eingesetzte Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA |
Organische Nitrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA02 |
Glyceroltrinitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA04 |
Methylpropylpropanedioldinitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA05 |
Pentaerythrityltetranitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA07 |
Propatylnitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA08 |
Isosorbiddinitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA09 |
Trolnitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA13 |
Erythrityltetranitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA14 |
Isosorbidmononitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA20 |
Organische Nitrate in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA38 |
Tenitramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA52 |
Glyceroltrinitrat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA54 |
Methylpropylpropanedioldinitrat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA55 |
Pentaerythrityltetranitrat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA57 |
Propatylnitrat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA58 |
Isosorbiddinitrat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA59 |
Trolnitrat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA63 |
Erythrityltetranitrat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DA70 |
Organische Nitrate in Kombination mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DB |
Chinolon-Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DB01 |
Flosequinan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX |
Andere bei Herzerkrankungen eingesetzte Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX01 |
Itramintosilat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX02 |
Prenylamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX03 |
Oxyfedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX04 |
Benziodaron |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX05 |
Carbocromen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX06 |
Hexobendin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX07 |
Etafenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX08 |
Heptaminol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX09 |
Imolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX10 |
Dilazep |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX11 |
Trapidil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX12 |
Molsidomin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX13 |
Efloxat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX14 |
Cinepazet |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX15 |
Cloridarol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX16 |
Nicorandil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX18 |
Linsidomin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX19 |
Nesiritid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX51 |
Itramintosilat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX52 |
Prenylamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX53 |
Oxyfedrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01DX54 |
Benziodaron, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01E |
Andere Herzmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EA |
Prostaglandine |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EA01 |
Alprostadil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB |
Andere Herzmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB02 |
Campher |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB03 |
Indometacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB04 |
Crataegus-Glykoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB05 |
Creatinolfosfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB06 |
Fosfocreatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB07 |
Fructose-1,6-diphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB09 |
Ubidecarenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB10 |
Adenosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB11 |
Tiracizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB12 |
Tedisamil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB13 |
Acadesin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB15 |
Trimetazidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB16 |
Ibuprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB17 |
Ivabradin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB18 |
Ranolazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EB21 |
Regadenoson |
2.16.840.1.113883.6.73 |
|
| 0-L |
C01EX |
Andere Herzmittel, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02 |
Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02A |
Antiadrenerge Mittel, zentral wirkend |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA |
Rauwolfia-Alkaloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA01 |
Rescinnamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA02 |
Reserpin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA03 |
Kombinationen von Rauwolfia-Alkaloiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA04 |
Rauwolfia-Alkaloide, ganze Wurzel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA05 |
Deserpidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA06 |
Methoserpidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA07 |
Bietaserpin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA52 |
Reserpin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA53 |
Kombinationen von Rauwolfia-Alkaloiden, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AA57 |
Bietaserpin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AB |
Methyldopa |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AB01 |
Methyldopa (linksdrehend) |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AB02 |
Methyldopa (racemisch) |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AC |
Imidazolin-Rezeptoragonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AC01 |
Clonidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AC02 |
Guanfacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AC04 |
Tolonidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AC05 |
Moxonidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02AC06 |
Rilmenidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02B |
Antiadrenerge Mittel, Ganglienblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02BA |
Sulfonium-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02BA01 |
Trimetaphan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02BB |
Sekundäre und tertiäre Amine |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02BB01 |
Mecamylamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02BC |
Bisquartäre Ammonium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02C |
Antiadrenerge Mittel, peripher wirkend |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CA |
Alpha-Adrenorezeptor-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CA01 |
Prazosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CA02 |
Indoramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CA03 |
Trimazosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CA04 |
Doxazosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CA06 |
Urapidil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CC |
Guanidin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CC01 |
Betanidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CC02 |
Guanethidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CC03 |
Guanoxan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CC04 |
Debrisoquin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CC05 |
Guanoclor |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CC06 |
Guanazodin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02CC07 |
Guanoxabenz |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02D |
mittel mit Wirkung auf die arterielle Gefässmuskulatur |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DA |
Thiazid-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DA01 |
Diazoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DB |
Hydrazinophthalazin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DB01 |
Dihydralazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DB02 |
Hydralazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DB03 |
Endralazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DB04 |
Cadralazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DC |
Pyrimidin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DC01 |
Minoxidil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DD |
Nitroferrocyanid-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DD01 |
Nitroprussid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DF |
Non-thiazide sulfonamides |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DG |
Guanidin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02DG01 |
Pinacidil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02K |
Andere Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KA |
Alkaloide, exkl. Rauwolfia |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KA01 |
Veratrum |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KB |
Tyrosinhydroxylasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KB01 |
Metirosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KC |
MAO-Hemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KC01 |
Pargylin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KD |
Serotonin-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KD01 |
Ketanserin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KX |
Andere Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KX01 |
Bosentan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KX02 |
Ambrisentan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02KX03 |
Sitaxentan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02L |
Antihypertonika und Diuretika in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA |
Rauwolfia-Alkaloide und Diuretika in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA01 |
Reserpin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA02 |
Rescinnamin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA03 |
Deserpidin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA04 |
Methoserpidin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA07 |
Bietaserpin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA08 |
Rauwolfia-Alkaloide, ganze Wurzel und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA09 |
Syrosingopin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA50 |
Kombinationen von Rauwolfia-Alkaloiden und Diuretika inkl. andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA51 |
Reserpin und Diuretika, Kombinationen mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA52 |
Rescinnamin und Diuretika, Kombinationen mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LA71 |
Reserpin und Diuretika, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LB |
Methyldopa und Diuretika in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LB01 |
Methyldopa (linksdrehend) und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LC |
Imidazolin-Rezeptoragonisten in Kombination mit Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LC01 |
Clonidin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LC05 |
Moxonidin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LC51 |
Clonidin und Diuretika, Kombinationen mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LE |
Alpha-Adrenorezeptor-Antagonisten und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LE01 |
Prazosin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LF |
Guanidin-Derivate und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LF01 |
Guanethidin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LG |
Hydrazinophthalazin-Derivate und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LG01 |
Dihydralazin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LG02 |
Hydralazin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LG03 |
Picodralazin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LG51 |
Dihydralazin und Diuretika, Kombinationen mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LG73 |
Picodralazin und Diuretika, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LI |
Calcium channel blockers and diuretics |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LK |
Alkaloide, exkl. Rauwolfia, in Kombination mit Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LK01 |
Veratrum und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LL |
MAO-Hemmer und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LL01 |
Pargylin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LN |
Serotonin-Antagonisten und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LX |
Andere Antihypertonika und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02LX01 |
Pinacidil und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C02N |
Kombinationen von antihypertensiven Wirkstoffen aus ATC-Gruppe C02 |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03 |
Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03A |
Low-Ceiling-Diuretika, Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA |
Thiazide, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA01 |
Bendroflumethiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA02 |
Hydroflumethiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA03 |
Hydrochlorothiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA04 |
Chlorothiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA05 |
Polythiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA06 |
Trichlormethiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA07 |
Cyclopenthiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA08 |
Methylclothiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA09 |
Cyclothiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AA13 |
Mebutizid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB |
Thiazide und Kalium in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB01 |
Bendroflumethiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB02 |
Hydroflumethiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB03 |
Hydrochlorothiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB04 |
Chlorothiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB05 |
Polythiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB06 |
Trichlormethiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB07 |
Cyclopenthiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB08 |
Methylclothiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AB09 |
Cyclothiazid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AH |
Thiazide, Kombinationen mit Psycholeptika und/oder Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AH01 |
Chlorothiazid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AH02 |
Hydroflumethiazid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AX |
Thiazide, Kombinationen mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03AX01 |
Hydrochlorothiazid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03B |
Low-Ceiling-Diuretika, exkl. Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA |
Sulfonamide, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA02 |
Quinethazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA03 |
Clopamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA04 |
Chlortalidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA05 |
Mefrusid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA07 |
Clofenamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA08 |
Metolazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA09 |
Meticran |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA10 |
Xipamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA11 |
Indapamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA12 |
Clorexolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA13 |
Fenquizon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BA82 |
Clorexolon, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BB |
Sulfonamide und Kalium in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BB02 |
Quinethazon und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BB03 |
Clopamid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BB04 |
Chlortalidon und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BB05 |
Mefrusid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BB07 |
Clofenamid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BC |
Quecksilber-haltige Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BC01 |
Mersalyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BD |
Xanthin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BD01 |
Theobromin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BK |
Sulfonamide, Kombinationen mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BX |
Andere Low-ceiling-Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03BX03 |
Cicletanin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03C |
High-Ceiling-Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CA |
Sulfonamide, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CA01 |
Furosemid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CA02 |
Bumetanid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CA03 |
Piretanid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CA04 |
Torasemid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CB |
Sulfonamide und Kalium in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CB01 |
Furosemid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CB02 |
Bumetanid und Kalium |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CC |
Aryloxyessigsäure-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CC01 |
Etacrynsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CC02 |
Tienilinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CD |
Pyrazolon-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CD01 |
Muzolimin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CX |
Andere High-ceiling-Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03CX01 |
Etozolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03D |
Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03DA |
Aldosteron-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03DA01 |
Spironolacton |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03DA02 |
Kaliumcanrenoat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03DA03 |
Canrenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03DA04 |
Eplerenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03DB |
Andere Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03DB01 |
Amilorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03DB02 |
Triamteren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03E |
Diuretika und Kalium sparende Mittel in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA |
Low-ceiling-Diuretika und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA01 |
Hydrochlorothiazid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA02 |
Trichlormethiazid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA03 |
Epitizid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA04 |
Altizid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA05 |
Mebutizid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA06 |
Chlortalidon und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA07 |
Cyclopenthiazid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA12 |
Metolazon und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA13 |
Bendroflumethiazid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EA14 |
Butizid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EB |
High-ceiling-Diuretika und Kalium sparende Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EB01 |
Furosemid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C03EB02 |
Bumetanid und Kalium sparende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04 |
Periphere Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04A |
Periphere Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AA |
2-Amino-1-phenylethanol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AA01 |
Isoxsuprin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AA02 |
Buphenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AA31 |
Bamethan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AB |
Imidazolin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AB01 |
Phentolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AB02 |
Tolazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AC |
Nicotinsäure und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AC01 |
Nicotinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AC02 |
Nicotinylalkohol (Pyridylcarbinol) |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AC03 |
Inositolnicotinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AC07 |
Ciclonicat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AD |
Purin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AD01 |
Pentifyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AD02 |
Xantinolnicotinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AD03 |
Pentoxifyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AD04 |
Etofyllinnicotinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AE |
Mutterkorn-Alkaloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AE01 |
Ergoloidmesylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AE02 |
Nicergolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AE04 |
Dihydroergocristin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AE51 |
Ergoloidmesylat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AE54 |
Dihydroergocristin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AF |
Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AF01 |
Kallidinogenase |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX |
Andere periphere Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX01 |
Cyclandelat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX02 |
Phenoxybenzamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX07 |
Vincamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX10 |
Moxisylyt |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX11 |
Bencyclan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX17 |
Vinburnin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX19 |
Suloctidil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX20 |
Buflomedil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX21 |
Naftidrofuryl |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX23 |
Butalamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX24 |
Visnadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX26 |
Cetiedil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX27 |
Cinepazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX28 |
Ifenprodil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX30 |
Azapetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C04AX32 |
Fasudil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05 |
Vasoprotektoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05A |
Hämorrhoidenmittel zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA |
Corticosteroid-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA01 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA04 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA05 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA06 |
Fluorometholon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA08 |
Fluocortolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA09 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA10 |
Fluocinolonacetonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AA11 |
Fluocinonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AB |
Antibiotika-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AD |
Lokalanästhetika-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AD01 |
Lidocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AD02 |
Tetracain |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AD03 |
Benzocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AD04 |
Cinchocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AD05 |
Procain |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AD06 |
Oxetacain |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AD07 |
Pramocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AE01 |
Glyceroltrinitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AX |
Andere Hämorrhoidenmittel zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AX01 |
Aluminium-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AX02 |
Bismutpräparate, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AX03 |
Andere Hämorrhoidenmittel, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AX04 |
Zinkpräparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05AX05 |
Tribenosid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05B |
Antivarikosa |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BA |
Heparine oder Heparinoide zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BA01 |
Heparinoide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BA02 |
Natriumapolat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BA03 |
Heparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BA04 |
Natriumpentosanpolysulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BA51 |
Heparinoid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BA53 |
Heparin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BB |
Sklerosierende Mittel zur lokalen Injektion |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BB01 |
Monoethanolaminoleat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BB02 |
Polidocanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BB03 |
Invertzucker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BB04 |
Natriumtetradecylsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BB05 |
Phenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BB56 |
Glucose, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BX |
Andere sklerosierende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BX01 |
Calciumdobesilat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05BX51 |
Calciumdobesilat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05C |
Kapillarstabilisierende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA |
Bioflavonoide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA01 |
Rutoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA02 |
Monoxerutin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA03 |
Diosmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA04 |
Troxerutin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA05 |
Hidrosmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA51 |
Rutosid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA53 |
Diosmin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CA54 |
Troxerutin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CP02 |
Weinlaubblätter |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CX |
Andere kapillarstabilisierende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C05CX01 |
Tribenosid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07 |
Beta-Adrenorezeptor-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07A |
Beta-Adrenorezeptor-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA |
Beta-Adrenorezeptor-Antagonisten, nichtselektiv |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA01 |
Alprenolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA02 |
Oxprenolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA03 |
Pindolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA05 |
Propranolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA06 |
Timolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA07 |
Sotalol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA12 |
Nadolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA14 |
Mepindolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA15 |
Carteolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA16 |
Tertatolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA17 |
Bopindolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA19 |
Bupranolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA23 |
Penbutolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA27 |
Cloranolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AA57 |
Sotalol, Kombinationspackungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB |
Beta-Adrenorezeptor-Antagonisten, selektiv |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB01 |
Practolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB02 |
Metoprolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB03 |
Atenolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB04 |
Acebutolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB05 |
Betaxolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB06 |
Bevantolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB07 |
Bisoprolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB08 |
Celiprolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB09 |
Esmolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB10 |
Epanolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB11 |
S-Atenolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB12 |
Nebivolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB13 |
Talinolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB52 |
Metoprolol, Kombinationspackungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AB57 |
Bisoprolol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AG |
Alpha- und Beta-Adrenorezeptor-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AG01 |
Labetalol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07AG02 |
Carvedilol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07B |
Beta-Adrenorezeptor-Antagonisten und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BA |
Beta-Adrenorezeptor-Antagonisten, nichtselektiv, und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BA02 |
Oxprenolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BA05 |
Propranolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BA06 |
Timolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BA07 |
Sotalol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BA12 |
Nadolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BA68 |
Metipranolol und Thiazide, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BB |
Beta-Adrenorezeptor-Antagonisten, selektiv, und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BB02 |
Metoprolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BB03 |
Atenolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BB04 |
Acebutolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BB06 |
Bevantolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BB07 |
Bisoprolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BB12 |
Nebivolol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BB52 |
Metoprolol und Thiazide, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BG |
Alpha- und Beta-Adrenorezeptor-Antagonisten und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07BG01 |
Labetalol und Thiazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07C |
Beta-Adrenorezeptor-Antagonisten und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CA |
Beta-Adrenorezeptor-Antagonisten, nichtselektiv, und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CA02 |
Oxprenolol und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CA03 |
Pindolol und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CA17 |
Bopindolol und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CA23 |
Penbutolol und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CB |
Beta-Adrenorezeptor-Antagonisten, selektiv, und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CB02 |
Metoprolol und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CB03 |
Atenolol und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CB53 |
Atenolol und andere Diuretika, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CG |
Alpha- und Beta-Adrenorezeptor-Antagonisten und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07CG01 |
Labetalol und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07D |
Beta-Adrenorezeptor-Antagonisten, Thiazide und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07DA |
Beta-Adrenorezeptor-Antagonisten, nichtselektiv, Thiazide und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07DA06 |
Timolol, Thiazide und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07DB |
Beta-Adrenorezeptor-Antagonisten, selektiv, Thiazide und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07DB01 |
Atenolol, Thiazide und andere Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07E |
Beta-Adrenorezeptor-Antagonisten und Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07EA |
Beta-Adrenorezeptor-Antagonisten, nichtselektiv, und Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07EB |
Beta-Adrenorezeptor-Antagonisten, selektiv, und Vasodilatatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07F |
Beta-Adrenorezeptor-Antagonisten und andere Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07FA |
Beta-Adrenorezeptor-Antagonisten, nichtselektiv, und andere Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07FA05 |
Propranolol und andere Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07FB |
Beta-Adrenorezeptor-Antagonisten, selektiv, und andere Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07FB02 |
Metoprolol und andere Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C07FB03 |
Atenolol und andere Antihypertonika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08 |
Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08C |
Selektive Calciumkanalblocker mit vorwiegender Gefässwirkung |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA |
Dihydropyridin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA01 |
Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA02 |
Felodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA03 |
Isradipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA04 |
Nicardipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA05 |
Nifedipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA06 |
Nimodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA07 |
Nisoldipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA08 |
Nitrendipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA09 |
Lacidipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA10 |
Nilvadipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA11 |
Manidipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA12 |
Barnidipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA13 |
Lercanidipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA14 |
Cilnidipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA15 |
Benidipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA16 |
Clevidipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CA55 |
Nifedipin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CX |
Andere selektive Calciumkanalblocker mit vorwiegender Gefässwirkung |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08CX01 |
Mibefradil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08D |
Selektive Calciumkanalblocker mit direkter Herzwirkung |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08DA |
Phenylalkylamin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08DA01 |
Verapamil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08DA02 |
Gallopamil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08DA51 |
Verapamil, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08DB |
Benzothiazepin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08DB01 |
Diltiazem |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08E |
Nichtselektive Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08EA |
Phenylalkylamin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08EA01 |
Fendilin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08EA02 |
Bepridil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08EX |
Andere nichtselektive Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08EX01 |
Lidoflazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08EX02 |
Perhexilin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08G |
Calciumkanalblocker und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08GA |
Calciumkanalblocker und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C08GA01 |
Nifedipin und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09 |
Mittel mit Wirkung auf das Renin-Angiotensin-System |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09A |
ACE-Hemmer, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA |
ACE-Hemmer, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA01 |
Captopril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA02 |
Enalapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA03 |
Lisinopril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA04 |
Perindopril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA05 |
Ramipril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA06 |
Quinapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA07 |
Benazepril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA08 |
Cilazapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA09 |
Fosinopril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA10 |
Trandolapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA11 |
Spirapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA12 |
Delapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA13 |
Moexipril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA14 |
Temocapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA15 |
Zofenopril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09AA16 |
Imidapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09B |
ACE-Hemmer, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA |
ACE-Hemmer und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA01 |
Captopril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA02 |
Enalapril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA03 |
Lisinopril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA04 |
Perindopril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA05 |
Ramipril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA06 |
Quinapril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA07 |
Benazepril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA08 |
Cilazapril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA09 |
Fosinopril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA12 |
Delapril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA13 |
Moexipril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BA15 |
Zofenopril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BB |
ACE-Hemmer und Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BB02 |
Enalapril und Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BB03 |
Lisinopril und Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BB04 |
Perindopril und Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BB05 |
Ramipril und Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BB07 |
Ramipril und Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BB10 |
Trandolapril und Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09BB12 |
Delapril und Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09C |
Angiotensin-Ii-Antagonisten, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA |
Angiotensin-II-Antagonisten, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA01 |
Losartan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA02 |
Eprosartan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA03 |
Valsartan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA04 |
Irbesartan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA05 |
Tasosartan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA06 |
Candesartan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA07 |
Telmisartan |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09CA08 |
Olmesartan medoxomil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09D |
Angiotensin-II-Antagonisten, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DA |
Angiotensin-II-Antagonisten und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DA01 |
Losartan und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DA02 |
Eprosartan und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DA03 |
Valsartan und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DA04 |
Irbesartan und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DA06 |
Candesartan und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DA07 |
Telmisartan und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DA08 |
Olmesartan medoxomil und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DB |
Angiotensin-II-Antagonisten und Calciumkanalblocker |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DB01 |
Valsartan und Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DB02 |
Olmesartanmedoxomil und Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DB04 |
Telmisartan/Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DX01 |
Valsartan, Amlodipin und Hydrochlorothiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09DX03 |
Olmesartan medoxomil, Amlodipin und Hydrochlorothiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09X |
Andere Mittel mit Wirkung auf das Renin-Angiotensin-System |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09XA |
Renin-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09XA01 |
Remikiren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09XA02 |
Aliskiren |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09XA52 |
Aliskiren und Hydrochlorothiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09XA53 |
Aliskiren und Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C09XA54 |
Aliskiren, Amlodipin und Hydrochlorothiazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10 |
Mittel, die den Lipidstoffwechsel beeinflussen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10A |
Mittel, die den Lipidstoffwechsel beeinflussen, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA |
HMG-CoA-Reduktasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA01 |
Simvastatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA02 |
Lovastatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA03 |
Pravastatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA04 |
Fluvastatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA05 |
Atorvastatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA06 |
Cerivastatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA07 |
Rosuvastatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AA08 |
Pitavastatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB |
Fibrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB01 |
Clofibrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB02 |
Bezafibrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB03 |
Aluminiumclofibrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB04 |
Gemfibrozil |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB05 |
Fenofibrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB06 |
Simfibrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB07 |
Ronifibrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB08 |
Ciprofibrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB09 |
Etofibrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AB10 |
Clofibrid |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AC |
Gallensäure bindende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AC01 |
Colestyramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AC02 |
Colestipol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AC03 |
Colextran |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AC04 |
Colesevelam |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AD |
Nicotinsäure und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AD01 |
Niceritrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AD02 |
Nicotinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AD03 |
Nicofuranose |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AD04 |
Aluminiumnicotinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AD05 |
Nicotinylalkohol (Pyridylcarbinol) |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AD06 |
Acipimox |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AD52 |
Nicotinsäure, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX |
Andere Mittel, die den Lipidstoffwechsel beeinflussen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX01 |
Dextrothyroxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX02 |
Probucol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX03 |
Tiadenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX04 |
Benfluorex |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX05 |
Meglutol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX06 |
Omega-3-triglyceride |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX07 |
Magnesiumpyridoxal-5-phosphatglutamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX08 |
Policosanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10AX09 |
Ezetimib |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10B |
Mittel, die den Lipidstoffwechsel beeinflussen, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10BA |
HMG-CoA-Reduktasehemmer in Kombination mit anderen Mitteln, die den Lipidstoffwechsel
beeinflussen
|
2.16.840.1.113883.6.73 |
|
| 0-L |
C10BA01 |
Lovastatin und Nicotinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10BA02 |
Simvastatin und Ezetimib |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10BA05 |
Atorvastatin und Ezetimib |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10BX |
HMG-CoA-Reduktasehemmer, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10BX01 |
Simvastatin und Acetylsalicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10BX02 |
Pravastatin und Acetylsalicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
C10BX03 |
Atorvastatin und Amlodipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D |
Dermatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01 |
Antimykotika zur dermatologischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01A |
Antimykotika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA |
Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA01 |
Nystatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA02 |
Natamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA03 |
Hachimycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA04 |
Pecilocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA06 |
Mepartricin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA07 |
Pyrrolnitrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA08 |
Griseofulvin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AA20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC |
Imidazol- und Triazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC01 |
Clotrimazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC02 |
Miconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC03 |
Econazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC04 |
Chlormidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC05 |
Isoconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC06 |
Tiabendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC07 |
Tioconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC08 |
Ketoconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC09 |
Sulconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC10 |
Bifonazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC11 |
Oxiconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC12 |
Fenticonazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC13 |
Omoconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC14 |
Sertaconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC15 |
Fluconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC16 |
Flutrimazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC52 |
Miconazol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AC60 |
Bifonazol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE |
Andere Antimykotika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE01 |
Bromchlorsalicylanilid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE02 |
Methylrosanilin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE03 |
Tribrommetacresol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE04 |
Undecylensäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE05 |
Polynoxylin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE06 |
2-(4-chlorphenoxy)-ethanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE07 |
Chlorphenesin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE08 |
Ticlaton |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE09 |
Sulbentin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE10 |
Ethylhydroxybenzoat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE11 |
Haloprogin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE12 |
Salicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE13 |
Selendisulfid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE14 |
Ciclopirox |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE15 |
Terbinafin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE16 |
Amorolfin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE17 |
Dimazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE18 |
Tolnaftat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE19 |
Tolciclat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE21 |
Flucytosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE22 |
Naftifin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE23 |
Butenafin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01AE54 |
Undecylensäure, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01B |
Antimykotika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01BA |
Antimykotika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01BA01 |
Griseofulvin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D01BA02 |
Terbinafin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02 |
Emollientia und Hautschutzmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02A |
Emollientia und Hautschutzmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AA |
Silikon-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AB |
Zink-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AC |
Vaseline und Fett-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AD |
Flüssige Pflaster |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AE |
Harnstoff-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AE01 |
Harnstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AE51 |
Harnstoff, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AF |
Salicylsäure-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02AX |
Andere Emollientia und Hautschutzmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02B |
Protektiva gegen UV-Strahlung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02BA |
Protektiva gegen UV-Strahlung zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02BA01 |
Aminobenzoesäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02BA02 |
Octinoxat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02BB |
Protektiva gegen UV-Strahlung zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D02BB01 |
Betacaroten |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03 |
Zubereitungen zur Behandlung von Wunden und Geschwüren |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03A |
Wundbehandlungsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AA |
Lebertransalben |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX |
Andere Wundbehandlungsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX01 |
Cadexomer-Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX02 |
Dextranomer |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX03 |
Dexpanthenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX04 |
Calciumpantothenat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX05 |
Hyaluronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX06 |
Becaplermin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX07 |
Glyceroltrinitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX08 |
Isosorbiddinitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX09 |
Crilanomer |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03AX10 |
Enoxolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03B |
Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03BA |
Proteolytische Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03BA01 |
Trypsin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03BA02 |
Clostridiopeptidase |
2.16.840.1.113883.6.73 |
|
| 0-L |
D03BA52 |
Clostridiopeptidase, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04 |
Antipruriginosa, inkl. Antihistaminika, Anästhetika etc. |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04A |
Antipruriginosa, inkl. Antihistaminika, Anästhetika etc. |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA |
Antihistaminika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA01 |
Thonzylamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA02 |
Mepyramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA03 |
Thenalidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA04 |
Tripelennamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA09 |
Chloropyramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA10 |
Promethazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA12 |
Tolpropamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA13 |
Dimetinden |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA14 |
Clemastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA15 |
Bamipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA22 |
Isothipendyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA32 |
Diphenhydramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA33 |
Diphenhydraminmethylbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AA34 |
Chlorphenoxamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AB |
Lokalanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AB01 |
Lidocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AB02 |
Cinchocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AB03 |
Oxybuprocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AB04 |
Benzocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AB05 |
Chinisocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AB06 |
Tetracain |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AB07 |
Pramocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
D04AX |
Andere Antipruriginosa |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05 |
Antipsoriatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05A |
Antipsoriatika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AA |
Teere |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AC |
Anthracen-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AC01 |
Dithranol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AC51 |
Dithranol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AD |
Psoralene zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AD01 |
Trioxysalen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AD02 |
Methoxsalen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AX |
Andere Antipsoriatika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AX01 |
Fumarsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AX02 |
Calcipotriol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AX03 |
Calcitriol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AX04 |
Tacalcitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AX05 |
Tazaroten |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05AX52 |
Calcipotriol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05B |
Antipsoriatika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BA |
Psoralene zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BA01 |
Trioxysalen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BA02 |
Methoxsalen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BA03 |
Bergapten |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BB |
Retinoide zur Behandlung der Psoriasis |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BB01 |
Etretinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BB02 |
Acitretin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BX |
Andere Antipsoriatika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D05BX51 |
Fumarsäure-Derivate, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06 |
Antibiotika und Chemotherapeutika zur Dermatologischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06A |
Antibiotika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AA |
Tetracyclin und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AA01 |
Demeclocyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AA02 |
Chlortetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AA03 |
Oxytetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AA04 |
Tetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX |
Andere Antibiotika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX01 |
Fusidinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX02 |
Chloramphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX04 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX05 |
Bacitracin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX07 |
Gentamicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX08 |
Tyrothricin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX09 |
Mupirocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX10 |
Virginiamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX11 |
Rifaximin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX12 |
Amikacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06AX13 |
Retapamulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06B |
Chemotherapeutika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BA |
Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BA01 |
Sulfadiazin-Silber |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BA02 |
Sulfathiazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BA03 |
Mafenid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BA04 |
Sulfamethizol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BA05 |
Sulfanilamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BA06 |
Sulfamerazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BA51 |
Sulfadiazin-Silber, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB |
Antivirale Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB01 |
Idoxuridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB02 |
Tromantadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB03 |
Aciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB04 |
Podophyllotoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB05 |
Inosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB06 |
Penciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB07 |
Lysozym |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB08 |
Ibacitabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB09 |
Edoxudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB10 |
Imiquimod |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB11 |
Docosanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BB53 |
Aciclovir, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BX |
Andere Chemotherapeutika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06BX01 |
Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D06C |
Antibiotika und Chemotherapeutika, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07 |
Corticosteroide, Dermatologische Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07A |
Corticosteroide, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AA |
Corticosteroide, schwach wirksam (Gruppe I) |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AA01 |
Methylprednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AA02 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AA03 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB |
Corticosteroide, mittelstark wirksam (Gruppe II) |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB01 |
Clobetason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB02 |
Hydrocortisonbutyrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB03 |
Flumetason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB04 |
Fluocortin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB05 |
Fluperolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB06 |
Fluorometholon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB07 |
Flupredniden |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB08 |
Desonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB09 |
Triamcinolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB10 |
Alclometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB11 |
Hydrocortisonbuteprat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB19 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB21 |
Clocortolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AB30 |
Kombinationen mittelstark wirksamer Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC |
Corticosteroide, stark wirksam (Gruppe III) |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC01 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC02 |
Fluclorolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC03 |
Desoximetason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC04 |
Fluocinolonacetonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC05 |
Fluocortolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC06 |
Diflucortolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC07 |
Fludroxycortid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC08 |
Fluocinonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC09 |
Budesonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC10 |
Diflorason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC11 |
Amcinonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC12 |
Halometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC13 |
Mometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC14 |
Methylprednisolonaceponat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC15 |
Beclometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC16 |
Hydrocortisonaceponat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC17 |
Fluticason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC18 |
Prednicarbat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC19 |
Difluprednat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AC21 |
Ulobetasol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AD |
Corticosteroide, sehr stark wirksam (Gruppe IV) |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AD01 |
Clobetasol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07AD02 |
Halcinonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07B |
Corticosteroide, Kombinationen mit Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BA |
Corticosteroide, schwach wirksam, Kombinationen mit Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BA01 |
Prednisolon und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BA04 |
Hydrocortison und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BB |
Corticosteroide, mittelstark wirksam, Kombinationen mit Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BB01 |
Flumetason und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BB02 |
Desonid und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BB03 |
Triamcinolon und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BB04 |
Hydrocortisonbutyrat und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BC |
Corticosteroide, stark wirksam, Kombinationen mit Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BC01 |
Betamethason und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BC02 |
Fluocinolonacetonid und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BC03 |
Fluocortolon und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BC04 |
Diflucortolon und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07BD |
Corticosteroide, sehr stark wirksam, Kombinationen mit Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07C |
Corticosteroide, Kombinationen mit Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CA |
Corticosteroide, schwach wirksam, Kombinationen mit Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CA01 |
Hydrocortison und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CA02 |
Methylprednisolon und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CA03 |
Prednisolon und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CB |
Corticosteroide, mittelstark wirksam, Kombinationen mit Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CB01 |
Triamcinolon und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CB02 |
Flupredniden und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CB03 |
Fluorometholon und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CB04 |
Dexamethason und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CB05 |
Flumetason und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CC |
Corticosteroide, stark wirksam, Kombinationen mit Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CC01 |
Betamethason und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CC02 |
Fluocinolonacetonid und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CC03 |
Fludroxycortid und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CC04 |
Beclometason und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CC05 |
Fluocinonid und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CC06 |
Fluocortolon und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CD |
Corticosteroide, sehr stark wirksam, Kombinationen mit Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07CD01 |
Clobetasol und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07X |
Corticosteroide, Andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XA |
Corticosteroide, schwach wirksam, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XA01 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XA02 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XB |
Corticosteroide, mittelstark wirksam, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XB01 |
Flumetason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XB02 |
Triamcinolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XB03 |
Flupredniden |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XB04 |
Fluorometholon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XB05 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XB30 |
Kombinationen mittelstark wirksamer Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XC |
Corticosteroide, stark wirksam, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XC01 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XC02 |
Desoximetason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XC03 |
Mometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XC04 |
Diflucortolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D07XD |
Corticosteroide, sehr stark wirksam, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08 |
Antiseptika und Desinfektionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08A |
Antiseptika und Desinfektionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AA |
Acridin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AA01 |
Ethacridinlactat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AA02 |
Aminoacridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AA03 |
Euflavin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AB |
Aluminium-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AC |
Biguanide und Amidine |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AC01 |
Dibrompropamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AC02 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AC03 |
Propamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AC04 |
Hexamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AC05 |
Polihexanid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AC52 |
Chlorhexidin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AD |
Borsäure-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AE |
Phenol und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AE01 |
Hexachlorophen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AE02 |
Policresulen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AE03 |
Phenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AE04 |
Triclosan |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AE05 |
Chloroxylenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AE06 |
Biphenylol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AF |
Nitrofuran-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AF01 |
Nitrofural |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AG |
Iod-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AG01 |
Iodoctylphenoxypolyglycolether |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AG02 |
Povidon-Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AG03 |
Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AG04 |
Diiodhydroxypropan |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AH |
Chinolin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AH01 |
Dequalinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AH02 |
Chlorquinaldol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AH03 |
Oxichinolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AH30 |
Clioquinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ |
Quartäre Ammonium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ01 |
Benzalkonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ02 |
Cetrimonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ03 |
Cetylpyridinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ04 |
Cetrimid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ05 |
Benzoxoniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ06 |
Didecyldimethylammoniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ57 |
Octenidin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ58 |
Benzethoniumchlorid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AJ59 |
Dodecloniumbromid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AK |
Quecksilber-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AK01 |
Quecksilberamidochlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AK02 |
Phenylmercuriborat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AK03 |
Quecksilberchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AK04 |
Merbromin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AK05 |
Metallisches Quecksilber |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AK06 |
Thiomersal |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AK30 |
Quecksilberiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AL |
Silber-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AL01 |
Silbernitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AL30 |
Silber |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX |
Andere Antiseptika und Desinfektionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX01 |
Wasserstoffperoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX02 |
Eosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX03 |
Propanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX04 |
Tosylchloramid-Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX05 |
Isopropanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX06 |
Kaliumpermanganat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX07 |
Natriumhypochlorit |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX08 |
Ethanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D08AX53 |
Propanol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09 |
Medizinische Verbände |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09A |
Medizinische Verbände |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA |
Medizinische verbände mit Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA01 |
Framycetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA02 |
Fusidinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA03 |
Nitrofural |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA04 |
Phenylquecksilbernitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA05 |
Benzododecinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA06 |
Triclosan |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA07 |
Cetylpyridinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA08 |
Aluminiumhydroxychlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA09 |
Povidon-Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA10 |
Clioquinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA11 |
Benzalkonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA12 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AA13 |
Iodoform |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AB |
Zink-haltige Verbände |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AB01 |
Zink-haltige Verbände ohne Zusätze |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AB02 |
Zink-haltige Verbände mit Zusätzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D09AX |
Vaselin-haltige Verbände |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10 |
Aknemittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10A |
Aknemittel zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AA |
Corticosteroide, Kombinationen zur Behandlung der Akne |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AA01 |
Fluorometholon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AA02 |
Methylprednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AA03 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AB |
Schwefel-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AB01 |
Bithionol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AB02 |
Schwefel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AB03 |
Tioxolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AB05 |
Mesulfen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD |
Retinoide zur topischen Anwendung bei Akne |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD01 |
Tretinoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD02 |
Retinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD03 |
Adapalen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD04 |
Isotretinoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD05 |
Motretinid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD51 |
Tretinoin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD53 |
Adapalen, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AD54 |
Isotretinoin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AE |
Peroxide |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AE01 |
Benzoylperoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AE51 |
Benzoylperoxid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AF |
Antiinfektiva zur Behandlung der Akne |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AF01 |
Clindamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AF02 |
Erythromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AF03 |
Chloramphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AF04 |
Meclocyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AF51 |
Clindamycin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AF52 |
Erythromycin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AX |
Andere Aknemittel zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AX01 |
Aluminiumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AX02 |
Resorcin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AX03 |
Azelainsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AX04 |
Aluminiumoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10AX30 |
Verschiedene Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10B |
Aknemittel zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10BA |
Retinoide zur Behandlung der Akne |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10BA01 |
Isotretinoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10BX |
Andere Aknemittel zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D10BX01 |
Natriumbituminosulfonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11 |
Andere Dermatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11A |
Andere Dermatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AA |
Antihidrotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AC |
Medizinische Haarwaschmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AC01 |
Cetrimid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AC02 |
Cadmium-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AC03 |
Selen-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AC06 |
Povidon-Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AC08 |
Schwefel-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AC09 |
Xenysalat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AC30 |
Andere |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AE |
Androgene zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AE01 |
Metandienon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AF |
Warzenmittel und Keratolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AH02 |
Pimecrolimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AH04 |
Alitretinoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX |
Andere Dermatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX01 |
Minoxidil |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX02 |
Gamolensäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX03 |
Calciumgluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX04 |
Lithiumsuccinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX05 |
Magnesiumsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX06 |
Mequinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX08 |
Tiratricol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX09 |
Oxaceprol |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX10 |
Finasterid |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX11 |
Hydrochinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX12 |
Pyrithion zink |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX13 |
Monobenzon |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX14 |
Tacrolimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX15 |
Pimecrolimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX16 |
Eflornithin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX17 |
Cromoglicinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX18 |
Diclofenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX19 |
Alitretinoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX52 |
Gamolensäure, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
D11AX57 |
Kollagen, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G |
Urogenitalsystem und Sexualhormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01 |
Gynäkologische Antiinfektiva und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01A |
Antiinfektiva und Antiseptika, exkl. Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA |
Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA01 |
Nystatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA02 |
Natamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA03 |
Amphotericin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA04 |
Candicidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA05 |
Chloramphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA06 |
Hachimycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA07 |
Oxytetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA08 |
Carfecillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA09 |
Mepartricin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA10 |
Clindamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA11 |
Pentamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AA51 |
Nystatin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AB |
Arsen-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AB01 |
Acetarsol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AC |
Chinolin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AC01 |
Diiodhydroxychinolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AC02 |
Clioquinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AC03 |
Chlorquinaldol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AC05 |
Dequalinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AC06 |
Broxychinolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AC30 |
Oxychinolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AD |
Organische Säuren |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AD01 |
Milchsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AD02 |
Essigsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AD03 |
Ascorbinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AE |
Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AE01 |
Sulfatolamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AE10 |
Kombinationen von Sulfonamiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF |
Imidazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF01 |
Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF02 |
Clotrimazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF04 |
Miconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF05 |
Econazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF06 |
Ornidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF07 |
Isoconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF08 |
Tioconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF11 |
Ketoconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF12 |
Fenticonazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF13 |
Azanidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF14 |
Propenidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF15 |
Butoconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF16 |
Omoconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF17 |
Oxiconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF18 |
Flutrimazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AF20 |
Kombinationen von Imidazol-Derivaten |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AG |
Triazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AG02 |
Terconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX |
Andere Antiinfektiva und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX01 |
Clodantoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX02 |
Inosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX03 |
Policresulen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX05 |
Nifuratel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX06 |
Furazolidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX09 |
Methylrosanilin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX11 |
Povidon-Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX12 |
Ciclopirox |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX13 |
Protiofat |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX14 |
Lactobacillus-Ferment |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX15 |
Kupferusnat |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01AX66 |
Octenidin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01B |
Antiinfektiva/Antiseptika in Kombination mit Corticosteroiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01BA |
Antibiotika und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01BC |
Chinolin-Derivate und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01BD |
Antiseptika und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01BE |
Sulfonamide und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
G01BF |
Imidazol-Derivate und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02 |
Andere Gynäkologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02A |
Wehen fördernde Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AB |
Mutterkorn-Alkaloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AB01 |
Methylergometrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AB02 |
Mutterkorn-Alkaloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AB03 |
Ergometrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AC |
Mutterkorn-Alkaloide und Oxytocin inkl. Derivate, in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AC01 |
Methylergometrin und Oxytocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AD |
Prostaglandine |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AD01 |
Dinoprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AD02 |
Dinoproston |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AD03 |
Gemeprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AD04 |
Carboprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AD05 |
Sulproston |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AD06 |
Misoprostol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02AX |
Andere Wehen fördernde Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02B |
Kontrazeptiva zur lokalen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02BA |
Intrauterine Kontrazeptiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02BA01 |
Plastik-IUP |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02BA02 |
Plastik-IUP mit Kupfer |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02BA03 |
Plastik-IUP mit Progesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02BB |
Intravaginale Kontrazeptiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02BB01 |
Vaginalring mit Gestagenen und Estrogenen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02C |
Andere Gynäkologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CA |
Sympathomimetika, Wehen hemmend |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CA01 |
Ritodrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CA02 |
Buphenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CA03 |
Fenoterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CB |
Prolactinhemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CB01 |
Bromocriptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CB02 |
Lisurid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CB03 |
Cabergolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CB04 |
Quinagolid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CB05 |
Metergolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CC |
Antiphlogistika zur vaginalen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CC01 |
Ibuprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CC02 |
Naproxen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CC03 |
Benzydamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CC04 |
Flunoxaprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CX |
Andere Gynäkologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G02CX01 |
Atosiban |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03 |
Sexualhormone und Modulatoren des Genitalsystems |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03A |
Hormonelle Kontrazeptiva zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA |
Gestagene und Estrogene, fixe Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA01 |
Etynodiol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA02 |
Quingestanol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA03 |
Lynestrenol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA04 |
Megestrol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA05 |
Norethisteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA06 |
Norgestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA07 |
Levonorgestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA08 |
Medroxyprogesteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA09 |
Desogestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA10 |
Gestoden und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA11 |
Norgestimat und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA12 |
Drospirenon und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA13 |
Norelgestromin und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA14 |
Nomegestrol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AA15 |
Chlormadinon und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB |
Gestagene und Estrogene, Sequenzialpräparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB01 |
Megestrol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB02 |
Lynestrenol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB03 |
Levonorgestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB04 |
Norethisteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB05 |
Desogestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB06 |
Gestoden und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB07 |
Chlormadinon und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AB08 |
dienogest and estradiol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC |
Gestagene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC01 |
Norethisteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC02 |
Lynestrenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC03 |
Levonorgestrel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC04 |
Quingestanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC05 |
Megestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC06 |
Medroxyprogesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC07 |
Norgestrienon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC08 |
Etonogestrel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AC09 |
Desogestrel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03AD01 |
Levonorgestrel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03B |
Androgene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03BA |
3-Oxoandrosten-4-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03BA01 |
Fluoxymesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03BA02 |
Methyltestosteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03BA03 |
Testosteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03BB |
5-Androstanon-3-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03BB01 |
Mesterolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03BB02 |
Androstanolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03C |
Estrogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA |
Natürliche und halbsynthetische Estrogene, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA01 |
Ethinylestradiol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA03 |
Estradiol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA04 |
Estriol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA06 |
Chlorotrianisen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA07 |
Estron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA09 |
Promestrien |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA53 |
Estradiol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CA57 |
Konjugierte Estrogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CB |
Synthetische Estrogene, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CB01 |
Dienestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CB02 |
Diethylstilbestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CB03 |
Methallenestril |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CB04 |
Moxestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CC |
Estrogene, Kombinationen mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CC02 |
Dienestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CC03 |
Methallenestril |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CC04 |
Estron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CC05 |
Diethylstilbestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CC06 |
Estriol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03CX01 |
Tibolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03D |
Gestagene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DA |
Pregnen-4-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DA01 |
Gestonoron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DA02 |
Medroxyprogesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DA03 |
Hydroxyprogesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DA04 |
Progesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB |
Pregnadien-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB01 |
Dydrogesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB02 |
Megestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB03 |
Medrogeston |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB04 |
Nomegestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB05 |
Demegeston |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB06 |
Chlormadinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB07 |
Promegeston |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DB08 |
Dienogest |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DC |
Estren-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DC01 |
Allylestrenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DC02 |
Norethisteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DC03 |
Lynestrenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DC04 |
Ethisteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DC05 |
Tibolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DC06 |
Etynodiol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03DC31 |
Methylestrenolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03E |
Androgene und weibliche Sexualhormone in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03EA |
Androgene und Estrogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03EA01 |
Methyltestosteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03EA02 |
Testosteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03EA03 |
Prasteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03EB |
Androgen, Gestagen und Estrogen in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03EK |
Androgene und weibliche Sexualhormone in Kombination mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03EK01 |
Methyltestosteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03F |
Gestagene und Estrogene in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA |
Gestagene und Estrogene, fixe Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA01 |
Norethisteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA02 |
Hydroxyprogesteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA03 |
Ethisteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA04 |
Progesteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA05 |
Methylnortestosteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA06 |
Etynodiol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA07 |
Lynestrenol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA08 |
Megestrol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA09 |
Noretynodrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA10 |
Norgestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA11 |
Levonorgestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA12 |
Medroxyprogesteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA13 |
Norgestimat und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA14 |
Dydrogesteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA15 |
Dienogest und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA16 |
Trimegeston und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FA17 |
Drospirenon und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB |
Gestagene und Estrogene, Sequenzialpräparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB01 |
Norgestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB02 |
Lynestrenol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB03 |
Chlormadinon und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB04 |
Megestrol und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB05 |
Norethisteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB06 |
Medroxyprogesteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB07 |
Medrogeston und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB08 |
Dydrogesteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB09 |
Levonorgestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB10 |
Desogestrel und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03FB11 |
Trimegeston und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03G |
Gonadotropine und andere Ovulationsauslöser |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA |
Gonadotropine |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA01 |
Choriongonadotrophin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA02 |
Humanes menopausales Gonadotrophin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA03 |
Serumgonadotrophin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA04 |
Urofollitropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA05 |
Follitropin alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA06 |
Follitropin beta |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA07 |
Lutropin alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA08 |
Choriongonadotropin alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GA09 |
Corifollitropin alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GB |
Ovulationsauslöser, synthetisch |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GB01 |
Cyclofenil |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GB02 |
Clomifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03GB03 |
Epimestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03H |
Antiandrogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03HA |
Antiandrogene, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03HA01 |
Cyproteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03HB |
Antiandrogene und Estrogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03HB01 |
Cyproteron und Estrogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03X |
Andere Sexualhormone und Modulatoren des Genitalsystems |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03XA |
Antigonadotropine und ähnliche Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03XA01 |
Danazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03XA02 |
Gestrinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03XB |
Antigestagene |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03XB01 |
Mifepriston |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03XC |
Selektive Estrogenrezeptor-Modulatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03XC01 |
Raloxifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G03XC02 |
Bazedoxifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04 |
Urologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04A |
Urinary antiseptics and antiinfectives |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04AA |
Methenamine preparations |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04AB |
Quinolone derivatives (excl. J01M) |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04AC |
Nitrofuran derivatives |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04AD |
Salicylates |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04AG |
Other urinary antiseptics and antiinfectives |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04AH |
Sulfonamides in combination with other drugs |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04AK |
Urinary antiseptics and antiinfectives comb., excl. sulfonamides |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04B |
Andere Urologika, inkl. Spasmolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BA |
Harn ansäuernde Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BA01 |
Ammoniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BA03 |
Calciumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BC |
Harnkonkrement lösende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD |
Urologische Spasmolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD01 |
Emepronium |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD02 |
Flavoxat |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD03 |
Meladrazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD04 |
Oxybutynin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD05 |
Terodilin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD06 |
Propiverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD07 |
Tolterodin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD08 |
Solifenacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD09 |
Trospium |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD10 |
Darifenacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BD11 |
Fesoterodin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE |
Mittel bei erektiler Dysfunktion |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE01 |
Alprostadil |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE02 |
Papaverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE03 |
Sildenafil |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE04 |
Yohimbin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE05 |
Phentolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE06 |
Moxisylyt |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE07 |
Apomorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE08 |
Tadalafil |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE09 |
Vardenafil |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BE52 |
Papaverin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BP30 |
Pflanzliche Urologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX |
Andere Urologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX01 |
Magnesiumhydroxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX03 |
Acetohydroxamsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX06 |
Phenazopyridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX10 |
Succinimid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX11 |
Collagen |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX12 |
Phenylsalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX13 |
Dimethylsulfoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04BX14 |
Dapoxetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04C |
Mittel bei Benigner Prostatahyperplasie |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CA |
Alpha-Adrenorezeptor-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CA01 |
Alfuzosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CA02 |
Tamsulosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CA03 |
Terazosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CA04 |
Silodosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CA52 |
Tamsulosin und Dutasterid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CA53 |
Tamsulosin und Solifenacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CB |
Testosteron-5-alfa-Reduktasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CB01 |
Finasterid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CB02 |
Dutasterid |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CX |
Andere Mittel bei benigner Prostatahyperplasie |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CX01 |
Pygeum africanum |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CX02 |
Serenoa repens |
2.16.840.1.113883.6.73 |
|
| 0-L |
G04CX03 |
Mepartricin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H |
Systemische Hormonpräparate, exkl. Sexualhormone und Insuline |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01 |
Hypophysen- und Hypothalamushormone und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01A |
Hypophysenvorderlappenhormone und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AA |
ACTH |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AA01 |
Corticotropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AA02 |
Tetracosactid |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AB |
Thyrotropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AB01 |
Thyrotropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AC |
Somatropin und Somatropin-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AC01 |
Somatropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AC02 |
Somatrem |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AC03 |
Mecasermin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AC04 |
Sermorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AX |
Andere Hypophysenvorderlappenhormone und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01AX01 |
Pegvisomant |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01B |
Hypophysenhinterlappenhormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BA |
Vasopressin und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BA01 |
Vasopressin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BA02 |
Desmopressin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BA03 |
Lypressin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BA04 |
Terlipressin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BA05 |
Ornipressin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BA06 |
Argipressin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BB |
Oxytocin und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BB01 |
Demoxytocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BB02 |
Oxytocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01BB03 |
Carbetocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01C |
Hypothalamushormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CA |
Gonadotropin-Releasing-Hormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CA01 |
Gonadorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CA02 |
Nafarelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CA03 |
Histrelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CA93 |
Gonadotrophin-releasing hormones |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CB |
Anti-Wachstumshormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CB01 |
Somatostatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CB02 |
Octreotid |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CB03 |
Lanreotid |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CC |
Gonadotropin-Releasing-Hormon-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CC01 |
Ganirelix |
2.16.840.1.113883.6.73 |
|
| 0-L |
H01CC02 |
Cetrorelix |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02 |
Corticosteroide zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02A |
Corticosteroide zur systemischen Anwendung, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AA |
Mineralocorticoide |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AA01 |
Aldosteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AA02 |
Fludrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AA03 |
Desoxycorton |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB |
Glucocorticoide |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB01 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB02 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB03 |
Fluocortolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB04 |
Methylprednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB05 |
Paramethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB06 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB07 |
Prednison |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB08 |
Triamcinolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB09 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB10 |
Cortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB11 |
Prednyliden |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB12 |
Rimexolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB13 |
Deflazacort |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB14 |
Cloprednol |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB15 |
Meprednison |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02AB17 |
Cortivazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02B |
Corticosteroide zur systemischen Anwendung, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02BX |
Corticosteroide zur systemischen Anwendung, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02BX01 |
Methylprednisolon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02C |
Nebennierenhemmstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02CA |
Anticorticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
H02CA01 |
Trilostan |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03 |
Schilddrüsentherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03A |
Schilddrüsenpräparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03AA |
Schilddrüsenhormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03AA01 |
Levothyroxin-Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03AA02 |
Liothyronin-Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03AA03 |
Kombinationen von Levothyroxin und Liothyronin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03AA04 |
Tiratricol |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03AA05 |
Zubereitungen aus Schilddrüsengewebe |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03B |
Thyreostatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BA |
Thiouracile |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BA01 |
Methylthiouracil |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BA02 |
Propylthiouracil |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BA03 |
Benzylthiouracil |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BB |
Schwefel-haltige Imidazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BB01 |
Carbimazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BB02 |
Thiamazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BB52 |
Thiamazol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BC |
Perchlorate |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BC01 |
Kaliumperchlorat |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BX |
Andere Thyreostatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BX01 |
Diiodtyrosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03BX02 |
Dibromtyrosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03C |
Iodtherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
H03CA |
Iodtherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
H04 |
Pankreashormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
H04A |
Glykogenolytische Hormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
H04AA |
Glykogenolytische Hormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
H04AA01 |
Glucagon |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05 |
Calciumhomöostase |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05A |
Nebenschilddrüsenhormone und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05AA |
Nebenschilddrüsenhormone und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05AA01 |
Nebenschilddrüsenextrakt |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05AA02 |
Teriparatid |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05AA03 |
Parathyroid Hormon |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05B |
Nebenschilddrüsen-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05BA |
Calcitonin-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05BA01 |
Calcitonin (Lachs, synthetisch) |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05BA02 |
Calcitonin (Schwein, natürlich) |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05BA03 |
Calcitonin (Mensch, synthetisch) |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05BA04 |
Elcatonin |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05BX |
Andere Nebenschilddrüsen-antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05BX01 |
Cinacalcet |
2.16.840.1.113883.6.73 |
|
| 0-L |
H05BX02 |
Paricalcitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
I07AA |
inactivated viral vaccines |
2.16.840.1.113883.6.73 |
|
| 0-L |
I07AA06 |
Canine Herpesvirus vaccine |
2.16.840.1.113883.6.73 |
|
| 0-L |
I09AA07 |
Inactivated Porcine Circovirus vaccine |
2.16.840.1.113883.6.73 |
|
| 0-L |
J |
Antiinfektiva zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01 |
Antibiotika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01A |
Tetracycline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA |
Tetracycline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA01 |
Demeclocyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA02 |
Doxycyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA03 |
Chlortetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA04 |
Lymecyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA05 |
Metacyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA06 |
Oxytetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA07 |
Tetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA08 |
Minocyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA09 |
Rolitetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA10 |
Penimepicyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA11 |
Clomocyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA12 |
Tigecyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA20 |
Kombinationen von Tetracyclinen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01AA56 |
Oxytetracyclin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01B |
Amphenicole |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01BA |
Amphenicole |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01BA01 |
Chloramphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01BA02 |
Thiamphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01BA52 |
Thiamphenicol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01C |
Betalactam-Antibiotika, Penicilline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA |
Penicilline mit erweitertem Wirkungsspektrum |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA01 |
Ampicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA02 |
Pivampicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA03 |
Carbenicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA04 |
Amoxicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA05 |
Carindacillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA06 |
Bacampicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA07 |
Epicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA08 |
Pivmecillinam |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA09 |
Azlocillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA10 |
Mezlocillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA11 |
Mecillinam |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA12 |
Piperacillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA13 |
Ticarcillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA14 |
Metampicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA15 |
Talampicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA16 |
Sulbenicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA17 |
Temocillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA18 |
Hetacillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CA51 |
Ampicillin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE |
Beta-Lactamase-sensitive Penicilline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE01 |
Benzylpenicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE02 |
Phenoxymethylpenicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE03 |
Propicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE04 |
Azidocillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE05 |
Pheneticillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE06 |
Penamecillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE07 |
Clometocillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE08 |
Benzylpenicillin-Benzathin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE09 |
Benzylpenicillin-procain |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE10 |
Phenoxymethylpenicillin-Benzathin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CE30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CF |
Beta-Lactamase-resistente Penicilline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CF01 |
Dicloxacillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CF02 |
Cloxacillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CF03 |
Meticillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CF04 |
Oxacillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CF05 |
Flucloxacillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CG |
Beta-Lactamase-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CG01 |
Sulbactam |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CG02 |
Tazobactam |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CR |
Kombinationen von Penicillinen, inkl. Beta-Lactamase-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CR01 |
Ampicillin und Enzym-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CR02 |
Amoxicillin und Enzym-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CR03 |
Ticarcillin und Enzym-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CR04 |
Sultamicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CR05 |
Piperacillin und Enzym-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01CR50 |
Kombinationen von Penicillinen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01D |
Andere Beta-Lactam-Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DA |
Cephalosporins and related substances * |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB |
Cephalosporine der 1. Generation |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB01 |
Cefalexin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB02 |
Cefaloridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB03 |
Cefalotin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB04 |
Cefazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB05 |
Cefadroxil |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB06 |
Cefazedon |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB07 |
Cefatrizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB08 |
Cefapirin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB09 |
Cefradin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB10 |
Cefacetril |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB11 |
Cefroxadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DB12 |
Ceftezol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC |
Cephalosporine der 2. Generation |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC01 |
Cefoxitin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC02 |
Cefuroxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC03 |
Cefamandol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC04 |
Cefaclor |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC05 |
Cefotetan |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC06 |
Cefonicid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC07 |
Cefotiam |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC08 |
Loracarbef |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC09 |
Cefmetazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC10 |
Cefprozil |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DC11 |
Ceforanid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD |
Cephalosporine der 3. Generation |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD01 |
Cefotaxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD02 |
Ceftazidim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD03 |
Cefsulodin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD04 |
Ceftriaxon |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD05 |
Cefmenoxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD06 |
Latamoxef |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD07 |
Ceftizoxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD08 |
Cefixim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD09 |
Cefodizim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD10 |
Cefetamet |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD11 |
Cefpiramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD12 |
Cefoperazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD13 |
Cefpodoxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD14 |
Ceftibuten |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD15 |
Cefdinir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD16 |
Cefditoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD54 |
Ceftriaxon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD62 |
Cefoperazon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DD91 |
Cefovecin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DE |
Cephalosporine der 4. Generation |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DE01 |
Cefepim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DE02 |
Cefpirom |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DF |
Monobactame |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DF01 |
Aztreonam |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DH |
Carbapeneme |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DH02 |
Meropenem |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DH03 |
Ertapenem |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DH04 |
Doripenem |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DH51 |
Imipenem und Enzym-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01DI02 |
Ceftarolin fosamil |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01E |
Sulfonamide und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EA |
Trimethoprim und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EA01 |
Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EA02 |
Brodimoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB |
Kurz wirkende Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB01 |
Sulfaisodimidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB02 |
Sulfamethizol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB03 |
Sulfadimidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB04 |
Sulfapyridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB05 |
Sulfafurazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB06 |
Sulfanilamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB07 |
Sulfathiazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB08 |
Sulfathiourea |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EB20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EC |
Mittellang wirkende Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EC01 |
Sulfamethoxazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EC02 |
Sulfadiazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EC03 |
Sulfamoxol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EC20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED |
Lang wirkende Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED01 |
Sulfadimethoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED02 |
Sulfalen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED03 |
Sulfametomidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED04 |
Sulfametoxydiazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED05 |
Sulfamethoxypyridazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED06 |
Sulfaperin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED07 |
Sulfamerazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED08 |
Sulfaphenazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED09 |
Sulfamazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01ED20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EE |
Kombinationen von Sulfonamiden und Trimethoprim, inkl. Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EE01 |
Sulfamethoxazol und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EE02 |
Sulfadiazin und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EE03 |
Sulfametrol und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EE04 |
Sulfamoxol und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EE05 |
Sulfadimidin und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EE06 |
Sulfadiazin und Tetroxoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01EE07 |
Sulfamerazin und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01F |
Makrolide, Lincosamide und Streptogramine |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA |
Makrolide |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA01 |
Erythromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA02 |
Spiramycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA03 |
Midecamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA05 |
Oleandomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA06 |
Roxithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA07 |
Josamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA08 |
Troleandomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA09 |
Clarithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA10 |
Azithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA11 |
Miocamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA12 |
Rokitamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA13 |
Dirithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA14 |
Flurithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA15 |
Telithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FA95 |
Gamithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FF |
Lincosamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FF01 |
Clindamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FF02 |
Lincomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FG |
Streptogramine |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FG01 |
Pristinamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01FG02 |
Quinupristin/Dalfopristin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01G |
Aminoglykosid-Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GA |
Streptomycine |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GA01 |
Streptomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GA02 |
Streptoduocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB |
Andere Aminoglykoside |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB01 |
Tobramycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB03 |
Gentamicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB04 |
Kanamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB05 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB06 |
Amikacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB07 |
Netilmicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB08 |
Sisomicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB09 |
Dibekacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB10 |
Ribostamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01GB11 |
Isepamicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01M |
Chinolone |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA |
Fluorchinolone |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA01 |
Ofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA02 |
Ciprofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA03 |
Pefloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA04 |
Enoxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA05 |
Temafloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA06 |
Norfloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA07 |
Lomefloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA08 |
Fleroxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA09 |
Sparfloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA10 |
Rufloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA11 |
Grepafloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA12 |
Levofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA13 |
Trovafloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA14 |
Moxifloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA15 |
Gemifloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA16 |
Gatifloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA17 |
Prulifloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA18 |
Pazufloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MA19 |
Garenoxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MB |
Andere Chinolone |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MB01 |
Rosoxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MB02 |
Nalidixinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MB03 |
Piromidsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MB04 |
Pipemidsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MB05 |
Oxolinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MB06 |
Cinoxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01MB07 |
Flumequin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01R |
Kombinationen von Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01RA |
Kombinationen von Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01RA01 |
Penicilline, Kombination mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01RA02 |
Sulfonamide, Kombination mit anderen Antibiotika (exkl. Trimethoprim) |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01RA03 |
Cefuroxim, Kombination mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01RA04 |
Spiramycin, Kombination mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01X |
Andere Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XA |
Glycopeptid-Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XA01 |
Vancomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XA02 |
Teicoplanin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XB |
Polymyxine |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XB01 |
Colistin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XB02 |
Polymyxin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XC |
Steroid-Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XC01 |
Fusidinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XD |
Imidazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XD01 |
Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XD02 |
Tinidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XD03 |
Ornidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XE |
Nitrofuran-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XE01 |
Nitrofurantoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XE02 |
Nifurtoinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX |
Andere Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX01 |
Fosfomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX02 |
Xibornol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX03 |
Clofoctol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX04 |
Spectinomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX05 |
Methenamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX06 |
Mandelsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX07 |
Nitroxolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX08 |
Linezolid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J01XX09 |
Daptomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02 |
Antimykotika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02A |
Antimykotika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AA |
Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AA01 |
Amphotericin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AA02 |
Hachimycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AB |
Imidazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AB01 |
Miconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AB02 |
Ketoconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AC |
Triazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AC01 |
Fluconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AC02 |
Itraconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AC03 |
Voriconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AC04 |
Posaconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AX |
Andere Antimykotika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AX01 |
Flucytosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AX04 |
Caspofungin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AX05 |
Micafungin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J02AX06 |
Anidulafungin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04 |
Mittel gegen Mykobakterien |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04A |
Mittel zur Behandlung der Tuberkulose |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AA |
Aminosalicylsäure und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AA01 |
Aminosalicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AA02 |
Natriumaminosalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AA03 |
Calciumaminosalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AB |
Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AB01 |
Cycloserin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AB02 |
Rifampicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AB03 |
Rifamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AB04 |
Rifabutin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AB05 |
Rifapentin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AB30 |
Capreomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AC |
Hydrazide |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AC01 |
Isoniazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AC51 |
Isoniazid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AD |
Thiocarbamid-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AD01 |
Protionamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AD02 |
Tiocarlid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AD03 |
Ethionamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AK |
Andere Mittel zur Behandlung der Tuberkulose |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AK01 |
Pyrazinamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AK02 |
Ethambutol |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AK03 |
Terizidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AK04 |
Morinamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AM |
Kombinationen von Mitteln zur Behandlung der Tuberkulose |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AM01 |
Streptomycin und Isoniazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AM02 |
Rifampicin und Isoniazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AM03 |
Ethambutol und Isoniazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AM04 |
Thioacetazon und Isoniazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AM05 |
Rifampicin, Pyrazinamid und Isoniazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04AM06 |
Rifampicin, Pyrazinamid, Ethambutol und Isoniazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04B |
Mittel zur Behandlung der Lepra |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04BA |
Mittel zur Behandlung der Lepra |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04BA01 |
Clofazimin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04BA02 |
Dapson |
2.16.840.1.113883.6.73 |
|
| 0-L |
J04BA03 |
Aldesulfonnatrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05 |
Antivirale Mittel zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05A |
Direkt wirkende antivirale Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AA |
Thiosemicarbazone |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AA01 |
Metisazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB |
Nukleoside und Nukleotide, exkl. Inhibitoren der Reversen Transkriptase |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB01 |
Aciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB02 |
Idoxuridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB03 |
Vidarabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB04 |
Ribavirin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB06 |
Ganciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB09 |
Famciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB11 |
Valaciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB12 |
Cidofovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB13 |
Penciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB14 |
Valganciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AB15 |
Brivudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AC |
Cyclische Amine |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AC02 |
Rimantadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AC03 |
Tromantadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AD |
Phosphonsäure-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AD01 |
Foscarnet |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AD02 |
Fosfonet |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE |
Proteasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE01 |
Saquinavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE02 |
Indinavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE03 |
Ritonavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE04 |
Nelfinavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE05 |
Amprenavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE06 |
Lopinavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE07 |
Fosamprenavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE08 |
Atazanavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE09 |
Tipranavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AE10 |
Darunavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF |
Nukleosidale und nukleotidale Inhibitoren der Reversen Transkriptase |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF01 |
Zidovudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF02 |
Didanosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF03 |
Zalcitabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF04 |
Stavudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF05 |
Lamivudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF06 |
Abacavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF07 |
Tenofovir Disoproxil |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF08 |
Adefovir dipivoxil |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF09 |
Emtricitabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF10 |
Entecavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AF11 |
Telbivudine |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AG |
Nicht-Nukleosidale Inhibitoren der Reverse-Transkriptase |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AG01 |
Nevirapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AG02 |
Delavirdin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AG03 |
Efavirenz |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AG04 |
Etravirin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AH |
Neuraminidasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AH01 |
Zanamivir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AH02 |
Oseltamivir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AR |
Antivirale Mittel zur Behandlung von HIV Infektionen, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AR01 |
Ziduvudin und Lamivudin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AR02 |
Lamivudin und Abacavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AR03 |
Tenofovir disoproxil und Emtricitabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AR04 |
Zidovudin, Lamivudin und Abacavir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AR05 |
Zidovudin, Lamivudin und Nevirapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AR06 |
Emtricitabin, Tenofovir disoproxil und Efavirenz |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AX |
Andere antivirale Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AX01 |
Moroxydin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AX02 |
Lysozym |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AX05 |
Inosin-Pranobex |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AX06 |
Pleconaril |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AX07 |
Enfuvirtid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AX08 |
Raltegravir |
2.16.840.1.113883.6.73 |
|
| 0-L |
J05AX09 |
Maraviroc |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06 |
Immunsera und Immunglobuline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06A |
Immunsera |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06AA |
Immunsera |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06AA01 |
Diphtherie-Antitoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06AA02 |
Tetanus-Antitoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06AA03 |
Schlangengift-Antiserum |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06AA04 |
Botulinum-Antitoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06AA05 |
Gasbrand-Serum |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06AA06 |
Tollwut-Serum |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06B |
Immunglobuline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BA |
Immunglobuline, normal human |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BA01 |
Immunglobuline, normal human, zur extravasalen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BA02 |
Immunglobuline, normal human, zur intravasalen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB |
Spezifische Immunglobuline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB01 |
Anti-D(rh)-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB02 |
Tetanus-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB03 |
Varicella/Zoster-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB04 |
Hepatitis B-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB05 |
Tollwut-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB06 |
Röteln-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB07 |
Kuhpocken-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB08 |
Staphylococcus-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB09 |
Cytomegalievirus-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB10 |
Diphtherie-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB11 |
Hepatitis-A-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB12 |
FSME-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB13 |
Pertussis-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB14 |
Masern-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB15 |
Mumps-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB16 |
Palivizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BB30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BC |
Andere Immunglobuline |
2.16.840.1.113883.6.73 |
|
| 0-L |
J06BC01 |
Nebacumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07 |
Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07A |
Bakterielle Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AC |
Milzbrand-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AC01 |
Anthrax-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AD |
Brucellose-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AD01 |
Brucella-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AE |
Cholera-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AE01 |
Cholera, inaktiviert, ganze Zelle |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AE02 |
Cholera, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AE51 |
Cholera, Kombinationen mit Typhus-Impfstoff, inaktiviert, ganze Zelle |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AF |
Diphtherie-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AF01 |
Diphtherie-Toxoid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AG |
Haemophilus-influenza-B-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AG01 |
Haemophilus-influenzae B, gereinigtes Antigen konjugiert |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AG51 |
Haemophilus-influenzae B, Kombinationen mit Toxoiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AG52 |
Haemophilus-influenzae B, Kombinationen mit Pertussis und Toxoiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AG53 |
Haemophilus-influenzae B, Kombinationen mit Meningokokkus C, konjugiert |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH |
Meningokokken-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH01 |
Meningokokkus A, gereinigtes Polysaccharid-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH02 |
Andere Meningokokken monovalent, gereinigtes Polysaccharid-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH03 |
Meningokokkus bivalent, gereinigtes Polysaccharid-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH04 |
Meningokokkus tetravalent, gereinigtes Polysaccharid-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH05 |
Andere Meningokokken polyvalent, gereinigtes Polysaccharid-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH06 |
Meningokokkus B, Äußeres-Membranvesikel-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH07 |
Meningokokkus C, gereinigtes Polysaccharid-Antigen, konjugiert |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AH08 |
Meningokokkus tetravalent, gereinigtes Polysaccharid-Antigen, konjugiert |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AJ |
Pertussis-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AJ01 |
Pertussis, inaktiviert, ganze Zelle |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AJ02 |
Pertussis, gereinigtes Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AJ51 |
Pertussis, inaktiviert, ganze Zelle, Kombinationen mit Toxoiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AJ52 |
Pertussis, gereinigtes Antigen, Kombinationen mit Toxoiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AK |
Pest-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AK01 |
Pest, inaktiviert, ganze Zelle |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AL |
Pneumokokken-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AL01 |
Pneumokokken, gereinigtes Polysaccharid-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AL02 |
Pneumokokken, gereinigtes Polysaccharid-Antigen, konjugiert |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AM |
Tetanus-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AM01 |
Tetanus-Toxoid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AM51 |
Tetanus-Toxoid, Kombinationen mit Diphtherie-Toxoid |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AM52 |
Tetanus-Toxoid, Kombinationen mit Tetanus-Immunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AN |
Tuberkulose-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AN01 |
Tuberkulose, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AP |
Typhus-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AP01 |
Typhus, oral, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AP02 |
Typhus, inaktiviert, ganze Zelle |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AP03 |
Typhus, gereinigtes Polysaccharid-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AP10 |
Typhus, Kombinationen mit Paratyphustypen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AR |
Typhus (exanthematicus)-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AR01 |
Typhus exanthematicus, inaktiviert, ganze Zelle |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07AX |
Andere bakterielle Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07B |
Virale Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BA |
Encephalitis-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BA01 |
FSME, inaktiviert, ganzes Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BA02 |
Encephalitis, japanische, inaktiviert, ganzes Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BB |
Influenza-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BB01 |
Influenza, inaktiviert, ganzes Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BB02 |
Influenza, gereinigtes Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BC |
Hepatitis-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BC01 |
Hepatitis B, gereinigtes Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BC02 |
Hepatitis A, inaktiviert, ganzes Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BC20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BD |
Masern-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BD01 |
Masern, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BD51 |
Masern, Kombinationen mit Mumps, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BD52 |
Masern, Kombinationen mit Mumps und Röteln, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BD53 |
Masern, Kombinationen mit Röteln, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BD54 |
Masern, Kombinationen mit Mumps, Röteln und Varicella, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BE |
Mumps-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BE01 |
Mumps, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BF |
Poliomyelitis-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BF01 |
Poliomyelitis, oral, monovalent, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BF02 |
Poliomyelitis, oral, trivalent, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BF03 |
Poliomyelitis, trivalent, inaktiviert, ganzes Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BG |
Tollwut-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BG01 |
Tollwut, inaktiviert, ganzes Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BH |
Rotavirus-Diarrhoe-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BH01 |
Rotavirus, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BH02 |
Rotavirus, pentavalent, lebend, Reassortanten |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BJ |
Röteln-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BJ01 |
Röteln, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BJ51 |
Röteln, Kombinationen mit Mumps, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BK |
Varicella Zoster Impfstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BK01 |
Varicella, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BK02 |
Zoster Virus lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BL |
Gelbfieber-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BL01 |
Gelbfieber, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BM |
Papillomvirus-Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BM01 |
Humaner Papillomvirus-Impfstoff (Typen 6,11,16,18) |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BM02 |
Humaner Papillomvirus-Impfstoff (Typen 16,18) |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07BX |
Varicella, lebend abgeschwächt |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07C |
Bakterielle und virale Impfstoffe, kombiniert |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA |
Bakterielle und virale Impfstoffe, kombiniert |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA01 |
Diphtherie-Poliomyelitis-Tetanus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA02 |
Diphtherie-Pertussis-Poliomyelitis-Tetanus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA03 |
Diphtherie-Röteln-Tetanus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA04 |
Haemophilus-influenzae B und Poliomyelitis |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA05 |
Diphtherie-Hepatitis B-Pertussis-Tetanus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA06 |
Diphtherie-Haemophilus-influenzae B-Pertussis-Poliomyelitis-Tetanus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA07 |
Diphtherie-Hepatitis B-Tetanus |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA08 |
Hämophilus influenzae B und Hepatitis B |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA09 |
Diphtherie-Haemophilus-influenzae B-Pertussis-Poliomyelitis-Tetanus-Hepatitis B |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA10 |
Typhus-Hepatitis A |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA11 |
Diphtherie-Haemophilus-influenzae B-Pertussis-Tetanus-Hepatitis B |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07CA12 |
Diphtherie-Pertussis-Poliomyelitis-Tetanus-Hepatitis B |
2.16.840.1.113883.6.73 |
|
| 0-L |
J07X |
Andere Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
J51DB90 |
Cefalonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
L |
Antineoplastische und Immunmodulierende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01 |
Antineoplastische Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01A |
Alkylierende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA |
Stickstofflost-Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA01 |
Cyclophosphamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA02 |
Chlorambucil |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA03 |
Melphalan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA05 |
Chlormethin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA06 |
Ifosfamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA07 |
Trofosfamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA08 |
Prednimustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AA09 |
Bendamustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AB |
Alkylsulfonate |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AB01 |
Busulfan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AB02 |
Treosulfan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AB03 |
Mannosulfan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AC |
Ethylenimine |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AC01 |
Thiotepa |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AC02 |
Triaziquon |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AC03 |
Carboquon |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AD |
Nitrosoharnstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AD01 |
Carmustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AD02 |
Lomustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AD03 |
Semustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AD04 |
Streptozocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AD05 |
Fotemustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AD06 |
Nimustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AD07 |
Ranimustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AG |
Epoxide |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AG01 |
Etoglucid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AX |
Andere alkylierende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AX01 |
Mitobronitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AX02 |
Pipobroman |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AX03 |
Temozolomid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01AX04 |
Dacarbazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01B |
Antimetabolite |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BA |
Folsäure-Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BA01 |
Methotrexat |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BA03 |
Raltitrexed |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BA04 |
Pemetrexed |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BB |
Purin-Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BB02 |
Mercaptopurin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BB03 |
Tioguanin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BB04 |
Cladribin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BB05 |
Fludarabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BB06 |
Clofarabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BB07 |
Nelarabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC |
Pyrimidin-Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC01 |
Cytarabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC02 |
Fluorouracil |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC03 |
Tegafur |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC04 |
Carmofur |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC05 |
Gemcitabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC06 |
Capecitabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC08 |
Decitabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC52 |
Fluorouracil, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01BC53 |
Tegafur, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01C |
Pflanzliche Alkaloide und andere Natürliche Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CA |
Vinka-Alkaloide und Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CA01 |
Vinblastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CA02 |
Vincristin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CA03 |
Vindesin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CA04 |
Vinorelbin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CB |
Podophyllotoxin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CB01 |
Etoposid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CB02 |
Teniposid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CC |
Colchicin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CC01 |
Demecolcin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CD |
Taxane |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CD01 |
Paclitaxel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CD02 |
Docetaxel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CX |
Andere pflanzliche Alkaloide und natürliche Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01CX01 |
Trabectedin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01D |
Zytotoxische Antibiotika und verwandte Substanzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DA |
Actinomycine |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DA01 |
Dactinomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB |
Anthracycline und verwandte Substanzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB01 |
Doxorubicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB02 |
Daunorubicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB03 |
Epirubicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB04 |
Aclarubicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB05 |
Zorubicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB06 |
Idarubicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB07 |
Mitoxantron |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB08 |
Pirarubicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB09 |
Valrubicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DB11 |
Pixantron |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DC |
Andere zytotoxische Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DC01 |
Bleomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DC02 |
Plicamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01DC03 |
Mitomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01X |
Andere antineoplastische Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XA |
Platin-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XA01 |
Cisplatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XA02 |
Carboplatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XA03 |
Oxaliplatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XB |
Methylhydrazine |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XB01 |
Procarbazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC |
Monoklonale Antikörper |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC01 |
Edrecolomab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC02 |
Rituximab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC03 |
Trastuzumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC04 |
Alemtuzumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC05 |
Gemtuzumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC06 |
Cetuximab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC07 |
Bevacizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC08 |
Panitumumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC09 |
Catumaxomab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC10 |
Ofatumumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XC11 |
Ipilimumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XD |
Sensibilisatoren für die photodynamische/Radio- Therapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XD01 |
Porfimer natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XD03 |
Methylaminolevulinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XD04 |
Aminolevulin-Säure |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XD05 |
Temoporfin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XD06 |
Efaproxiral |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE |
Proteinkinase Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE01 |
Imatinib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE02 |
Gefitinib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE03 |
Erlotinib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE04 |
Sunitinib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE05 |
Sorafenib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE06 |
Dasatinib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE07 |
Lapatinib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE08 |
Nilotinib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE09 |
Temsirolimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XE11 |
Pazopanib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX |
Andere antineoplastische Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX01 |
Amsacrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX02 |
Asparaginase |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX03 |
Altretamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX05 |
Hydroxycarbamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX07 |
Lonidamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX08 |
Pentostatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX09 |
Miltefosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX10 |
Masoprocol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX11 |
Estramustin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX14 |
Tretinoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX16 |
Mitoguazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX17 |
Topotecan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX18 |
Tiazofurin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX19 |
Irinotecan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX22 |
Alitretinoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX23 |
Mitotan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX24 |
Pegaspargase |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX25 |
Bexaroten |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX27 |
Arsentrioxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX29 |
Denileukin diftitox |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX32 |
Bortezomib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX33 |
Celecoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XX35 |
Anagrelid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L01XY |
Kombinationen von antineoplastischen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02 |
Endokrine Therapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02A |
Hormone und verwandte Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AA |
Estrogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AA01 |
Diethylstilbestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AA02 |
Polyestradiolphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AA03 |
Ethinylestradiol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AA04 |
Fosfestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AB |
Gestagene |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AB01 |
Megestrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AB02 |
Medroxyprogesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AB03 |
Gestonoron |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AE |
Gonadotropin-Releasing-Hormon-Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AE01 |
Buserelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AE02 |
Leuprorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AE03 |
Goserelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AE04 |
Triptorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02AX |
Andere Hormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02B |
Hormonantagonisten und verwandte Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BA |
Antiestrogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BA01 |
Tamoxifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BA02 |
Toremifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BA03 |
Fulvestrant |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BB |
Antiandrogene |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BB01 |
Flutamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BB02 |
Nilutamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BB03 |
Bicalutamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BG |
Enzym-Inhibitoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BG01 |
Aminoglutethimid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BG02 |
Formestan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BG03 |
Anastrozol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BG04 |
Letrozol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BG05 |
Vorozol |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BG06 |
Exemestan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BX |
Andere Hormonantagonisten und verwandte Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BX01 |
Abarelix |
2.16.840.1.113883.6.73 |
|
| 0-L |
L02BX02 |
Degarelix |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03 |
Immunstimulanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03A |
Zytokine und Immunmodulatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AA |
Koloniestimulierende Faktoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AA02 |
Filgrastim |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AA03 |
Molgramostim |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AA09 |
Sargramostim |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AA10 |
Lenograstim |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AA12 |
Ancestim |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AA13 |
Pegfilgrastim |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB |
Interferone |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB01 |
Interferon-alfa, natürlich |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB02 |
Interferon-beta, natürlich |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB03 |
Interferon-gamma |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB04 |
Interferon-alfa-2a |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB05 |
Interferon-alfa-2b |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB06 |
Interferon-alfa-n1 |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB07 |
Interferon-beta-1a |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB08 |
Interferon-beta-1b |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB09 |
Interferon alfacon-1 |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB10 |
Peginterferon alfa-2b |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB11 |
Peginterferon alfa-2a |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AB60 |
Peginterferon alfa-2b, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AC |
Interleukine |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AC01 |
Aldesleukin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AC02 |
Oprelvekin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX |
Andere Zytokine und Immunmodulatoren |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX01 |
Lentinan |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX02 |
Roquinimex |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX03 |
BCG-Impfstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX04 |
Pegademase |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX05 |
Pidotimod |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX07 |
Poly I:C |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX08 |
Poly ICLC |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX09 |
Thymopentin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX10 |
Immunocyanin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX11 |
Tasonermin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX12 |
Melanom-Impfstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX13 |
Glatirameracetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
L03AX14 |
Histamin dihydrochlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04 |
Immunsuppressiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04A |
Immunsuppressiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA |
Selektive Immunsuppressiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA01 |
Ciclosporin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA02 |
Muromonab-CD3 |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA03 |
Antilymphocytäres Immunglobulin (Pferd) |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA04 |
Antithymocytäres Immunglobulin (Kaninchen) |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA05 |
Tacrolimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA06 |
Mycophenolsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA08 |
Daclizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA09 |
Basiliximab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA10 |
Sirolimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA11 |
Etanercept |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA12 |
Infliximab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA13 |
Leflunomid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA14 |
Anakinra |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA15 |
Alefacept |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA16 |
Afelimomab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA17 |
Adalimumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA18 |
Everolimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA19 |
Gusperimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA21 |
Efalizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA22 |
Abetimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA23 |
Natalizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA24 |
Abatacept |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA25 |
Eculizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA26 |
Belimumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AA28 |
Belatacept |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AB02 |
Infliximab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AC03 |
Anakinra |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AC05 |
Ustekinumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AC07 |
Tocilizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AD01 |
Ciclosporin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AD02 |
Tacrolimus |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AX |
Andere Immunsuppressiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AX01 |
Azathioprin |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AX02 |
Thalidomid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AX03 |
Methotrexat |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AX04 |
Lenalidomid |
2.16.840.1.113883.6.73 |
|
| 0-L |
L04AX05 |
Pirfenidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M |
Muskel- und Skelettsystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01 |
Antiphlogistika und Antirheumatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01A |
Nichtsteroidale antiphlogistika und Antirheumatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AA |
Butylpyrazolidine |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AA01 |
Phenylbutazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AA02 |
Mofebutazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AA03 |
Oxyphenbutazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AA05 |
Clofezon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AA06 |
Kebuzon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB |
Essigsäure-Derivate und verwandte Substanzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB01 |
Indometacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB02 |
Sulindac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB03 |
Tolmetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB04 |
Zomepirac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB05 |
Diclofenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB06 |
Alclofenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB07 |
Bumadizon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB08 |
Etodolac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB09 |
Lonazolac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB10 |
Fentiazac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB11 |
Acemetacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB12 |
Difenpiramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB13 |
Oxametacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB14 |
Proglumetacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB15 |
Ketorolac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB16 |
Aceclofenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB17 |
Bufexamac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB51 |
Indometacin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AB55 |
Diclofenac, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AC |
Oxicame |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AC01 |
Piroxicam |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AC02 |
Tenoxicam |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AC04 |
Droxicam |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AC05 |
Lornoxicam |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AC06 |
Meloxicam |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE |
Propionsäure-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE01 |
Ibuprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE02 |
Naproxen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE03 |
Ketoprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE04 |
Fenoprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE05 |
Fenbufen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE06 |
Benoxaprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE07 |
Suprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE08 |
Pirprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE09 |
Flurbiprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE10 |
Indoprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE11 |
Tiaprofensäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE12 |
Oxaprozin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE13 |
Ibuproxam |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE14 |
Dexibuprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE15 |
Flunoxaprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE16 |
Alminoprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE17 |
Dexketoprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE51 |
Ibuprofen, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE52 |
Naproxen und Esomeprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AE53 |
Ketoprofen, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AG |
Fenamate |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AG01 |
Mefenaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AG02 |
Tolfenaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AG03 |
Flufenaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AG04 |
Meclofenaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AH |
Coxibe |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AH01 |
Celecoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AH02 |
Rofecoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AH03 |
Valdecoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AH04 |
Parecoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AH05 |
Etoricoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AH06 |
Lumiracoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX |
Andere nichtsteroidale Antiphlogistika und Antirheumatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX01 |
Nabumeton |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX02 |
Nifluminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX04 |
Azapropazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX05 |
Glukosamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX07 |
Benzydamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX12 |
Glukosaminoglycanpolysulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX13 |
Proquazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX14 |
Orgotein |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX17 |
Nimesulid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX18 |
Feprazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX21 |
Diacerein |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX22 |
Morniflumat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX23 |
Tenidap |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX24 |
Oxaceprol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX25 |
Chondroitinsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01AX68 |
Feprazon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01B |
Antiphlogistika/Antirheumatika in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01BA |
Antiphlogistika/Antirheumatika in Kombination mit Corticosteroiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01BA01 |
Phenylbutazon und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01BA02 |
Dipyrocetyl und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01BA03 |
Acetylsalicylsäure und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01BX |
Andere Antiphlogistika/Antirheumatika in Kombination mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01C |
Spezifische Antirheumatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CA |
Chinoline |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CA03 |
Oxycinchophen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CB |
Gold-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CB01 |
Natriumaurothiomalat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CB02 |
Natrium aurothiosulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CB03 |
Auranofin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CB04 |
Aurothioglucose |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CB05 |
Aurotioprol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CC |
Penicillamin und ähnliche Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CC01 |
Penicillamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CC02 |
Bucillamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M01CX |
Andere spezifische Antirheumatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02 |
Topische Mittel gegen Gelenk- und Muskelschmerzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02A |
Topische Mittel gegen Gelenk- und Muskelschmerzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA |
Nichtsteroidale Antiphlogistika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA01 |
Phenylbutazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA02 |
Mofebutazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA03 |
Clofezon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA04 |
Oxyphenbutazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA05 |
Benzydamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA06 |
Etofenamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA07 |
Piroxicam |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA08 |
Felbinac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA09 |
Bufexamac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA10 |
Ketoprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA11 |
Bendazac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA12 |
Naproxen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA13 |
Ibuprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA14 |
Fentiazac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA15 |
Diclofenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA16 |
Feprazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA17 |
Nifluminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA18 |
Meclofenaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA19 |
Flurbiprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA21 |
Tolmetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA22 |
Suxibuzon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA23 |
Indometacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA24 |
Nifenazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AA25 |
Aceclofenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AB |
Capsicum-haltige Zubereitungen und ähnliche Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AC |
Zubereitungen mit Salicylsäure-Derivaten |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AX |
Andere topische Mittel gegen Gelenk- und Muskelschmerzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AX02 |
Tolazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AX03 |
Dimethylsulfoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M02AX10 |
Verschiedene |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03 |
Muskelrelaxanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03A |
Muskelrelaxanzien, peripher wirkende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AA |
Curare-Alkaloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AA01 |
Alcuronium |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AA02 |
Tubocurarin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AA04 |
Dimethyltubocurarin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AB |
Cholin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AB01 |
Suxamethonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC |
Andere quartäre Ammonium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC01 |
Pancuronium |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC02 |
Gallamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC03 |
Vecuronium |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC04 |
Atracurium |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC05 |
Hexafluronium |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC06 |
Pipecuroniumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC07 |
Doxacuriumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC08 |
Fazadiniumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC09 |
Rocuroniumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC10 |
Mivacuriumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AC11 |
Cisatracurium |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AX |
Andere Muskelrelaxanzien, peripher wirkende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03AX01 |
Botulinumtoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03B |
Muskelrelaxanzien, zentral wirkende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA |
Carbaminsäureester |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA01 |
Phenprobamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA02 |
Carisoprodol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA03 |
Methocarbamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA04 |
Styramat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA05 |
Febarbamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA51 |
Phenprobamat, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA52 |
Carisoprodol, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA53 |
Methocarbamol, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA71 |
Phenprobamat, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA72 |
Carisoprodol, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BA73 |
Methocarbamol, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BB |
Oxazol-, Thiazin- und Triazin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BB02 |
Chlormezanon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BB03 |
Chlorzoxazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BB52 |
Chlormezanon, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BB53 |
Chlorzoxazon, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BB72 |
Chlormezanon, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BB73 |
Chlorzoxazon, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BC |
Ether, chemisch den Antihistaminika verwandt |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BC01 |
Orphenadrin (citrat) |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BC51 |
Orphenadrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX |
Andere zentral wirkende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX01 |
Baclofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX02 |
Tizanidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX03 |
Pridinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX04 |
Tolperison |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX05 |
Thiocolchicosid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX06 |
Mephenesin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX07 |
Tetrazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX08 |
Cyclobenzaprin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03BX30 |
Fenyramidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03C |
Muskelrelaxanzien, direkt wirkende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03CA |
Dantrolen und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
M03CA01 |
Dantrolen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04 |
Gichtmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04A |
Gichtmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AA |
Urikostatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AA01 |
Allopurinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AA02 |
Tisopurin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AA03 |
Febuxostat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AA51 |
Allopurinol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AB |
Urikosurika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AB01 |
Probenecid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AB02 |
Sulfinpyrazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AB03 |
Benzbromaron |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AB04 |
Isobromindion |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AC |
Gichtmittel ohne Effekt auf den Harnsäuremetabolismus |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AC01 |
Colchicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AC02 |
Cinchophen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AX |
Andere Gichtmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
M04AX01 |
Uratoxidase |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05 |
Mittel zur Behandlung von Knochenerkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05B |
Mittel mit Einfluss auf die Knochenstruktur und die Mineralisation |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA |
Bisphosphonate |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA01 |
Etidronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA02 |
Clodronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA03 |
Pamidronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA04 |
Alendronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA05 |
Tiludronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA06 |
Ibandronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA07 |
Risedronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BA08 |
Zoledronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BB |
Bisphosphonate, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BB01 |
Etidronsäure und Calcium, Sequenzialpräparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BB02 |
Risedronsäure und Calcium, Sequenzialpräparat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BB03 |
Alendronsäure und Colecalciferol |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BC |
Knochenmorphogene Proteine |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BC01 |
Dibotermin alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BC02 |
Eptotermin alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BX |
Andere Mittel mit Einfluß auf die Knochenstruktur und die Mineralisation |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BX01 |
Ipriflavon |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BX02 |
Aluminiumhydroxychlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BX03 |
Strontium ranelat |
2.16.840.1.113883.6.73 |
|
| 0-L |
M05BX04 |
Denosumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09 |
Andere Mittel gegen Störungen des Muskel- und Skelettsystems |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09A |
Andere Mittel gegen Störungen des Muskel- und Skelettsystems |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AA |
Chinin und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AA01 |
Hydrochinin |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AA72 |
Chinin, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AB |
Enzyme |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AB01 |
Chymopapain |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AB02 |
Kollagenase aus Clostridium histolyticum |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AB52 |
Trypsin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AX |
Andere Mittel gegen Störungen des Muskel- und Skelettsystems |
2.16.840.1.113883.6.73 |
|
| 0-L |
M09AX01 |
Hyaluronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N |
Nervensystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01 |
Anästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01A |
Allgemeinanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AA |
Ether |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AA01 |
Diethylether |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AA02 |
Vinylether |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB |
Halogenierte Kohlenwasserstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB01 |
Halothan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB02 |
Chloroform |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB03 |
Methoxyfluran |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB04 |
Enfluran |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB05 |
Trichlorethylen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB06 |
Isofluran |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB07 |
Desfluran |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AB08 |
Sevofluran |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AF |
Barbiturate, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AF01 |
Methohexital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AF02 |
Hexobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AF03 |
Thiopental |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AG |
Barbiturate in Kombination mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AG01 |
Narcobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AH |
Opioidanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AH01 |
Fentanyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AH02 |
Alfentanil |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AH03 |
Sufentanil |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AH04 |
Phenoperidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AH05 |
Anileridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AH06 |
Remifentanil |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AH51 |
Fentanyl, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX |
Andere Allgemeinanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX01 |
Droperidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX03 |
Ketamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX04 |
Propanidid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX05 |
Alfaxalon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX07 |
Etomidate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX10 |
Propofol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX11 |
Hydroxybuttersäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX13 |
Distickstoffmonoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX14 |
Esketamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX15 |
Xenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01AX63 |
Distickstoffmonoxid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01B |
Lokalanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BA |
Ester der Aminobenzoesäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BA01 |
Metabutethamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BA02 |
Procain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BA03 |
Tetracain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BA04 |
Chloroprocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BA05 |
Benzocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BA52 |
Procain, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB |
Amide |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB01 |
Bupivacain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB02 |
Lidocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB03 |
Mepivacain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB04 |
Prilocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB05 |
Butanilicain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB06 |
Cinchocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB07 |
Etidocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB08 |
Articain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB09 |
Ropivacain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB10 |
Levobupivacain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB51 |
Bupivacain, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB52 |
Lidocain, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB53 |
Mepivacain, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB54 |
Prilocain, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB57 |
Etidocain, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BB58 |
Articain, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BC |
Ester der Benzoesäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BC01 |
Cocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BX |
Andere Lokalanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BX01 |
Ethylchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BX02 |
Dyclonin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BX03 |
Phenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N01BX04 |
Capsaicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02 |
Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02A |
Opioide |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA |
Natürliche Opium-Alkaloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA01 |
Morphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA02 |
Opium |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA03 |
Hydromorphon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA04 |
Nicomorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA05 |
Oxycodon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA08 |
Dihydrocodein |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA09 |
Diamorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA10 |
Papaveretum |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA51 |
Morphin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA55 |
Oxycodon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA58 |
Dihydrocodein, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA59 |
Codein, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AA79 |
Codein, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AB |
Phenylpiperidin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AB01 |
Ketobemidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AB02 |
Pethidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AB03 |
Fentanyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AB52 |
Pethidin, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AB72 |
Pethidin, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AC |
Diphenylpropylamin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AC01 |
Dextromoramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AC03 |
Piritramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AC04 |
Dextropropoxyphen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AC05 |
Bezitramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AC52 |
Methadon, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AC54 |
Dextropropoxyphen, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AC74 |
Dextropropoxyphen, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AD |
Benzomorphan-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AD01 |
Pentazocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AD02 |
Phenazocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AE |
Oripavin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AE01 |
Buprenorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AF |
Morphinan-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AF01 |
Butorphanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AF02 |
Nalbufin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AG |
Opioide in Kombination mit Spasmolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AG01 |
Morphin mit Spasmolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AG02 |
Ketobemidon mit Spasmolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AG03 |
Pethidin mit Spasmolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AG04 |
Hydromorphon mit Spasmolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AX |
Andere Opioide |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AX01 |
Tilidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AX02 |
Tramadol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AX03 |
Dezocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AX06 |
Tapentadol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02AX52 |
Tramadol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02B |
Andere Analgetika und Antipyretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA |
Salicylsäure und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA01 |
Acetylsalicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA02 |
Aloxiprin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA03 |
Cholinsalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA04 |
Natriumsalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA05 |
Salicylamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA06 |
Salsalat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA07 |
Ethenzamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA08 |
Morpholinsalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA09 |
Dipyrocetyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA10 |
Benorilat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA11 |
Diflunisal |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA12 |
Kaliumsalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA14 |
Guacetisal |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA15 |
Carbasalat calcium |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA16 |
Imidazolsalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA51 |
Acetylsalicylsäure, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA55 |
Salicylamid, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA57 |
Ethenzamid, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA59 |
Dipyrocetyl, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA65 |
Carbasalat calcium, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA71 |
Acetylsalicylsäure, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA75 |
Salicylamid, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA77 |
Ethenzamid, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BA79 |
Dipyrocetyl, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB |
Pyrazolone |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB01 |
Phenazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB02 |
Metamizol-Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB03 |
Aminophenazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB04 |
Propyphenazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB05 |
Nifenazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB51 |
Phenazon, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB52 |
Metamizol-Natrium, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB53 |
Aminophenazon, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB54 |
Propyphenazon, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB71 |
Phenazon, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB72 |
Metamizol-Natrium, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB73 |
Aminophenazon, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BB74 |
Propyphenazon, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE |
Anilide |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE01 |
Paracetamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE03 |
Phenacetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE04 |
Bucetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE05 |
Propacetamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE51 |
Paracetamol, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE53 |
Phenacetin, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE54 |
Bucetin, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE71 |
Paracetamol, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE73 |
Phenacetin, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BE74 |
Bucetin, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG |
Andere Analgetika und Antipyretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG02 |
Rimazolium |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG03 |
Glafenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG04 |
Floctafenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG05 |
Viminol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG06 |
Nefopam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG07 |
Flupirtin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG08 |
Ziconotid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02BG10 |
Nabiximols |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02C |
Migränemittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CA |
Mutterkorn-Alkaloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CA01 |
Dihydroergotamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CA02 |
Ergotamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CA04 |
Methysergid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CA07 |
Lisurid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CA51 |
Dihydroergotamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CA52 |
Ergotamin, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CA72 |
Ergotamin, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CB |
Corticosteroid-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CB01 |
Flumedroxon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CC |
Selektive Serotonin-5HT1-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CC01 |
Sumatriptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CC02 |
Naratriptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CC03 |
Zolmitriptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CC04 |
Rizatriptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CC05 |
Almotriptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CC06 |
Eletriptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CC07 |
Frovatriptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CX |
Andere Migränemittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CX01 |
Pizotifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CX02 |
Clonidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CX03 |
Iprazochrom |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CX05 |
Dimetotiazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N02CX06 |
Oxetoron |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03 |
Antiepileptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03A |
Antiepileptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AA |
Barbiturate und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AA01 |
Methylphenobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AA02 |
Phenobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AA03 |
Primidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AA04 |
Barbexaclon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AA30 |
Metharbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AB |
Hydantoin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AB01 |
Ethotoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AB02 |
Phenytoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AB03 |
Amino(diphenylhydantoin)valeriansäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AB04 |
Mephenytoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AB05 |
Fosphenytoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AB52 |
Phenytoin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AB54 |
Mephenytoin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AC |
Oxazolidin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AC01 |
Paramethadion |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AC02 |
Trimethadion |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AC03 |
Ethadion |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AD |
Succinimid-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AD01 |
Ethosuximid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AD02 |
Phensuximid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AD03 |
Mesuximid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AD51 |
Ethosuximid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AE |
Benzodiazepin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AE01 |
Clonazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AF |
Carboxamid-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AF01 |
Carbamazepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AF02 |
Oxcarbazepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AF03 |
Rufinamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AF04 |
Eslicarbazepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AG |
Fettsäure-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AG01 |
Valproinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AG02 |
Valpromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AG03 |
Aminobuttersäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AG04 |
Vigabatrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AG05 |
Progabid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AG06 |
Tiagabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX |
Andere Antiepileptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX03 |
Sultiam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX07 |
Phenacemid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX09 |
Lamotrigin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX10 |
Felbamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX11 |
Topiramat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX12 |
Gabapentin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX13 |
Pheneturid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX14 |
Levetiracetam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX15 |
Zonisamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX16 |
Pregabalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX17 |
Stiripentol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX18 |
Lacosamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX22 |
Perampanel |
2.16.840.1.113883.6.73 |
|
| 0-L |
N03AX30 |
Beclamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04 |
Antiparkinsonmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04A |
Anticholinergika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA |
Tertiäre Amine |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA01 |
Trihexyphenidyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA02 |
Biperiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA03 |
Metixen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA04 |
Procyclidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA05 |
Profenamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA08 |
Dexetimid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA09 |
Phenglutarimid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA10 |
Mazaticol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA11 |
Bornaprin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AA12 |
Tropatepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AB |
Ether, chemisch den Antihistaminika verwandt |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AB01 |
Etanautin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AB02 |
Orphenadrin (chlorid) |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AC |
Tropinether oder Tropin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AC01 |
Benzatropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04AC30 |
Etybenzatropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04B |
Dopaminerge Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BA |
Dopa und Dopa-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BA01 |
Levodopa |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BA02 |
Levodopa und Decarboxylasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BA03 |
Levodopa, Decarboxylasehemmer und COMT-Hemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BA04 |
Melevodopa |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BA05 |
Melevodopa und Decarboxylasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BA06 |
Etilevodopa und Decarboxylasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BB |
Adamantan-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BB01 |
Amantadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC |
Dopamin-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC01 |
Bromocriptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC02 |
Pergolid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC03 |
Dihydroergocryptinmesilat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC04 |
Ropinirol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC05 |
Pramipexol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC06 |
Cabergolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC07 |
Apomorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC08 |
Piribedil |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BC09 |
Rotigotin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BD |
Monoaminoxidase-B-Hemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BD01 |
Selegilin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BD02 |
Rasagilin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BX |
Andere dopaminerge Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BX01 |
Tolcapon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BX02 |
Entacapon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N04BX03 |
Budipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05 |
Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05A |
Antipsychotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AA |
Phenothiazine mit aliphatischer Seitenkette |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AA01 |
Chlorpromazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AA02 |
Levomepromazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AA03 |
Promazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AA04 |
Acepromazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AA05 |
Triflupromazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AA06 |
Cyamemazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AA07 |
Chlorproethazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB |
Phenothiazine mit Piperazinstruktur |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB01 |
Dixyrazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB02 |
Fluphenazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB03 |
Perphenazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB04 |
Prochlorperazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB05 |
Thiopropazat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB06 |
Trifluoperazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB07 |
Acetophenazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB08 |
Thioproperazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB09 |
Butaperazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AB10 |
Perazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AC |
Phenothiazine mit Piperidinstruktur |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AC01 |
Periciazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AC02 |
Thioridazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AC03 |
Mesoridazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AC04 |
Pipotiazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD |
Butyrophenon-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD01 |
Haloperidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD02 |
Trifluperidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD03 |
Melperon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD04 |
Moperon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD05 |
Pipamperon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD06 |
Bromperidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD07 |
Benperidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD08 |
Droperidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AD09 |
Fluanison |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AE |
Indol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AE01 |
Oxypertin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AE02 |
Molindon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AE03 |
Sertindol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AE04 |
Ziprasidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AF |
Thioxanthen-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AF01 |
Flupentixol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AF02 |
Clopenthixol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AF03 |
Chlorprothixen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AF04 |
Tiotixen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AF05 |
Zuclopenthixol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AG |
Diphenylbutylpiperidin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AG01 |
Fluspirilen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AG02 |
Pimozid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AG03 |
Penfluridol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AH |
Diazepine, Oxazepine und Thiazepine |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AH01 |
Loxapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AH02 |
Clozapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AH03 |
Olanzapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AH04 |
Quetiapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AH05 |
Asenapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AK |
Neuroleptika bei Spätdyskinesien |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AK01 |
Tetrabenazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AL |
Benzamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AL01 |
Sulpirid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AL02 |
Sultoprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AL03 |
Tiaprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AL04 |
Remoxiprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AL05 |
Amisulprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AL06 |
Veraliprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AL07 |
Levosulpirid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AN |
Lithium |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AN01 |
Lithium |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AX |
Andere Antipsychotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AX07 |
Prothipendyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AX08 |
Risperidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AX09 |
Clotiapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AX10 |
Mosapramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AX11 |
Zotepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AX12 |
Aripiprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05AX13 |
Paliperidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05B |
Anxiolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA |
Benzodiazepin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA01 |
Diazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA02 |
Chlordiazepoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA03 |
Medazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA04 |
Oxazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA05 |
Dikaliumclorazepat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA06 |
Lorazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA07 |
Adinazolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA08 |
Bromazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA09 |
Clobazam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA10 |
Ketazolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA11 |
Prazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA12 |
Alprazolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA13 |
Halazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA14 |
Pinazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA15 |
Camazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA16 |
Nordazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA17 |
Fludiazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA18 |
Ethylloflazepat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA19 |
Etizolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA21 |
Clotiazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA22 |
Cloxazolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA23 |
Tofisopam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BA56 |
Lorazepam, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BB |
Diphenylmethan-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BB01 |
Hydroxyzin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BB02 |
Captodiam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BB51 |
Hydroxyzin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BC |
Carbamate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BC01 |
Meprobamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BC03 |
Emylcamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BC04 |
Mebutamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BC51 |
Meprobamat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BD |
Dibenzo-bicyclo-octadien-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BD01 |
Benzoctamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BE |
Azaspirodecandion-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BE01 |
Buspiron |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BX |
Andere Anxiolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BX01 |
Mephenoxalon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BX02 |
Gedocarnil |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05BX03 |
Etifoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05C |
Hypnotika und Sedativa |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA |
Barbiturate, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA01 |
Pentobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA02 |
Amobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA03 |
Butobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA04 |
Barbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA05 |
Aprobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA06 |
Secobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA07 |
Talbutal |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA08 |
Vinylbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA09 |
Vinbarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA10 |
Cyclobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA11 |
Heptabarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA12 |
Reposal |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA15 |
Methohexital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA16 |
Hexobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA19 |
Thiopental |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA20 |
Etallobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA21 |
Allobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CA22 |
Proxibarbal |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CB |
Barbiturate, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CB01 |
Kombinationen von Barbituraten |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CB02 |
Barbiturate in Kombination mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CC |
Aldehyde und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CC01 |
Chloralhydrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CC02 |
Chloralodol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CC03 |
Acetylglycinamidchloralhydrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CC04 |
Dichloralphenazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CC05 |
Paraldehyd |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD |
Benzodiazepin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD01 |
Flurazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD02 |
Nitrazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD03 |
Flunitrazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD04 |
Estazolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD05 |
Triazolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD06 |
Lormetazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD07 |
Temazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD08 |
Midazolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD09 |
Brotizolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD10 |
Quazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD11 |
Loprazolam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD12 |
Doxefazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CD13 |
Cinolazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CE |
Piperidindion-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CE01 |
Glutethimid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CE02 |
Methyprylon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CE03 |
Pyrithyldion |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CF |
Benzodiazepin-verwandte Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CF01 |
Zopiclon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CF02 |
Zolpidem |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CF03 |
Zaleplon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM |
Andere Hypnotika und Sedativa |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM01 |
Methaqualon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM02 |
Clomethiazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM03 |
Bromisoval |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM04 |
Carbromal |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM05 |
Scopolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM06 |
Propiomazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM07 |
Triclofos |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM08 |
Ethchlorvynol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM09 |
Baldrian |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM10 |
Hexapropymate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM11 |
Bromide |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM12 |
Apronal |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM13 |
Valnoctamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM15 |
Methylpentynol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM16 |
Niaprazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM17 |
Melatonin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CM18 |
Dexmedetomidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CX |
Hypnotika und Sedativa in Kombination, exkl. Barbiturate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CX01 |
Meprobamat, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CX02 |
Methaqualon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CX03 |
Methylpentynol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CX04 |
Clomethiazol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CX05 |
Emepronium, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N05CX06 |
Dipiperonylaminoethanol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06 |
Psychoanaleptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06A |
Antidepressiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA |
Nichtselektive Monoamin-Wiederaufnahmehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA01 |
Desipramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA02 |
Imipramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA03 |
Imipraminoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA04 |
Clomipramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA05 |
Opipramol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA06 |
Trimipramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA07 |
Lofepramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA08 |
Dibenzepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA09 |
Amitriptylin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA10 |
Nortriptylin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA11 |
Protriptylin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA12 |
Doxepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA13 |
Iprindol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA14 |
Melitracen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA15 |
Butriptylin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA16 |
Dosulepin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA17 |
Amoxapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA18 |
Dimetacrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA19 |
Amineptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA21 |
Maprotilin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AA23 |
Quinupramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB |
Selektive Serotonin-Wiederaufnahmehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB02 |
Zimeldin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB03 |
Fluoxetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB04 |
Citalopram |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB05 |
Paroxetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB06 |
Sertralin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB07 |
Alaproclat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB08 |
Fluvoxamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB09 |
Etoperidon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AB10 |
Escitalopram |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AC |
N06AC |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AD |
N06AD |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AE |
N06AE |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AF |
Monoaminoxidasehemmer, nichtselektiv |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AF01 |
Isocarboxazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AF02 |
Nialamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AF03 |
Phenelzin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AF04 |
Tranylcypromin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AF05 |
Iproniazid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AF06 |
Iproclozid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AG |
Monoaminoxidase-A-Hemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AG02 |
Moclobemid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AG03 |
Toloxaton |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX |
Andere Antidepressiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX01 |
Oxitriptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX02 |
Tryptophan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX03 |
Mianserin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX04 |
Nomifensin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX05 |
Trazodon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX06 |
Nefazodon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX07 |
Minaprin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX08 |
Bifemelan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX09 |
Viloxazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX10 |
Oxaflozan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX11 |
Mirtazapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX12 |
Bupropion |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX13 |
Medifoxamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX14 |
Tianeptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX15 |
Pivagabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX16 |
Venlafaxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX17 |
Milnacipran |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX18 |
Reboxetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX19 |
Gepiron |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX21 |
Duloxetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX22 |
Agomelatin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX23 |
Desvenlafaxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06AX25 |
Hyperici herba |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06B |
Psychostimulanzien, Mittel für die ADHD und Nootropika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA |
Zentral wirkende Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA01 |
Amfetamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA02 |
Dexamfetamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA03 |
Metamfetamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA04 |
Methylphenidat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA05 |
Pemolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA06 |
Fencamfamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA07 |
Modafinil |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA08 |
Fenozolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA09 |
Atomoxetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BA10 |
Fenetyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BC |
Xanthin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BC01 |
Coffein |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BC02 |
Propentofyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX |
Andere Psychostimulanzien und Nootropika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX01 |
Meclofenoxat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX02 |
Pyritinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX03 |
Piracetam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX04 |
Deanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX05 |
Fipexid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX06 |
Citicolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX07 |
Oxiracetam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX08 |
Pirisudanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX09 |
Linopirdin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX10 |
Nizofenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX11 |
Aniracetam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX12 |
Acetylcarnitin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX13 |
Idebenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX14 |
Prolintan |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX15 |
Pipradrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX16 |
Pramiracetam |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX17 |
Adrafinil |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06BX18 |
Vinpocetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06C |
Psycholeptikau und Psychoanaleptika in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06CA |
Antidepressiva in Kombination mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06CA01 |
Amitriptylin und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06CA02 |
Melitracen und Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06CB |
Psychostimulanzien in Kombination mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06D |
Antidementiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06DA |
Cholinesterasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06DA01 |
Tacrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06DA02 |
Donepezil |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06DA03 |
Rivastigmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06DA04 |
Galantamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06DX |
Andere Antidementiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06DX01 |
Memantin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N06DX02 |
Ginkgo biloba |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07 |
Andere Mittel für das Nervensystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07A |
Parasympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AA |
Cholinesterasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AA01 |
Neostigmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AA02 |
Pyridostigmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AA03 |
Distigmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AA30 |
Ambenonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AA51 |
Neostigmin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AB |
Cholinester |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AB01 |
Carbachol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AB02 |
Bethanechol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AX |
Andere Parasympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AX01 |
Pilocarpin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07AX02 |
Cholinalfoscerat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07B |
Mittel zur Behandlung von Suchterkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BA |
Mittel zur Behandlung der Nikotinabhängigkeit |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BA01 |
Nicotin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BA02 |
Bupropion |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BA03 |
Vareniclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BB |
Mittel zur Behandlung der Alkoholabhängigkeit |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BB01 |
Disulfiram |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BB02 |
Calcium carbimid |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BB03 |
Acamprosat |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BB04 |
Naltrexon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BC |
Mittel zur Behandlung der Opiatabhängigkeit |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BC01 |
Buprenorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BC02 |
Methadon |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BC03 |
Levacetylmethadol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BC04 |
Lofexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07BC51 |
Buprenorphin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07C |
Antivertiginosa |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07CA |
Antivertiginosa |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07CA01 |
Betahistin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07CA02 |
Cinnarizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07CA03 |
Flunarizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07CA04 |
Acetylleucin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07CA52 |
Cinnarizin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07X |
Andere Mittel für das Nervensystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XA |
Ganglioside und Gangliosid-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XX |
Andere Mittel für das Nervensystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XX01 |
Tirilazad |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XX02 |
Riluzol |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XX03 |
Xaliproden |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XX04 |
Hydroxybuttersäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XX05 |
Amifampridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XX06 |
Tetrabenazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
N07XX07 |
Fampridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P |
Antiparasitäre Mittel, Insektizide und Repellenzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01 |
Mittel gegen Protozoen-Erkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01A |
Mittel gegen Amöben und andere Protozoen-Erkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AA |
Hydroxychinolin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AA01 |
Broxychinolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AA02 |
Clioquinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AA04 |
Chlorquinaldol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AA05 |
Tilbroquinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AA52 |
Clioquinol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AB |
Nitroimidazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AB01 |
Metronidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AB02 |
Tinidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AB03 |
Ornidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AB04 |
Azanidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AB05 |
Propenidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AB06 |
Nimorazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AB07 |
Secnidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AC |
Dichloracetamid-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AC01 |
Diloxanid |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AC02 |
Clefamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AC03 |
Etofamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AC04 |
Teclosan |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AR |
Arsen-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AR01 |
Arsthinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AR02 |
Difetarson |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AR03 |
Glycobiarsol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AR53 |
Glycobiarsol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX |
Andere Mittel gegen Amöbiasis und andere Protozoen-Erkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX01 |
Chiniofon |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX02 |
Emetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX04 |
Phanquinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX05 |
Mepacrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX06 |
Atovaquon |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX07 |
Trimetrexat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX08 |
Tenonitrozol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX09 |
Dehydroemetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX10 |
Fumagillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01AX52 |
Emetin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01B |
Malariamittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BA |
Aminochinoline |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BA01 |
Chloroquin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BA02 |
Hydroxychloroquin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BA03 |
Primaquin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BA06 |
Amodiaquin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BB |
Biguanide |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BB01 |
Proguanil |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BB02 |
Cycloguanilembonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BB51 |
Proguanil, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BC |
Methanolchinoline |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BC01 |
Chinin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BC02 |
Mefloquin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BD |
Diaminopyrimidine |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BD01 |
Pyrimethamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BD51 |
Pyrimethamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BE |
Artemisinin und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BE01 |
Artemisinin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BE02 |
Artemether |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BE03 |
Artesunat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BE04 |
Artemotil |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BE05 |
Artenimol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BE52 |
Artemether, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BF01 |
Artemether und Lumefantrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BF05 |
Artenimol und Piperaquin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BX |
Andere Malariamittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01BX01 |
Halofantrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01C |
Mittel gegen Leishmaniasis und Trypanosomiasis |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CA |
Nitroimidazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CA02 |
Benznidazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CB |
Antimon-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CB01 |
Megluminantimonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CB02 |
Natriumstibogluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CC |
Nitrofuran-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CC01 |
Nifurtimox |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CC02 |
Nitrofural |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CD |
Arsen-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CD01 |
Melarsoprol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CD02 |
Acetarsol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CX |
Andere Mittel gegen Leishmaniasis und Trypanosomiasis |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CX01 |
Pentamidinisethionat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CX02 |
Suramin natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
P01CX03 |
Eflornithin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02 |
Anthelmintika |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02B |
Trematodenmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BA |
Chinolin-Derivate und verwandte Substanzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BA01 |
Praziquantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BA02 |
Oxamniquin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BB |
Organophosphat-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BB01 |
Metrifonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BX |
Andere Trematodenmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BX01 |
Bithionol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BX02 |
Niridazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BX03 |
Stibophen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02BX04 |
Triclabendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02C |
Nematodenmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CA |
Benzimidazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CA01 |
Mebendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CA02 |
Tiabendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CA03 |
Albendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CA04 |
Ciclobendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CA05 |
Flubendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CA06 |
Fenbendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CA51 |
Mebendazol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CB |
Piperazin und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CB01 |
Piperazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CB02 |
Diethylcarbamazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CC |
Tetrahydropyrimidin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CC01 |
Pyrantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CC02 |
Oxantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CE |
Imidazothiazol-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CE01 |
Levamisol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CF |
Avermektine |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CF01 |
Ivermectin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CX |
Andere Nematodenmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CX01 |
Pyrvinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02CX02 |
Bephenium |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02D |
Bandwurmmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02DA |
Salicylsäure-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02DA01 |
Niclosamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02DX |
Andere Bandwurmmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02DX01 |
Desaspidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P02DX02 |
Dichlorophen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03 |
Mittel gegen Ektoparasiten, inkl. Antiscabiosa, Insektizide und Repellenzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03A |
Mittel gegen Ektoparasiten, inkl. Antiscabiosa |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AA |
Schwefel-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AA01 |
Dixanthogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AA02 |
Kaliumpolysulfid |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AA03 |
Mesulfen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AA04 |
Disulfiram |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AA05 |
Thiram |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AA54 |
Disulfiram, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AB |
Chlor-haltige Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AB01 |
Clofenotan |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AB02 |
Lindan |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AB51 |
Clofenotan, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC |
Pyrethrine, inkl. synthetische Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC01 |
Pyrethrum |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC02 |
Bioallethrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC03 |
Phenothrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC04 |
Permethrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC51 |
Pyrethrum, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC52 |
Bioallethrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC53 |
Phenothrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AC54 |
Permethrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AX |
Andere Mittel gegen Ektoparasiten, inkl. Antiscabiosa |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AX01 |
Benzylbenzoat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AX02 |
Kupferoleat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AX03 |
Malathion |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03AX04 |
Quassia |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03B |
Insektizide und Repellenzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BA |
Pyrethrine |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BA01 |
Cyfluthrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BA02 |
Cypermethrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BA03 |
Decamethrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BA04 |
Tetramethrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BX |
Andere Insektizide und Repellenzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BX01 |
Diethyltoluamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BX02 |
Dimethylphthalat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BX03 |
Dibutylphthalat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BX04 |
Dibutylsuccinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BX05 |
Dimethylcarbat |
2.16.840.1.113883.6.73 |
|
| 0-L |
P03BX06 |
Etohexadiol |
2.16.840.1.113883.6.73 |
|
| 0-L |
P52AF03 |
Oxantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
P52AG09 |
Closantel Natrium Dihydrat für Tiere |
2.16.840.1.113883.6.73 |
|
| 0-L |
P53AX25 |
Metaflumizon |
2.16.840.1.113883.6.73 |
|
| 0-L |
Q |
veterinär ATC |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA02BC01 |
Omeprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA03AB91 |
Synthetische Anticholinergika, quaternäre Ammoniumverbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA03AX |
andere Medikamente für funktionelle Darmstörung |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA03AX13 |
Silikone |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA03BB01 |
Butylscopolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA03DB04 |
Butylscopolamin und Analgetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA03FA01 |
Metoclopramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA04AD90 |
Maropitant |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA05AX90 |
Menbuton |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07AA06 |
Paromomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07AA10 |
Colistin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07AA51 |
Neomycin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07AA91 |
Gentamicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07AA99 |
Antibiotika, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07BB |
Bismuth Präparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07BC30 |
Kombinationen, andere intestinale Adsorbentien |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07CQ |
Orale Elektrolyte und Kohlenhydrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07FA01 |
Milchsäurebildner |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA07XA91 |
Zinkoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA08AB90 |
Mitratapid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA08AB91 |
Dirlotapide |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA10AC03 |
Insulin (Schwein) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA11A |
Multivitamine, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA11AB |
Multivitamins, other combinations |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA11CC05 |
Colecalciferol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA11HA |
andere Vitaminpräparate, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA11JA |
Kombinationen von Vitaminen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA11JC |
Vitamine, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA12 |
andere Mineralstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA12AA03 |
Calciumgluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA12AA07 |
Calciumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA12AX |
Calcium, Kombinationen mit Vitamin D und/oder anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA12CE99 |
Selen-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA12CX91 |
Butafosfan |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA12CX99 |
andere Mineralstoffe, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA16Q |
Präparate zur Prävention und/oder Behandlung von Acetonämie |
2.16.840.1.113883.6.73 |
|
| 0-L |
QA16QA06 |
Monensin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB02BA01 |
Phytomenadion |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB03AA02 |
Eisen(II)fumarat |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB03AC |
Eisen dreiwertig, parenterale Präparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB03AC06 |
ferric oxide dextran complexes |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB03AC90 |
Eisen Dextran Komplex |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB03AC91 |
Gleptoferron |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB05AA90 |
Blutsubstitut und Plasmaprotein-Fraktion |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB05B |
I.V.-Lösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB05BB |
Lösungen für Elektrolytenhaushalt |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB05BB01 |
Elektrolyte |
2.16.840.1.113883.6.73 |
|
| 0-L |
QB05XA30 |
Kombinationen von Elektrolyten |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC01CE90 |
Pimobendan |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC03AA56 |
Trichlormethiazide Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC03CA01 |
Furosemid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC03DA01 |
Spironolacton |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC04AD90 |
Propentofyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC09AA02 |
Enalapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC09AA05 |
Ramipril |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC09AA07 |
Benazepril |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC09AA16 |
Imidapril |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC09BA07 |
Benazepril und Diuretika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QC09CA07 |
Telmisartan |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD |
Dermatologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD01AA20 |
Antibiotika, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD01AC90 |
Enilconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD01AE20 |
Kombinationen, Antimykotika für topische Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD02AX |
Andere Emollentia und Hautschutzmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD03AX90 |
Ketanserin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD06A |
Antibiotika für topische Anwendungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD06AA02 |
Chlortetracycline |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD06AA03 |
Oxytetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD07AC |
Corticosteroide, stark wirksam (Gruppe III) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD07AC16 |
Hydrocortisonaceponat |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD07AC90 |
Resocortolbutyrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD07CC01 |
Betamethason und Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD07X |
Kortikosteroide, sehr potent, andere Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD08 |
Antiseptika und Desinfektionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD08A |
Antiseptika und Desinfektionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD08AC02 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD08AC52 |
Chlorhexidin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD08AE02 |
Policresulen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD08AG02 |
Povidon Jod |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD08AG03 |
Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
QD08AX |
Antiseptika und Desinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG01AX |
andere Antiinfektiva und Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG02AD01 |
Dinoprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG02AD90 |
Cloprostenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG02AD91 |
Luprostiol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG02CB01 |
Bromocriptin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG02CB03 |
Cabergolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03AC06 |
Medroxyprogesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03CA04 |
Estriol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03DA04 |
Progesteron |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03DA90 |
Proligeston |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03DB06 |
Chlormadinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03DX90 |
Altrenogest |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03DX91 |
Delmadinone |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03GA01 |
Chorion-Gonadotropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03GA03 |
Serum-Gonadotropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03GA90 |
Follikel stimulierende Hormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03GA99 |
Gonadotropine, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03GB |
synthetische Eisprungstimulanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03XA91 |
Gonadotropin-Releasing-Faktor-Analogon, konjugiert |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG03XB90 |
Aglepriston |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG04BX91 |
Phenylpropanolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG04CX |
Arzneimittel zur Behandlung der benignen Prostatahypertrophie |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG51A |
Antiinfektiva und Antiseptika für die intrauterine Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG51AA |
Antibakterielle Wirkstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG51AA02 |
Tetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG51AA09 |
Formosulfathiazol (intrauterin) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG51AA30 |
Antibiotika-Kombinationen zur intrauterinen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG52A |
Desinfektionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QG52X |
diverse Produkte für Zitzen und Euter |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH01BB02 |
Oxytocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH01BB03 |
Carbetocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH01CA |
Gonadotropin-Releasing-Hormone |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH01CA01 |
Gonadorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH01CA90 |
Buserelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH01CA92 |
Lecirelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH01CA93 |
Deslorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH02AB01 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH02AB02 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH02AB56 |
Prednisolon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH02CA01 |
Trilostan |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH03AA01 |
Levothyroxin-Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH03BB01 |
Carbimazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QH03BB02 |
Thiamazole |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI |
Immunologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI 09AB07 |
Tocopherolacetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01 |
Immunologika für Aves |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AA03 |
aviäre Infektiöse Bronchitis Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AA06 |
aviäres infektiöse Bronchitis Virus + aviäres infekt.Bursitis (Gumboro) Virus + Newcastle
Disease Virus/Paramyxo-Virus + aviäres Rhinotracheitis Virus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AA13 |
Newcastle Disease Virus / Paramyxvirus + aviäre infektiöse Bronchitis Virus + aviäre
Adenovirus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AA17 |
aviäre Rhinotracheitis-Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AA18 |
aviäre infektiöse Bronchitis Virus + Newcastle Disease Virus / Paramyxovirus + aviäre
Adenovirus + aviäre Rhinotracheitisvirus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AA21 |
aviäre infektiöse Bronchitis Virus + Newcastle Disease Virus / Paramyxovirus + aviäre
Rhinotracheitis Virus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AA23 |
aviäres Influenza Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AB |
Inaktivierter bakterieller Impfstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AB01 |
Salmonella |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AB02 |
Pasteurella |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AB05 |
Escherichia (Aves) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AB07 |
Ornithobacterium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AB08 |
Clostridium (Aves) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD |
aviärer lebend Virus-Impfstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD01 |
avian rhinotracheitis virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD02 |
aviäre Enzephalomyelitis Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD03 |
Aviäres Herpesvirus (Mareksche Krankheit) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD04 |
Hühner Anaemie Virus (CIA) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD06 |
Newcastle Disease Virus / Paramyxovirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD07 |
aviäres Infektiöse Bronchitis Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD08 |
Infektiöse Laryngotracheitis Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD09 |
avian infectious bursal disease virus (gumboro disease) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AD15 |
aviärs infektiöses Bursitis Virus (Gumboro) + aviäres Herpesvirus (Marek-Krankheit) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AE |
Bakterieller Lebendimpfstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AE01 |
Salmonella |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AE03 |
Mycoplasma (Aves) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AE04 |
Escherichia (Aves) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01AN01 |
Kokzidien |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01BE |
bakterieller Lebendimpfstoff für Ente |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01CA |
inaktivierter viraler Impfstoff für Puten |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01CD01 |
Rhinotracheitisvirus, Puten- |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI01EA01 |
Paramyxovirus (Tauben) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02 |
Immunologika für Bovidae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AA01 |
Bovinen Virusdiarrhoe |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AA02 |
Boviner respiratorische Syncytialvirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AA03 |
Bovine Rhinotracheitis Virus (IBR) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AA04 |
Maul- und Klauenseuchen Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AA08 |
Blauzungen Virus (Bovidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AB |
Inaktivierte bakterielle Impfstoffe (inkl. Mycoplasma, Toxoid und Chlamydien) - Bovidae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AB01 |
Clostridium (Bovidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AB04 |
Pasteurella (Bovidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AD01 |
Bovines Rhinotracheitis Virus (IBR) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AD07 |
Bovines Respiratorisches Synzytialvirus + Bovines Parainfluenza Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AI01 |
lebend bovines Rotavirus + lebend bovines Coronavirus + inakt. Escherichia |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AL01 |
bovines Rotavirus + bovines Coronavirus + Escherichia |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AL04 |
Bovines Parainfluenza Virus + Bovines Respiratorisches Synzytialvirus + Pasteurella |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AM05 |
bovine Rotavirus Antiserum + bovine Coronavirus Antiserum + Escherichia Antiserum |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AP01 |
Trichophyton |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AR01 |
bovines Tuberculin PPD |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AR02 |
aviäres Tuberculin PPD |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI02AT01 |
Escherichia |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI03 |
Immunologika für Capridae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI03AB |
Inaktiviere bakterielle Impfung (inkl. Mycoplasma, Toxoid und Chlamydien) - Capridae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI03AC |
Inaktivierte bakterielle Impfungen und Antisera |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI04 |
Immunologika für Ovidae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI04AA02 |
Blauzungen Virus (Ovidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI04AB01 |
Clostridium (Ovidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI04AB03 |
Bacteroides (Ovidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05 |
Immunologika für Equidae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AA |
Virale Impfstoffe, inaktiviert |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AA01 |
equine Influenza Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AA04 |
equine Rhinopneumonitis-Virus + equine Influenzavirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AA05 |
Equines Rhinopneumonitis Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AA10 |
West Nile Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AB |
inakt. bakterielle Impfung (inkl. Mycoplasma, Toxoid u. Chlamydien) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AB01 |
Streptococcen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AB03 |
Clostridium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AD02 |
Equines Influenza Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AI01 |
Equines Influenza Virus + Clostridium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AL01 |
equine Influenza Virus + Clostridium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AM01 |
Clostridium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AQ |
Trichophyton + Microsporum (Equidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI05AX |
andere Immunologika (Equidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06 |
Immunologika für Felidae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AA01 |
Feline Leukämievirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AA02 |
Feline Panleukopenie Virus / Parvovirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AA04 |
felines Rhinotracheitis Virus + felines Calicivirus + felines Panleukopenie Virus
/ Parvovirus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AA06 |
Felines infektiöses Peritonitis (FIP) Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AA09 |
Panleukopenie + Calicivirus + Rhinotracheitis + Tollwut Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AD01 |
felines Panleukopenie Virus / Parvovirus (lebend viral) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AD03 |
felines Rhinotracheitisvirus und felines Calicivirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AD04 |
Felines Panleukopenievirus + felines Rhinotracheitisvirus + felines Calicivirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AE02 |
Bordetella (Felidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AF01 |
Felines Panleukopenievirus + felines Rhinotracheitisvirus + felines Calicivirus +
Chlamydia
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AH |
Lebende und inaktivierte virale Impfungen (Felidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AH04 |
lebend felines Panleukopenie Virus / Parovirus + inakt. Tollwut Virus + inakt. felines
Rhinotracheitis Virus + inakt. felines Calicivirus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AH05 |
lebend felines Panleukopenie Virus / Parvovirus + lebend felines Rhinotracheitis Virus
+ lebend felines Calicivirus + inakt. Tollwut Virus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AH07 |
lebend felines Panleukopenie Virus / Parvovirus + lebend felines Rhinotracheitis Virus
+ lebend felines Calicivirus + inakt. felines Leukaemie Virus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AH08 |
lebend felines Rhinotracheitis Virus + inakt. felines Calicivirus-Antigen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AH09 |
lebend felines Rhinotracheitis Virus + lebend felines Panleukpenie Virus / Parvovirus
+ inakt. felines Calicivirus-Antigen
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AJ |
lebende und inaktivierte virale und bakterielle Impfstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AJ02 |
lebend felines Rhinotracheitis Virus + inakt. felines Calicivirus-Antigen + lebend
Chlamydien
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AJ03 |
lebend felinesRhinotracheitis Virus + inakt. felines Calicivirus-Antigen + lebend
felines Panleukopenie Virus / Parvovirus + lebend Chlamydien
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AL01 |
felines Panleukopenie Virus / Parvovirus + felines Rhinotracheitis Virus + felines
Calicivirus + felines infektiöse Leukaemie Virus + Chlamydia
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI06AL02 |
felines Panleukopenie Virus / Parvovirus + felines Rhinotracheitis Virus + felines
Calicivirus + inakt. Chlamydia
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07 |
Immunologika für Canidae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AA01 |
Parvovirose Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AA02 |
Rabiesvirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AA06 |
Canines Herpes-Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AB01 |
Leptospira |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AB04 |
Borrelia |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AD01 |
canines Parvovirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AD02 |
canines Staupe Virus + canines Adenovirus + canines Parvovirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AD03 |
canines Staupe Virus + canines Parovirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AD04 |
canines Staupe Virus + canines Adenovirus + canines Parvovirus + canines Parainfluenza
Virus
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AD08 |
canine Parainfluenza-Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AE01 |
Bordetella |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AF |
Lebende bakterielle und virale Impfungen (Canidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AI01 |
lebend canines Staupevirus + lebend canines Adenovirus + inakt. Leptospira |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AI02 |
lebend canines Staupevirus + lebend canines Adenovirus + lebend canines Parainfluenza
Virus + lebend canines Parvovirus + inakt. Leptospira
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AJ |
Lebende virale und inaktivierte virale und bakterielle Impfungen (Canidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AJ01 |
Staupe Virus (lebend) + Adenovirus (inakt.) + Tollwut (inakt.) + Leptospirose (inakt.)
Viren
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AJ02 |
Staupevirus (lebend) + Adenovirus (inakt.) + Leptospirose (inakt.) Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AJ03 |
Staup Virus (lebend) + Adenovirus (inakt.) + Parvovirus (inakt.) + Leptospirose (inakt.)
Viren
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AJ04 |
Staupe Virus (lebend) + Adenovirus (inakt.) + Parvovirose (inakt.) + Tollwut (inakt.)
+ Leptospirose (inakt.) Viren
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AJ05 |
lebend canines Staupevirus + lebend canines Adenovirus + lebend canines Parvovirus
+ inakt. Tollwut Virus + inakt. Leptospira
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AJ06 |
lebend canines Staupevirus + lebend canines Adenovirus + lebend Parainfluenzavirus
+ lebend canines Parvovirus + inakt. Tollwutvirus + inakt. Leptospira
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AJ10 |
canine Staupe Virus (lebend) + canine Adenovirus (lebend) + Parainfluenza Virus (lebend)
+ canine Parvovirus (lebend) + canine Coronavirus (inakt.) + Leptospira (inakt.)
|
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AL01 |
Tollwut Virus + Leptospira |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AL05 |
Bordetella + Parainfluenza Virus (Canidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07AO |
Inaktivierte Impfungen gegen Parasiten |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI07BD |
lebend viraler Impfstoff (Fuchs) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI08 |
Immunologika für Leporidae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI08AA01 |
Haemorrhagie-Virus (Kaninchen) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI08AD |
viraler Lebendimpfstoff (Leporidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI08AD02 |
Myxomatose Virus (Leporidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09 |
Immunologika für Suidae |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AA02 |
porcines Parvovirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AA03 |
Porcine Influenza Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AA05 |
Schweine-reproduktive und respiratorische Syndrom (PRRS)-Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AA06 |
Europäisches Schweinepestvirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AA07 |
Porcines Circovirus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AB02 |
Escherichia (Suidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AB03 |
Erysipelothrix |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AB04 |
Bordetella + Pasteurella (Suidae) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AB07 |
Actinobacillus/Haemophilus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AB08 |
Escherichia + Clostridium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AB13 |
Mycoplasma |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AB17 |
Mykoplasmen + Haemophilus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AD01 |
Aujeszkyʹscher Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AD03 |
PRRS-Virus |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AE04 |
Lawsonia |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI09AL01 |
porcines Parvovirus + Erysipelothrix |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI10 |
Immunologika für Pisces |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI10AB01 |
Aeromonas |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI10BB03 |
Yersinia |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI11 |
Immunologika für Rodentia |
2.16.840.1.113883.6.73 |
|
| 0-L |
QI20 |
Andere Immunologika (Bienen, Frettchen, Nerz,...) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01AA02 |
Doxycyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01AA03 |
Chlortetrazyklin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01AA06 |
Oxytetracycline |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01AA09 |
Oxytetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01AA53 |
Chlortetracyclin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01AA56 |
oxytetracycline, combinations |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01BA01 |
Chloramphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01BA02 |
Thiamphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01BA90 |
Florfenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01BA99 |
Amfenicol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01CA |
Penicilline mit erweitertem Spektrum |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01CA01 |
Ampicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01CA04 |
Amoxicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01CE02 |
Phenoxymethylpenicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01CE09 |
Procain-Penicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01CE90 |
Penethamat Hydroiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01CR02 |
Amoxicillin und Enzyminhibitor |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01DB01 |
Cefalexin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01DD90 |
Ceftiofur |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01DD91 |
Cefovecin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01DE90 |
Cefquinom |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01EQ03 |
Sulfadimidine |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01EW03 |
Sulfadimidin und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01EW10 |
Sulfadiazin und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01EW11 |
Sulfamethoxazol und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01EW12 |
Sulfachlorpyridazin und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01EW13 |
Sulfadoxin und Trimethoprim |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FA02 |
Spiramycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FA90 |
Tylosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FA91 |
Tilmicosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FA92 |
Tylvalosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FA94 |
Tulathromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FA95 |
Gamithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FA96 |
Tildipirosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FF01 |
Clindamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01FF52 |
Lincomycin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01GA90 |
Dihydrostreptomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01GB03 |
Gentamicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01GB04 |
Kanamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01GB05 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01GB90 |
Apramycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01MA90 |
Enrofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01MA92 |
Danofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01MA93 |
Marbofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01MA94 |
Difloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01MA95 |
Orbifloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01MA96 |
Ibafloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01MA97 |
Pardofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01RA01 |
Penicilline, Kombinationen mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01RA02 |
Sulfonamide, Kombinationen mit anderen Antibiotika (exkl.Trimethoprim) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01RA04 |
Spiramycin, Kombination mit anderen antibakteriellen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01RA91 |
Makrolide, Kombinationen mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01XB01 |
Colistin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01XQ01 |
Tiamulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01XQ02 |
Valnemulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ01XX92 |
Tiamulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ02AC02 |
Itraconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51CA51 |
Ampicillin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51CE09 |
Procaine-Benzylpenicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51CF02 |
Cloxacillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51CR50 |
Kombinationen von Penicillinen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51DA32 |
Cefoperazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51DA92 |
Cefquinom |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51DB01 |
Cefalexin (intramammär) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51DB04 |
Cefazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51DB90 |
Cefalonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51DD12 |
Cefoperazone |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51DE90 |
Cefquinom |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51E |
Sulfonamiden und Trimethoprim für intramammäre Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51FF90 |
Pirlimycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RC |
Antibiotika Kombinationen für intramammäre Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RC01 |
Antibiotika Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RC22 |
Benzylpenicillin, Kombinationen mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RC23 |
Procain Benzylpenicillin, Kombinationen mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RC26 |
Cloxacillin, Kombinationen mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RD01 |
Cefalexin, Kombinationen mit anderen antibakteriellen Substanzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RF03 |
Lincomycin, Kombinationen mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RG01 |
Neomycin, Kombinationen mit anderen Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51RV01 |
Antibiotika und Kortikosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
QJ51XX01 |
Rifaximin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QL01XE90 |
Protein-Kinase-Inhibitor |
2.16.840.1.113883.6.73 |
|
| 0-L |
QL01XE91 |
Toceranib |
2.16.840.1.113883.6.73 |
|
| 0-L |
QL03AB |
Interferone |
2.16.840.1.113883.6.73 |
|
| 0-L |
QL03AX |
Immunstimulanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
QL04AD01 |
Ciclosporin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AA01 |
Phenylbutazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AA90 |
Suxibuzon |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AC06 |
Meloxicam |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AE03 |
Ketoprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AE90 |
Vedaprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AE91 |
Carprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AE92 |
Tepoxalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AG02 |
Tolfenaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AG90 |
Flunixin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AH90 |
Firocoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AH91 |
Robenacoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AH92 |
Mavacoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AH93 |
Cimicoxib |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AX12 |
Glykosaminoglykan Polysulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01AX90 |
Pentosan Polysulfat Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM01BA01 |
Phenylbutazon und Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM02AC99 |
Zubereitungen mit Salicylsäure-Derivaten, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM03BX90 |
Guaifenesin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM05BA05 |
Tiludronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM05BC01 |
Dibotermin alfa |
2.16.840.1.113883.6.73 |
|
| 0-L |
QM09AX01 |
Hyaluronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN01 |
Anaesthetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN01AB06 |
Isofluran |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN01AB08 |
Sevofluran |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN01AC52 |
Methadon-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN01AX03 |
Ketamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN01AX10 |
Propofol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN01BA02 |
Procain |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02AB03 |
Fentanyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02AC52 |
Methadon-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02AE01 |
Buprenorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02AF |
Morphinderivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02AF01 |
Butorphanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02BA01 |
Acetylsalicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02BA04 |
Natriumsalicylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02BB02 |
Metamizol Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02BB52 |
Metamizol Natrium, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN02BE01 |
Paracetamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN03AA02 |
Phenobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN03AX90 |
Imepitoin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN04BC02 |
Pergolid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN05AA04 |
Acepromazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN05BA01 |
Diazepam |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN05CB02 |
Barbiturate in Kombination mit anderen Substanzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN05CM11 |
Bromide |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN05CM18 |
Dexmedetomidine |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN05CM90 |
Detomidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN05CM91 |
Medetomidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN05CM92 |
Xylazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN06AA04 |
Clomipramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN06AB03 |
Fluoxetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN06BC01 |
Xanthin-Derivate, Coffein |
2.16.840.1.113883.6.73 |
|
| 0-L |
QN51AA01 |
Pentobarbital |
2.16.840.1.113883.6.73 |
|
| 0-L |
QNO5AD90 |
Azaperon |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP51AJ01 |
Toltrazuril |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP51AJ03 |
Diclazuril |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP51AX08 |
Halofuginon |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AA01 |
Praziquantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AA51 |
Praziquantel-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AA54 |
Epsiprantel, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC01 |
Triclabendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC02 |
Oxfendazole |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC05 |
Fenbantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC06 |
Netobimin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC08 |
Cambendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC09 |
Mebendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC11 |
Albendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC12 |
Flubendazole |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC13 |
Fenbendazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AC55 |
Febantel-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52ACO1 |
Triclabendazole |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AE01 |
Levamisol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AE51 |
Levamisol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AF02 |
Pyrantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AG05 |
Rafoxanid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AG09 |
Closantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AX09 |
Monepantel |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP52AX60 |
Emodepsid und Toltrazuril |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AC04 |
Permethrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AC05 |
Flumethrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AC11 |
Deltamethrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AC54 |
Permethrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AC55 |
Flumethrin-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AD01 |
Amitraz |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AD51 |
Amitraz, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AE02 |
Propoxur |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AF01 |
Phoxime |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AF08 |
Guaifenesin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX04 |
Crotamiton |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX15 |
Fipronil |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX17 |
Imidacloprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX22 |
Thymol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX23 |
Pyriproxifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX25 |
Metaflumizone |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX26 |
Pyriprole |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX27 |
Indoxacarb |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53AX65 |
Fipronil-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53BC01 |
Lufenuron |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53BC51 |
Lufenuron, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53BD01 |
Methopren |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53BX02 |
Nitenpyram |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP53BX03 |
Spinosad |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP54AA01 |
Ivermectin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP54AA03 |
Doramectin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP54AA04 |
Epinomectin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP54AA05 |
Selamectin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP54AA51 |
Ivermectin-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP54AB02 |
Moxidectin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP54AB51 |
Milbemycin Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QP54AB52 |
Moxidectin-Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
QR03CC13 |
Clenbuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
QR03CC90 |
Clentbuterol Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QR05CB01 |
Acetylcystein |
2.16.840.1.113883.6.73 |
|
| 0-L |
QR05CB02 |
Bromhexin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QR05CB90 |
Dembrexin hydrochlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
QS01AA13 |
Fusidinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
QS01AA90 |
Cloxacillin (ophtalmologische Präparate) |
2.16.840.1.113883.6.73 |
|
| 0-L |
QS01XA18 |
Ciclosporin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QS02CA |
Corticosteroide und Antiinfektiva in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
QS02CA01 |
Prednisolon und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
QS02CA03 |
Hydrocortison und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
QS02CA91 |
Mometasone und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
QS02QA03 |
Ivermectin |
2.16.840.1.113883.6.73 |
|
| 0-L |
QV03AB90 |
Atipamezole |
2.16.840.1.113883.6.73 |
|
| 0-L |
QV03AN01 |
Oxygen |
2.16.840.1.113883.6.73 |
|
| 0-L |
QV03AX |
Nalfurafine |
2.16.840.1.113883.6.73 |
|
| 0-L |
QV06DE |
Kombinationen aus Aminosäuren, Elektroylten, Glucose und Vitaminen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R |
Respirationstrakt |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01 |
Rhinologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01A |
Dekongestiva und andere Rhinologika zur topischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA |
Sympathomimetika, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA02 |
Cyclopentamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA03 |
Ephedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA04 |
Phenylephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA05 |
Oxymetazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA06 |
Tetryzolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA07 |
Xylometazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA08 |
Naphazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA09 |
Tramazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA10 |
Metizolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA11 |
Tuaminoheptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA12 |
Fenoxazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA13 |
Tymazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AA14 |
Epinephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AB |
Sympathomimetika, Kombinationen exkl. Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AB01 |
Phenylephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AB02 |
Naphazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AB03 |
Tetryzolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AB05 |
Ephedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AB06 |
Xylometazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AB07 |
Oxymetazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AB08 |
Tuaminoheptan |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC |
Antiallergika, exkl. Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC01 |
Cromoglicinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC02 |
Levocabastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC03 |
Azelastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC04 |
Antazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC05 |
Spagluminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC06 |
Thonzylamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC07 |
Nedocromil |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC08 |
Olopatadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AC51 |
Cromoglicinsäure, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD |
Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD01 |
Beclometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD02 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD03 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD04 |
Flunisolid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD05 |
Budesonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD06 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD07 |
Tixocortol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD08 |
Fluticason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD09 |
Mometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD11 |
Triamcinolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD12 |
Fluticasonfuroat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD52 |
Prednisolon, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD53 |
Dexamethason, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD57 |
Tixocortol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD58 |
Fluticason, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AD60 |
Hydrocortison, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX |
Andere Rhinologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX01 |
Calciumhexaminthiocyanat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX02 |
Retinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX03 |
Ipratropiumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX05 |
Ritiometan |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX06 |
Mupirocin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX07 |
Hexamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX08 |
Framycetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX10 |
Verschiedene |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01AX30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01B |
Nasale Dekongestiva zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01BA |
Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01BA01 |
Phenylpropanolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01BA02 |
Pseudoephedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01BA03 |
Phenylephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01BA51 |
Phenylpropanolamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01BA52 |
Pseudoephedrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R01BA53 |
Phenylephrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02 |
Hals- und Rachentherapeutika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02A |
Hals- und Rachentherapeutika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA |
Antiseptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA01 |
Ambazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA02 |
Dequalinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA03 |
Dichlorbenzylalkohol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA05 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA06 |
Cetylpyridinium |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA09 |
Benzethonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA10 |
Myristylbenzalkonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA11 |
Chlorquinaldol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA12 |
Hexylresorcinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA13 |
Acriflaviniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA14 |
Oxychinolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA15 |
Povidon-Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA16 |
Benzalkonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA17 |
Cetrimonium |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA18 |
Hexamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA19 |
Phenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AA20 |
Verschiedene |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AB |
Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AB01 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AB02 |
Tyrothricin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AB03 |
Fusafungin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AB04 |
Bacitracin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AB30 |
Gramicidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AD |
Lokalanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AD01 |
Benzocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AD02 |
Lidocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AD03 |
Cocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AD04 |
Dyclonin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R02AX01 |
Flurbiprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03 |
Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03A |
Inhalative Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AA |
Alpha- und Beta-Adrenorezeptor-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AA01 |
Epinephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AB |
Nichtselektive Beta-Adrenorezeptor-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AB02 |
Isoprenalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AB03 |
Orciprenalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC |
Selektive Beta-2-Adrenorezeptor-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC02 |
Salbutamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC03 |
Terbutalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC04 |
Fenoterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC05 |
Rimiterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC06 |
Hexoprenalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC07 |
Isoetarin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC08 |
Pirbuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC09 |
Tretoquinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC10 |
Carbuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC11 |
Tulobuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC12 |
Salmeterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC13 |
Formoterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC14 |
Clenbuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC15 |
Reproterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC16 |
Procaterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AC17 |
Bitolterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AH |
Kombinationen von Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AK |
Sympathomimetika und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AK01 |
Epinephrin und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AK02 |
Isoprenalin und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AK03 |
Fenoterol und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AK04 |
Salbutamol und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AK05 |
Reproterol und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AK06 |
Salmeterol und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03AK07 |
Formoterol und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03B |
Andere inhalative Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA |
Glucocorticoide |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA01 |
Beclometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA02 |
Budesonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA03 |
Flunisolid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA04 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA05 |
Fluticason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA06 |
Triamcinolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA07 |
Mometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BA08 |
Ciclesonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BB |
Anticholinergika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BB01 |
Ipratropiumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BB02 |
Oxitropiumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BB03 |
Stechapfel-haltige Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BB04 |
Tiotropiumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BC |
Antiallergika, exkl. Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BC01 |
Cromoglicinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BC03 |
Nedocromil |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BX |
Andere inhalative Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03BX01 |
Fenspirid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03C |
Sympathomimetika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CA |
Alpha- und Beta-Adrenorezeptor-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CA02 |
Ephedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CB |
Nichtselektive Beta-Adrenorezeptor-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CB01 |
Isoprenalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CB02 |
Methoxyphenamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CB03 |
Orciprenalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CB51 |
Isoprenalin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CB53 |
Orciprenalin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC |
Selektive Beta2-Adrenorezeptor-Agonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC02 |
Salbutamol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC03 |
Terbutalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC04 |
Fenoterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC05 |
Hexoprenalin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC06 |
Isoetarin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC07 |
Pirbuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC08 |
Procaterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC09 |
Tretoquinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC10 |
Carbuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC11 |
Tulobuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC12 |
Bambuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC13 |
Clenbuterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC14 |
Reproterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CC53 |
Terbutalin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03CK |
Sympathomimetika und andere Mittel bei obstruktiven Atemwegserkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03D |
Andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA |
Xanthine |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA01 |
Diprophyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA02 |
Cholintheophyllinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA03 |
Proxyphyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA04 |
Theophyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA05 |
Aminophyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA06 |
Etamiphyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA07 |
Theobromin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA08 |
Bamifyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA09 |
Acefyllinpiperazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA10 |
Bufyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA11 |
Doxofyllin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA20 |
Kombinationen von Xanthinen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA51 |
Diprophyllin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA54 |
Theophyllin, Kombinationen exkl. Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA55 |
Aminophyllin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA57 |
Theobromin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DA74 |
Theophyllin, Kombinationen mit Psycholeptika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DB |
Xanthine und Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DB01 |
Diprophyllin und Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DB02 |
Cholintheophyllinat und Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DB03 |
Proxyphyllin und Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DB04 |
Theophyllin und Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DB05 |
Aminophyllin und Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DB06 |
Etamiphyllin und Sympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DC |
Leukotrienrezeptor-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DC01 |
Zafirlukast |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DC02 |
Pranlukast |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DC03 |
Montelukast |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DC04 |
Ibudilast |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DX |
Andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DX01 |
Amlexanox |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DX02 |
Eprozinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DX03 |
Fenspirid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DX05 |
Omalizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DX06 |
Seratrodast |
2.16.840.1.113883.6.73 |
|
| 0-L |
R03DX07 |
Roflumilast |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05 |
Husten- und Erkältungspräparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05C |
Expektoranzien, exkl. Kombinationen mit Antitussiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA |
Expektoranzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA01 |
Tyloxapol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA02 |
Kaliumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA03 |
Guaifenesin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA04 |
Ipecacuanha |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA05 |
Eibischwurzel |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA06 |
Senega |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA07 |
Antimonpentasulfid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA08 |
Kreosot |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA09 |
Guajacolsulfonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA11 |
Levoverbenon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CA12 |
Hederae helicis folium |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB |
Mukolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB01 |
Acetylcystein |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB02 |
Bromhexin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB03 |
Carbocistein |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB04 |
Eprazinon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB05 |
Mesna |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB06 |
Ambroxol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB07 |
Sobrerol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB08 |
Domiodol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB09 |
Letostein |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB10 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB11 |
Stepronin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB12 |
Tiopronin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB13 |
Dornase alfa (Desoxyribonuclease) |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB14 |
Neltenexin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CB15 |
Erdostein |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CP01 |
Thymiankraut |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05CP02 |
Efeublätter |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05D |
Antitussiva, exkl. Kombinationen mit Expektoranzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA |
Opium-Alkaloide und Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA01 |
Ethylmorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA03 |
Hydrocodon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA04 |
Codein |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA05 |
Opium-Alkaloide mit Morphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA06 |
Normethadon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA07 |
Noscapin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA08 |
Pholcodin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA09 |
Dextromethorphan |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA10 |
Thebacon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA11 |
Dimemorfan |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA12 |
Acetyldihydrocodein |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DA20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB |
Andere Antitussiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB01 |
Benzonatat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB02 |
Benproperin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB03 |
Clobutinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB04 |
Isoaminil |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB05 |
Pentoxyverin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB07 |
Oxolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB09 |
Oxeladin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB10 |
Clofedanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB11 |
Pipazetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB12 |
Bibenzoniumbromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB13 |
Butamirat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB14 |
Fedrilat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB15 |
Zipeprol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB16 |
Dibunat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB17 |
Droxypropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB18 |
Prenoxdiazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB19 |
Dropropizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB20 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB21 |
Cloperastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB22 |
Meprotixol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB23 |
Piperidion |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB24 |
Tipepidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB25 |
Morclofon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB26 |
Nepinalon |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB27 |
Levodropropizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05DB28 |
Dimethoxanat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05F |
Antitussiva und Expektoranzien, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05FA |
Opium-Derivate und Expektoranzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05FA01 |
Opium-Derivate und Mukolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05FA02 |
Opium-Derivate und Expektoranzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05FB |
Andere Antitussiva und Expektoranzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05FB01 |
Antitussiva und Mukolytika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05FB02 |
Antitussiva und Expektoranzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
R05X |
Andere Kombinationspräparate gegen Erkältungskrankheiten |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06 |
Antihistaminika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06A |
Antihistaminika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA |
Aminoalkylether |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA01 |
Bromazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA02 |
Diphenhydramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA04 |
Clemastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA06 |
Chlorphenoxamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA07 |
Diphenylpyralin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA08 |
Carbinoxamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA09 |
Doxylamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA52 |
Diphenhydramin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA54 |
Clemastin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA56 |
Chlorphenoxamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AA57 |
Diphenylpyralin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB |
Substituierte Alkylamine |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB01 |
Brompheniramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB02 |
Dexchlorpheniramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB03 |
Dimetinden |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB04 |
Chlorphenamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB05 |
Pheniramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB06 |
Dexbrompheniramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB07 |
Talastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB51 |
Brompheniramin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB52 |
Dexchlorpheniramin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB54 |
Chlorphenamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AB56 |
Dexbrompheniramin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC |
Substituierte Ethylendiamine |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC01 |
Mepyramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC02 |
Histapyrrodin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC03 |
Chloropyramin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC04 |
Tripelennamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC05 |
Methapyrilen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC06 |
Thonzylamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC52 |
Histapyrrodin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AC53 |
Chloropyramin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD |
Phenothiazin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD01 |
Alimemazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD02 |
Promethazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD03 |
Thiethylperazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD04 |
Methdilazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD05 |
Hydroxyethylpromethazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD06 |
Thiazinam |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD07 |
Mequitazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD08 |
Oxomemazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD09 |
Isothipendyl |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD52 |
Promethazin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AD55 |
Hydroxyethylpromethazin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE |
Piperazin-Derivate |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE01 |
Buclizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE03 |
Cyclizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE04 |
Chlorcyclizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE05 |
Meclozin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE06 |
Oxatomid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE07 |
Cetirizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE09 |
Levocetirizin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE51 |
Buclizin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE53 |
Cyclizin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AE55 |
Meclozin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AK |
Kombinationen von Antihistaminika |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX |
Andere Antihistaminika zur systemischen Anwendung |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX01 |
Bamipin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX02 |
Cyproheptadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX03 |
Thenalidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX04 |
Phenindamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX05 |
Antazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX07 |
Triprolidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX08 |
Pyrrobutamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX09 |
Azatadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX11 |
Astemizol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX12 |
Terfenadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX13 |
Loratadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX15 |
Mebhydrolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX16 |
Deptropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX17 |
Ketotifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX18 |
Acrivastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX19 |
Azelastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX21 |
Tritoqualin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX22 |
Ebastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX23 |
Pimethixen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX24 |
Epinastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX25 |
Mizolastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX26 |
Fexofenadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX27 |
Desloratadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX28 |
Rupatadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX29 |
Bilastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX53 |
Thenalidin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R06AX58 |
Pyrrobutamin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07 |
Andere Mittel für den Respirationstrakt |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07A |
Andere Mittel für den Respirationstrakt |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AA |
Surfactant-Präparate |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AA01 |
Colfoscerilpalmitat |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AA02 |
Natürliche Phospholipide |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AA30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB |
Atemstimulanzien |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB01 |
Doxapram |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB02 |
Nikethamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB03 |
Pentetrazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB04 |
Etamivan |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB05 |
Bemegrid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB06 |
Prethcamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB07 |
Almitrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB08 |
Dimeflin |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB09 |
Mepixanox |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB52 |
Nikethamid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AB53 |
Pentetrazol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AX |
Andere Mittel für den Respirationstrakt |
2.16.840.1.113883.6.73 |
|
| 0-L |
R07AX01 |
Stickoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S |
Sinnesorgane |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01 |
Ophthalmika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01A |
Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA |
Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA01 |
Chloramphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA02 |
Chlortetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA03 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA04 |
Oxytetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA05 |
Tyrothricin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA07 |
Framycetin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA09 |
Tetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA10 |
Natamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA11 |
Gentamicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA12 |
Tobramycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA13 |
Fusidinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA14 |
Benzylpenicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA15 |
Dihydrostreptomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA16 |
Rifamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA17 |
Erythromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA18 |
Polymyxin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA19 |
Ampicillin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA20 |
Antibiotika in Kombination mit anderen Mitteln |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA21 |
Amikacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA22 |
Micronomicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA23 |
Netilmicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA24 |
Kanamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA25 |
Azidamfenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA26 |
Azithromycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA27 |
Cefuroxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AA30 |
Kombinationen von Antibiotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AB |
Sulfonamide |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AB01 |
Sulfamethizol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AB02 |
Sulfafurazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AB03 |
Sulfadicramid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AB04 |
Sulfacetamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AB05 |
Sulfafenazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD |
Antivirale Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD01 |
Idoxuridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD02 |
Trifluridin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD03 |
Aciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD05 |
Interferon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD06 |
Vidarabin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD07 |
Famciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD08 |
Fomivirsen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AD09 |
Ganciclovir |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AE01 |
Ofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX |
Andere Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX01 |
Quecksilber-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX02 |
Silber-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX03 |
Zink-haltige Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX04 |
Nitrofural |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX05 |
Bibrocathol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX06 |
Resorcin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX07 |
Natriumborat |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX08 |
Hexamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX09 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX10 |
Natriumpropionat |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX11 |
Ofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX12 |
Norfloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX13 |
Ciprofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX14 |
Dibrompropamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX15 |
Propamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX16 |
Picloxydin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX17 |
Lomefloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX18 |
Povidon-Iod |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX19 |
Levofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX21 |
Gatifloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01AX22 |
Moxifloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01B |
Antiphlogistika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA |
Corticosteroide, rein |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA01 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA02 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA03 |
Cortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA04 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA05 |
Triamcinolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA06 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA07 |
Fluorometholon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA08 |
Medryson |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA09 |
Clobetason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA10 |
Alclometason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA11 |
Desonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA12 |
Formocortal |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA13 |
Rimexolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA14 |
Loteprednol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BA15 |
Fluocinolon acetonid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BB |
Corticosteroide und Mydriatika in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BB01 |
Hydrocortison und Mydriatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BB02 |
Prednisolon und Mydriatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BB03 |
Fluorometholon und Mydriatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BB04 |
Betamethason und Mydriatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC |
Nichtsteroidale Antiphlogistika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC01 |
Indometacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC02 |
Oxyphenbutazon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC03 |
Diclofenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC04 |
Flurbiprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC05 |
Ketorolac |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC06 |
Piroxicam |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC07 |
Bendazac |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC08 |
Salicylsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC09 |
Pranoprofen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC10 |
Nepafenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01BC11 |
Bromfenac |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01C |
Antiphlogistika und Antiinfektiva in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA |
Corticosteroide und Antiinfektiva in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA01 |
Dexamethason und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA02 |
Prednisolon und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA03 |
Hydrocortison und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA04 |
Fluocortolon und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA05 |
Betamethason und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA06 |
Fludrocortison und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA07 |
Fluorometholon und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA08 |
Methylprednisolon und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA09 |
Chlorprednison und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA10 |
Fluocinolonacetonid und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CA11 |
Clobetason und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CB |
Corticosteroide/Antiinfektiva/Mydriatika in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CB01 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CB02 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CB03 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CB04 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CB05 |
Fluorometholon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CC |
Nichtsteroidale Antiphlogistika und Antiinfektiva in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01CC01 |
Diclofenac und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01E |
Glaukommittel und Miotika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EA |
Sympathomimetika in der Glaukomtherapie |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EA01 |
Epinephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EA02 |
Dipivefrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EA03 |
Apraclonidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EA04 |
Clonidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EA05 |
Brimonidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EA51 |
Epinephrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB |
Parasympathomimetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB01 |
Pilocarpin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB02 |
Carbachol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB03 |
Ecothiopat |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB04 |
Demecarium |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB05 |
Physostigmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB06 |
Neostigmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB07 |
Fluostigmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB08 |
Aceclidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB09 |
Acetylcholin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB10 |
Paraoxon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB51 |
Pilocarpin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EB58 |
Aceclidin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EC |
Carboanhydrasehemmer |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EC01 |
Acetazolamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EC02 |
Diclofenamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EC03 |
Dorzolamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EC04 |
Brinzolamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EC05 |
Methazolamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED |
Beta-Adrenorezeptor-Antagonisten |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED01 |
Timolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED02 |
Betaxolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED03 |
Levobunolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED04 |
Metipranolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED05 |
Carteolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED06 |
Befunolol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED51 |
Timolol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED52 |
Betaxolol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED54 |
Metipranolol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01ED55 |
Carteolol, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EE |
Prostaglandin-Analoga |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EE01 |
Latanoprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EE02 |
Unoproston |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EE03 |
Bimatoprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EE04 |
Travoprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EE05 |
Tafluprost |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EX |
Andere Glaukommittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EX01 |
Guanethidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01EX02 |
Dapiprazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01F |
Mydriatika und Zykloplegika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FA |
Anticholinergika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FA01 |
Atropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FA02 |
Scopolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FA03 |
Methylscopolamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FA04 |
Cyclopentolat |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FA05 |
Homatropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FA06 |
Tropicamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FA56 |
Tropicamid, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FB |
Sympathomimetika, exkl. Glaukommittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FB01 |
Phenylephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FB02 |
Ephedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01FB03 |
Ibopamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01G |
Dekongestiva und Antiallergika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA |
Sympathomimetika als Dekongestiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA01 |
Naphazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA02 |
Tetryzolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA03 |
Xylometazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA04 |
Oxymetazolin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA05 |
Phenylephrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA06 |
Oxedrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA51 |
Naphazolin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA52 |
Tetryzolin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA53 |
Xylometazolin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA55 |
Phenylephrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GA56 |
Oxedrin, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX |
Andere Antiallergika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX01 |
Cromoglicinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX02 |
Levocabastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX03 |
Spagluminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX04 |
Nedocromil |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX05 |
Lodoxamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX06 |
Emedastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX07 |
Azelastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX08 |
Ketotifen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX09 |
Olopatadin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX10 |
Epinastin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01GX51 |
Cromoglicinsäure, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01H |
Lokalanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA |
Lokalanästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA01 |
Cocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA02 |
Oxybuprocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA03 |
Tetracain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA04 |
Proxymetacain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA05 |
Procain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA06 |
Cinchocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA07 |
Lidocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01HA30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01J |
Diagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01JA |
Farbstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01JA01 |
Fluorescein |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01JA02 |
Bengalrosa-Natrium |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01JA51 |
Fluorescein, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01JX |
Andere ophthalmologische Diagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01K |
Chirurgische Hilfsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01KA |
Viskoelastische Substanzen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01KA01 |
Hyaluronsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01KA02 |
Hypromellose |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01KA51 |
Hyaluronsäure, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01KX |
Andere chirurgische Hilfsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01KX01 |
Chymotrypsin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01L |
Mittel gegen vaskuläre Augenerkrankungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01LA |
Antineovaskuläre Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01LA01 |
Verteporfin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01LA02 |
Anecortav |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01LA03 |
Pegaptanib |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01LA04 |
Ranibizumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01X |
Andere Ophthalmika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA |
Andere Ophthalmika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA01 |
Guajazulen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA02 |
Retinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA03 |
Natriumchlorid, hyperton |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA04 |
Kaliumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA05 |
Natriumedetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA06 |
Ethylmorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA07 |
Alaun |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA08 |
Acetylcystein |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA09 |
Iodoheparinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA10 |
Inosin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA11 |
Nandrolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA12 |
Dexpanthenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA13 |
Alteplase |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA14 |
Heparin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA15 |
Ascorbinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
S01XA20 |
Künstliche Tränen und andere indifferente Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02 |
Otologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02A |
Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA |
Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA01 |
Chloramphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA02 |
Nitrofural |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA03 |
Borsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA04 |
Aluminiumacetattartrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA05 |
Clioquinol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA06 |
Hydrogenperoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA07 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA08 |
Tetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA09 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA10 |
Essigsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA11 |
Polymyxin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA12 |
Rifamycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA13 |
Miconazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA14 |
Gentamicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA15 |
Ciprofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA16 |
Ofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02AA30 |
Antiinfektiva, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02B |
Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02BA |
Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02BA01 |
Hydrocortison |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02BA03 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02BA06 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02BA07 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02C |
Corticosteroide und Antiinfektiva in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02CA |
Corticosteroide und Antiinfektiva in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02CA01 |
Prednisolon und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02CA02 |
Flumetason und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02CA03 |
Hydrocortison und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02CA04 |
Triamcinolon und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02CA05 |
Fluocinolonacetonid und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02CA06 |
Dexamethason und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02CA07 |
Fludrocortison und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02D |
Andere Otologika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02DA |
Analgetika und Anästhetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02DA01 |
Lidocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02DA02 |
Cocain |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02DA30 |
Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S02DC |
Indifferente Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03 |
Ophthalmologische und otologische Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03A |
Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA |
Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA01 |
Neomycin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA02 |
Tetracyclin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA03 |
Polymyxin B |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA04 |
Chlorhexidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA05 |
Hexamidin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA06 |
Gentamicin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA07 |
Ciprofloxacin |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA08 |
Chloramphenicol |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03AA30 |
Antiinfektiva, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03B |
Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03BA |
Corticosteroide |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03BA01 |
Dexamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03BA02 |
Prednisolon |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03BA03 |
Betamethason |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03C |
Corticosteroide und Antiinfektiva in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03CA |
Corticosteroide und Antiinfektiva in Kombination |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03CA01 |
Dexamethason und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03CA02 |
Prednisolon und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03CA04 |
Hydrocortison und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03CA05 |
Fludrocortison und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03CA06 |
Betamethason und Antiinfektiva |
2.16.840.1.113883.6.73 |
|
| 0-L |
S03D |
Andere ophthalmologische und otologische Zubereitungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V |
Varia |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01 |
Allergene |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01A |
Allergene |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA |
Allergen-Extrakte |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA01 |
Federn |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA02 |
Gräserpollen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA03 |
Hausstaub |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA04 |
Schimmel- und Hefepilze |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA05 |
Baumpollen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA07 |
Insekten |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA08 |
Nahrungsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA09 |
Textilien |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA10 |
Blüten |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA11 |
Tiere |
2.16.840.1.113883.6.73 |
|
| 0-L |
V01AA20 |
Verschiedene |
2.16.840.1.113883.6.73 |
|
| 0-L |
V02 |
Immunosupressive agents |
2.16.840.1.113883.6.73 |
|
| 0-L |
V02C |
Immunosupressive agents |
2.16.840.1.113883.6.73 |
|
| 0-L |
V02CA |
Selective immunosuppressive agents |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03 |
Alle übrigen therapeutischen Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03A |
Alle übrigen therapeutischen Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AA |
Drugs for treatment on chronic alcoholism |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB |
Antidote |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB01 |
Ipecacuanha |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB02 |
Nalorphin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB03 |
Edetate |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB04 |
Pralidoxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB05 |
Prednisolon und Promethazin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB06 |
Thiosulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB08 |
Natriumnitrit |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB09 |
Dimercaprol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB13 |
Obidoxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB14 |
Protamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB15 |
Naloxon |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB16 |
Ethanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB17 |
Methylthioniniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB18 |
Kaliumpermanganat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB19 |
Physostigmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB20 |
Kupfersulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB21 |
Kaliumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB22 |
Amylnitrit |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB23 |
Acetylcystein |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB24 |
Digitalis-Antitoxin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB25 |
Flumazenil |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB26 |
Methionin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB27 |
4-Dimethylaminophenol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB29 |
Cholinesterase |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB31 |
Eisen(III)hexacyanoferrat(II) |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB32 |
Glutathion |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB33 |
Hydroxocobalamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB34 |
Fomepizol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AB35 |
Sugammadex |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AC |
Eisen-Chelatbildner |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AC01 |
Deferoxamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AC02 |
Deferipron |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AC03 |
Deferasirox |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AE |
Mittel zur Behandlung der Hyperkaliämie und Hyperphosphatämie |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AE01 |
Polystyrolsulfonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AE02 |
Sevelamer |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AE03 |
Lanthan(III)-carbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AE04 |
Calciumacetat und Mangesiumcarbonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF |
Entgiftungsmittel für die Behandlung mit Zytostatika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF01 |
Mesna |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF02 |
Dexrazoxan |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF03 |
Calciumfolinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF04 |
Calciumlevofolinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF05 |
Amifostin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF06 |
Natriumfolinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF07 |
Rasburicase |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF08 |
Palifermin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AF09 |
Glucarpidase |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AG |
Mittel zur Behandlung der Hyperkalzämie |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AG01 |
Natriumcellulosephosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AH |
Mittel zur Behandlung der Hypoglykämie |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AH01 |
Diazoxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AK |
Gewebekleber |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AM |
Mittel zur Embolisation |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AN |
Medizinische Gase |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AN01 |
Sauerstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AN02 |
Kohlendioxid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AN03 |
Helium |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AN04 |
Stickstoff |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AN05 |
Medizinische Luft |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AX |
Andere therapeutische Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AZ |
Nerven dämpfende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V03AZ01 |
Ethanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04 |
Diagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04AX |
Other contrast media |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04B |
Urin-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04C |
Andere Diagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CA |
Diabetes-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CA01 |
Tolbutamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CA02 |
Glucose |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CB |
Fettabsorptions-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CB01 |
Vitamin-A-Konzentrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CC |
Gallenfluss-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CC01 |
Sorbitol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CC02 |
Magnesiumsulfat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CC03 |
Sincalid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CC04 |
Ceruletid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CD |
Hypophysenfunktions-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CD01 |
Metyrapon |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CD03 |
Sermorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CD04 |
Corticoliberin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CD05 |
Somatorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CE |
Leberfunktions-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CE01 |
Galactose |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CE02 |
Bromsulfalein |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CF |
Tuberkulose-Diagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CF01 |
Tuberkulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CG |
Magensäuresekretions-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CG01 |
Kationenaustauscherharze |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CG02 |
Betazol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CG03 |
Histaminphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CG04 |
Pentagastrin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CG05 |
Methylthioniniumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CG30 |
Coffein und Natriumbenzoat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CH |
Nierenfunktions-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CH01 |
Inulin und andere Polyfructosane |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CH02 |
Indigokarmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CH03 |
Phenolsulfonphthalein |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CH04 |
Alsactid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CH30 |
Aminohippursäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CJ |
Schilddrüsenfunktions-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CJ01 |
Thyrotropin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CJ02 |
Protirelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CK |
Pankreasfunktions-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CK01 |
Sekretin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CK02 |
Pankreozymin (Cholecystokinin) |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CK03 |
Bentiromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CL |
Allergie-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CM |
Fertilitäts-Tests |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CM01 |
Gonadorelin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04CX |
Andere Diagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V04D |
Diagnostic radiopharmaceuticals |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06 |
Allgemeine Diätetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06A |
Diätetika zur Behandlung der Adipositas |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06AA |
Niedrigkalorische Diäten |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06B |
Proteinzusatznahrung |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06C |
Säuglingsnahrung |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06CA |
Diätetika ohne Phenylalanin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06D |
Andere Diätetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DA |
Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DB |
Fette/Kohlenhydrate/Proteine/Mineralstoffe/Vitamine, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DC |
Kohlenhydrate |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DC01 |
Glucose |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DC02 |
Fructose |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DD |
Aminosäuren, inkl. Kombination mit Polypeptiden |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DE |
Aminosäuren/Kohlenhydrate/Mineralstoffe/Vitamine, Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DF |
Milchersatzstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
V06DX |
Andere Diätetika-Kombinationen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07 |
Alle übrigen nichttherapeutischen Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07A |
Alle übrigen nichttherapeutischen Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AA |
Pflaster |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AB |
Lösungs- und Verdünnungsmittel, inkl. Spüllösungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AB01 |
Wasser |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AB02 |
Physiologische Kochsalzlösung |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AC |
Bluttransfusionen, Hilfsstoffe |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AD |
Blut-Tests, Hilfsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AN |
Inkontinenz-Artikel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AR |
Sensitivitäts-Tests, Plättchen und Tabletten |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AS |
Stoma-Artikel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AT |
Kosmetika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AV |
Technische Desinfektionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AX |
Waschsubstanzen etc. |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AY |
Andere nichttherapeutische Hilfsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V07AZ |
Chemikalien und Reagenzien zur Analyse |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08 |
Kontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08A |
Röntgenkontrastmittel, Iod-haltig |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA |
Wasserlösliche nephrotrope hochosmolare Röntgenkontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA01 |
Amidotrizoesäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA02 |
Metrizoesäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA03 |
Iodamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA04 |
Iotalaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA05 |
Ioxitalaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA06 |
Ioglicinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA07 |
Acetrizoinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA08 |
Iocarminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA09 |
Methiodal |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AA10 |
Diodon |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB |
Wasserlösliche nephrotrope niederosmolare Röntgenkontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB01 |
Metrizamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB02 |
Iohexol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB03 |
Ioxaglinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB04 |
Iopamidol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB05 |
Iopromid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB06 |
Iotrolan |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB07 |
Ioversol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB08 |
Iopentol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB09 |
Iodixanol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB10 |
Iomeprol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB11 |
Iobitridol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AB12 |
Ioxilan |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC |
Wasserlösliche hepatotrope Röntgenkontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC01 |
Iodoxaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC02 |
Iotroxinsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC03 |
Ioglycaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC04 |
Adipiodon |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC05 |
Iobenzaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC06 |
Iopansäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC07 |
Iocetaminsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC08 |
Natriumiopodat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC09 |
Tyropansäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AC10 |
Calciumiopodat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AD |
Wasserunlösliche Röntgenkontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AD01 |
Ethylester iodierter Fettsäuren |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AD02 |
Iopydol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AD03 |
Propyliodon |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08AD04 |
Iofendylat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08B |
Röntgenkontrastmittel, nicht Iod-haltig |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08BA |
Bariumsulfat-haltige Röntgenkontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08BA01 |
Bariumsulfat mit Suspensionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08BA02 |
Bariumsulfat ohne Suspensionsmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08C |
Kontrastmittel für die Magnetresonanztomographie |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA |
Paramagnetische Kontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA01 |
Gadopentetsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA02 |
Gadotersäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA03 |
Gadodiamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA04 |
Gadoteridol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA05 |
Mangafodipir |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA06 |
Gadoversetamid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA07 |
Ammoniumeisen(III)citrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA08 |
Gadobensäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA09 |
Gadobutrol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA10 |
Gadoxetsäure |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CA11 |
Gadofosveset |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CB |
Superparamagnetische Kontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CB01 |
Ferumoxsil |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CB02 |
Ferristen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CB03 |
Eisenoxid, Nanopartikel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CX |
Andere Kontrastmittel für die Magnetresonanztomographie |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08CX01 |
Perflubron |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08D |
Ultraschall-Kontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08DA |
Ultraschall-Kontrastmittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08DA01 |
Humanalbumin-Mikrosphären |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08DA02 |
Galactose-Mikropartikel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08DA03 |
Perflenapent |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08DA04 |
Phospholipid-Mikrosphären |
2.16.840.1.113883.6.73 |
|
| 0-L |
V08DA05 |
Schwefelhexafluorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09 |
Radiodiagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09A |
Zentrales Nervensystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AA |
[99mTc]Technetium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AA01 |
[99mTc]Technetium-Exametazim |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AA02 |
[99mTc]Technetiumbicisat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AB |
[123I]Iod-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AB01 |
[123I]Iod-Iofetamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AB02 |
[123I]Iod-Ioloprid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AB03 |
[123I]Iod-Ioflupan |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AX |
Andere Radiodiagnostika für das zentrale Nervensystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09AX01 |
[111In]Indiumpentetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09B |
Skelett |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09BA |
[99mTc]Technetium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09BA01 |
[99mTc]Technetiumoxidronat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09BA02 |
[99mTc]Technetiummedronat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09BA03 |
[99mTc]Technetiumpyrophosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09BA04 |
[99mTc]Technetiumbutedronat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09C |
Nierensystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CA |
[99mTc]Technetium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CA01 |
[99mTc]Technetiumpentetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CA02 |
[99mTc]Technetium-Succimer |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CA03 |
[99mTc]Technetiummertiatid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CA04 |
[99mTc]Technetiumglucoheptonat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CA05 |
[99mTc]Technetiumgluconat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CX |
Andere Radiodiagnostika für das Nierensystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CX01 |
[123I]Natrium-Iodhippurat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CX02 |
[131I]Natrium-Iodhippurat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CX03 |
[125I]Natrium-Iodthalamat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09CX04 |
[51Cr]Chromedetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09D |
Leber- und Retikuloendothelialsystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DA |
[99mTc]Technetium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DA01 |
[99mTc]Technetium-Disofenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DA02 |
[99mTc]Technetium-Etifenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DA03 |
[99mTc]Technetium-Lidofenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DA04 |
[99mTc]Technetium-Mebrofenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DA05 |
[99mTc]Technetium-Galtifenin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DB |
[99mTc]Technetium, Partikel und Kolloide |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DB01 |
[99mTc]Technetium-Nanokolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DB02 |
[99mTc]Technetium-Mikrokolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DB03 |
[99mTc]Technetium-Millimikrosphären |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DB04 |
[99mTc]Technetium-Zinn-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DB05 |
[99mTc]Technetium-Schwefel-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DB06 |
[99mTc]Technetium-Rheniumsulfid-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DB07 |
[99mTc]Technetiumphytat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DX |
Andere Radiodiagnostika für das Leber- und Retikuloendothelialsystem |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09DX01 |
[75Se]Selenium-tauroselcholinat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09E |
Respirationstrakt |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EA |
[99mTc]Technetium, Inhalate |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EA01 |
[99mTc]Technetiumpentetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EA02 |
[99mTc]Technetium, Technegas |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EA03 |
[99mTc]Technetium-Nanokolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EB |
[99mTc]Technetium, Partikel zur Injektion |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EB01 |
[99mTc]Technetium-Macrosalb |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EB02 |
[99mTc]Technetium-Mikrosphären |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EX |
Andere Radiodiagnostika für den Respirationstrakt |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EX01 |
[81mKr]Kryptongas |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EX02 |
[127Xe]Xenongas |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09EX03 |
[133Xe]Xenongas |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09F |
Schilddrüse |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09FX |
Verschiedene Radiodiagnostika für die Schilddrüse |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09FX01 |
[99mTc]Technetiumpertechnetat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09FX02 |
[123I]Natriumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09FX03 |
[131I]Natriumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09G |
Kardiovaskuläres System |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GA |
[99mTc]Technetium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GA01 |
[99mTc]Technetiumsestamibi |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GA02 |
[99mTc]Technetiumtetrofosmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GA03 |
[99mTc]Technetiumteboroxim |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GA04 |
[99mTc]Technetium-Humanalbumin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GA05 |
[99mTc]Technetiumfurifosmin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GA06 |
[99mTc]Technetium-Zinn-markierte Zellen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GA07 |
[99mTc]Technetiumapcitid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GB |
[125I]Iod-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GB01 |
[125I]Fibrinogen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GB02 |
[125I]Iod-Humanalbumin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GX |
Andere Radiodiagnostika für das kardiovaskuläre System |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GX01 |
[201Tl]Thalliumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GX02 |
[111In]Indiumimciromab |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09GX03 |
[51Cr]Chromchromat-markierte Zellen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09H |
ENtzündungs- und Infektionserkennung |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HA |
[99mTc]Technetium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HA01 |
[99mTc]Technetium-Humanimmunglobulin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HA02 |
[99mTc]Technetium-Exametazim-markierte Zellen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HA03 |
[99mTc]Technetium-Antigranulozyten-Antikörper |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HA04 |
[99mTc]Technetium-Sulesomab |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HB |
[111In]Indium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HB01 |
[111In]Indiumoxinat-markierte Zellen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HB02 |
[111In]Indiumtropolonat-markierte Zellen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HX |
Andere Radiodiagnostika zur Erkennung von Entzündungen und Infektionen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09HX01 |
[67Ga]Galliumcitrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09I |
Tumorerkennung |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IA |
[99mTc]Technetium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IA01 |
[99mTc]Technetium-Anticarcinoembryoantigen-Antikörper |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IA02 |
[99mTc]Technetium-Antimelanom-Antikörper |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IA03 |
[99mTc]Technetiumsuccimer, pentavalent |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IA04 |
[99mTc]Technetiumvotumumab |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IA05 |
[99mTc]Technetiumdepreotid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IA06 |
[99mTc]Technetiumarcitumomab |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IB |
[111In]Indium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IB01 |
[111In]Indiumpentetreotid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IB02 |
[111In]Indium-Satumomab-pendetid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IB03 |
[111In]Indium-Antiovariumkarzinom-Antikörper |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IB04 |
[111In]Indium-Capromab-Pendetid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IX |
Andere Radiodiagnostika zur Tumorerkennung |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IX01 |
[123I]Iobenguan |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IX02 |
[131I]Iobenguan |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IX03 |
[125I]Iod-CC49-Monoklonaler Antikörper |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IX04 |
[18F]Fludeoxyglucose |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IX05 |
[18F]Fluorodopa |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IX06 |
[18F]Natriumfluorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09IX07 |
[18F]Fluormethylcholin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09X |
Andere Radiodiagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XA |
[131I]Iod-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XA01 |
[131I]Iodnorcholesterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XA02 |
[131I]Iodcholesterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XA03 |
[131I]Iod- Humanalbumin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XX |
Verschiedene Radiodiagnostika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XX01 |
[57Co]Cobaltcyanocobalamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XX02 |
[58Co]Cobaltcyanocobalamin |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XX03 |
[75Se]Selennorcholesterol |
2.16.840.1.113883.6.73 |
|
| 0-L |
V09XX04 |
[59Fe]Eisen(III)-citrat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10 |
Radiotherapeutika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10A |
Entzündungshemmende Mittel |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AA |
[90Y]Yttrium-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AA01 |
[90Y]Yttriumcitrat-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AA02 |
[90Y]Yttrium-Eisen(III)hydroxid-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AA03 |
[90Y]Yttriumsilicat-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AX |
Andere entzündungshemmende Radiotherapeutika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AX01 |
[32P]Chrom(III)phosphat-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AX02 |
[153Sm]Samariumhydroxyapatit-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AX03 |
[165Dy]Dysprosium-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AX04 |
[169Er]Erbiumcitrat-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AX05 |
[186Re]Rheniumsulfid-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10AX06 |
[198Au]Gold-Kolloid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10B |
Schmerzlinderung (Knochenmetastasen) |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10BX |
Verschiedene Radiopharmaka zur Schmerzlinderung |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10BX01 |
[89Sr]Strontiumchlorid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10BX02 |
[153Sm]Samariumlexidronam |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10BX03 |
[186Re]Rheniumetidronat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10X |
Andere Radiotherapeutika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10XA |
[131I]Iod-Verbindungen |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10XA01 |
[131I]Natriumiodid |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10XA02 |
[131I]Iobenguan |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10XA53 |
Tositumomab/[131I]Iod-Tositumomab |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10XX |
Verschiedene Radiotherapeutika |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10XX01 |
[32P]Natriumphosphat |
2.16.840.1.113883.6.73 |
|
| 0-L |
V10XX02 |
[90Y] Ibritumomab tiuxetan |
2.16.840.1.113883.6.73 |
|
| 0-L |
V20 |
Wundverbände |
2.16.840.1.113883.6.73 |
|
Value Set ELGA_whoATC 2013‑01‑10